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CHAPTER 1: INTRODUCTION TO 
PROTEIN FOLDING AND STRATEGIES TO DISULFIDE BOND FORMATION IN 
NEUROACTIVE PEPTIDES. 
 
1.1 Disulfide Bonds in Proteins and peptides 
 In both proteins and peptides, disulfide bonds are formed as a reversible covalent 
bond between the side chain thiol groups of two cysteine residues. The cysteine amino 
acid residue is the only amino acid capable of forming disulfide bonds, and thus it become 
a unique residue among the proteinogenic amino acids.1 Disulfide bonds enforce 
conformational constraints and stabilize the tertiary structure of peptides.2 In addition, 
disulfide bonds prevent proteins from aggregation and subsequent degradation by cellular 
proteases, thus increasing their half-life.3,4 The formation of disulfide bonds is a key post-
translational modification in the folding and assembly of the extracellular domains of many 
membranes and secreted proteins.5,6,7   
Most classes of extracellular proteins and peptides, including hormones, 
neurotransmitters, growth factors, toxins and enzyme inhibitors often have several 
disulfide bonds.8 In nature, disulfide bonds are common in bacteria, microalgae, plant and 
animal peptide toxins.9 Disulfide-rich mini-proteins derived from plants are known as 
cyclotides, which consist of 28-37 residues and display a cysteine knot motif composed 
of three disulfide bonds.10,11 Cyclotides are exceptionally stable and serve a range of 
natural bioactivities such as antiviral and antimicrobial behaviors, which make them 
potential therapeutics.12,13,14,15 The poisonous and venomous animals such as spiders, 
snakes, scorpions, shellfish, cone snails produce complex venom cocktails with 
thousands of unique bioactive compounds.16,17 The disulfide-rich compact architectures 
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of these venoms make them resistant to extreme pH conditions and stable to high 
temperatures and organic solvents.18,19 In addition, these disulfide-rich peptides have 
high binding affinity and specificity towards their cognate receptors, which make animal 
toxins extremely valuable pharmacological tools.20,21,22   
 Conus peptides are natural peptides with sufficiently complex and diverse disulfide 
bond patterns in their structure. Hence, in this study, among all toxins, conotoxins were 
chosen as excellent model system to study disulfide bond formation in peptides.   
1.2 Conotoxins as Source of Disulfide-Rich Mini-peptides 
 Conotoxins are neurotoxic peptides isolated from venom of Conus marine snails.23 
They are mini-proteins consisting of 10 – 50 amino acid residues and typically have one 
or more disulfide linkages. Over 500 different species of cone snails have been identified 
and majority of them are carnivorous predatory sea snails and marine gastropod molluscs 
that use venom-based strategy to capture their prey.24 All of the cone snails are 
venomous and produce conotoxins of 20 – 200 extremely complex components 
composed of modified peptides.25  The exact composition of conotoxins varied widely 
from one species of cone snail to another; a rough estimate of the conotoxin diversity is 
that ~ 50,000 different peptides.26 Generation of such a huge diversity of conotoxin is 
based on specific target macromolecules, mainly ion channels or receptors, and target 
animals, such as prey, predator or competitor. The huge diversity of conotoxins also 
evolved from various hyper mutations of the primary amino acid sequence, different 
cysteine patterns and  disulfide scaffolds27,28 (Figure 1.1).  
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Conotoxins have well-defined, compact structures, stabilized by different patterns of 
disulfide bonds. For two disulfide-bond conotoxins, either a ribbon or globular shape is 
more prominent.29 For three disulfide-bond conotoxins, the structure varies from a 
globular shape to compact, cage-like structures.  
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 Moreover, diversity of disulfide-bond mediated structural frameworks improve the 
stability, potency and selectivity of conotoxins.30,31 Many of these conotoxins modulate 
the activity of ion channels. The action of conotoxins is fast, which can immobilize the 
injected prey by affecting its nervous system to cause massive membrane depolarization 
followed by an irreversible neuromuscular block.32 This effect results from simultaneous 
inhibition of voltage-gated sodium and potassium channels.33 This phenomena indicates 
the potential of conotoxins as inhibitors for specific ion channels (voltage-gated Na+, K+ 
and Ca2+ ion channels) and receptors (serotonin, acetylcholine) with high affinities and 
selectivities. 
The conotoxins have been divided into a number of major classes based on their 
cysteine frameworks and physiologically relevant target (Table 1.1).34 The high selectivity 
of conotoxins facilitates discrimination of closely related molecular isoforms of members 
of a particular ion channel family. For example, µ-conotoxins, which targets tissue specific 
sodium ion channel, inhibit voltage-sensitive sodium ion channels in muscles, with only 
minimum binding to neuronal sodium channel.35 Some conotoxins show species-specific 
binding, where they have the ability to bind to same site of receptors, but produce different 
results. For example, d-conotoxin such as conotoxin SVIA from Conus striatus bind with 
high affinity to voltage-independent sodium channels, and in contrast, Conus 
purpurascens which produce d-conotoxin such as conotoxin PVIA have specific binding 
to voltage-sensitive channel.36  
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Conotoxins Primary sequence Molecular targets
A-superfamily
α-GI
α-ImI
α-SI
T-superfamily
χ-MrIA
M-superfamily
µ-GIIA
µ-PIIA
µ-SmIIIA
µ-SIIIA
µM-RIIIK
O-superfamily
ω-MVIIA
ω-MVIIC
ω-GVIA
µ-Ο-MrVIB
δ-SVIE
δ-PVIA
δ-TxVIA
ECCNPACGRHYSC#
GCCSDPRCAWRC#
ICCNPACGPKYSC#
NGVCCGYKLCHOC
RDCCTOOKKCKDRQCKOQRCCA#
CKGKCAKCSRLMYDCCTGSCRSGKC#
ZRLCCGFOKSCRSRQCKOHRCC#
ZRCCNGRRGCSSRWCRDHSRCC#
LOSCCSLNLRLCOVOACKRNOCCT
CKGKGAPCRKTMYDCCSGSCGRRGKC#
CKSOGSSCSOTSYNCCRSCNOOYTKRCY#
ACSKKWEYCIVPILGFVYCCPGLICGPFVCV
EASSSGGTFCGIHPGLCCSEFCFLWCITFID
EACYAPGTFCGIKPGGLCCSEFCLPGVCFG#
CKQSGEMCNLLDQNCCDGYCIVLVCT
nAChRs
nAChRs
nAChRs
NET
ZNCCNGGCSSKWCRDHARCC#
VGSCs
VGSCs
VGCCs
VGSCs
VGSCs
VGKCs
VGCCs
VGCCs
VGSCs
VGSCs
VGSCs
VGSCs
nAChRs - nicotinic acetylicholine receptors, VGSCs - voltage-gated sodium channels, VGCCs - voltage-gated 
calcium channels, VGKCS - voltage-gated potassium chennels, NET - norepinephrine transporter, O - 
hydroxyproline, Z - puroglutamatae, # - Amidated C-terminal,
Table 1.1 Diversity conotoxins and their molecular targets
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There are thousands of conotoxin-mediated selective bindings toward ion 
channels and receptors, which make conotoxins extremely valuable tools in biomedical 
research. The venom produced from Conus magus have shown promising activity as a 
non-addictive pain reliever 1000 times as powerful as morphine.37 Furthermore, conotoxin 
AVCI from Conus victoriae has excellent potential for treating post-surgical and 
neuropathic pain, even accelerating recovery from nerve injury.38 The first venom-derived 
painkiller, Ziconotide, was approved by the U.S. Food and Drug Administration in 2004 
under the name “Prialt”. It is an w-conotoxin and acts by blocking calcium channels on 
the surface of the nerve cells that transmit the pain signal. Ziconotide can interfere with 
the transmission of pain signals within the spine, which aids to relieve pain.29 There are 
many venom-based drugs in clinical and preclinical trials, which have potential in 
treatment of Alzheimer’s disease, Parkinson’s disease and epilepsy.39  
1.3 Disulfide Bonds and Protein Folding 
 The mechanism by which the small, disulfide-rich peptides form their native 
disulfide bonds remain far from understood, and how these mini-proteins fold in vivo is 
one of the key unsolved problems in the field.40 This is mainly due the challenges in 
identification and characterization of folding intermediates that are only very transiently 
present. However, majority of detailed in vitro folding studies have been done using model 
peptides such as BPTI,41,42 Hirudin43  and RNase A44,45 These extensive studies have 
provided interesting insights for folding mechanism of disulfide-rich peptides. It was 
observed that most of the information needed to specify three-dimensional structure of a 
protein is encoded in its primary amino acid sequence and disulfide bonds greatly 
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influence the thermodynamics of protein folding process.46 Generally accepted method 
by which the disulfide bonds stabilize the native conformation of a protein is lowering the 
entropy of the unfolded form and making it less favorable compared to the folded form.47 
This process of protein folding can be seen as a folding funnel (Figure 1.2).48 
 
The folding process begins from a reduced, high energy, unfolded ensemble and the 
protein molecules work their way down a funnel of decreasing energy. For proteins such 
as BPTI, a limited number of native-like intermediates adopt protein conformation towards 
the native structure ((a). Figure 1.2). Hirudin-like proteins fold through an initial stage of 
disulfide bond formation, process known as packing, followed by the reshuffling of 
scrambled isomers to form the native protein ((b). Figure 1.2). Disulfide bonds in proteins 
are formed by two thiol exchange reactions (Scheme 1.1). First, the ionized thiolate form 
reacts with one of the sulfur atoms in the redox reagent to form a mixed disulfide bond 
between the protein and redox reagent. Then, the remaining thiol anion in the protein 
attacks the mixed disulfide to form the oxidized protein.49  
Figure 1.2 Schematic overview of folding funnels for BPTI and Hirudin-like proteins
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The kinetics of protein folding are greatly affected by the location of disulfide bond relative 
to the folding nucleus. When disulfide bonds are in or near the folding nucleus, it can 
accelerate the folding process, whereas when disulfide bonds are far away from the 
folding nucleus, the folding process can decelerate up to three order of magnitude.50 In 
addition, accessibility, proximity and reactivity of the thiol groups and disulfide bonds 
influence the formation of disulfide bonds.51 
 Disulfide bond formation is one of the major rate-limiting steps in protein folding in 
vivo. Therefore, protein folding catalysts called oxidoreductases are required to form 
disulfide bonds in vivo. Oxidoreductases are consist of catalytic disulfides at the active 
site and these disulfides are serve as the oxidant for disulfide formation. The reduced 
form facilitates the reduction or isomerization of disulfide bonds. In addition, 
oxidoreductases accelerate oxidative folding by eliminating misfolding in protein folding.52 
Formation of disulfide bonds in the bacterial periplasm has been extensively studied over 
past decades.53 Those studies reveal that disulfide bonds in the periplasm of Escherichia 
coli are introduced by the Dsb family of proteins. The family includes DsbA and DsbB, 
which are involved in disulfide bond formation, and DsbC and DsbD, which are involved 
in disulfide bond isomerization.54 In eukaryotic cells, disulfide bond formation occurs in 
the lumen of the endoplasmic reticulum (ER) and two proteins, protein disulfide isomerase 
(PDI) and EroIp, are primarily responsible for controlling the process of oxidative folding. 
Reduced 
protein
SH S-
Mixed
Disulfide
S- S
Oxidized
protein
S SS S
R2
R1
S
R1
Scheme 1.1 Thiol-disulfide exchange reaction between a protein and a redox reagent
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These folding catalysts reduce and shuffle non-native disulfide bonds at early stages of 
folding to avoid misfolding.55 As mentioned earlier, there is little known about the in vivo 
folding of small, disulfide-rich proteins, hence more future research should be focused on 
analyzing disulfide-mediated folding processes under physiological conditions.  
With the attractive potential of conotoxin-like small, disulfide rich-proteins as 
valuable tools in pharmacological and biological studies, there is a huge need for isolation 
and/or synthesis of these bioactive molecules. As mentioned earlier in this chapter, the  
marine snails produce relativity small quantities of the toxins, and they are a complex 
mixture of thousands of bioactive compounds. Therefore, isolation of each interested 
bioactive compound is very difficult and the amount recovered after lengthy isolation 
protocol is not sufficient for those experimental studies. Moreover, production of these 
disulfide-rich bioactive peptides by recombinant methods using suitable host organisms 
is very challenging. The major obstacles are low expression rates, high susceptibility for 
degradation by the host cell proteases and a significant toxicity for the host organism.56 
In order to access these disulfide-rich mini-proteins in large quantities, many methods 
have been developed to perform chemical synthesis of these bioactive molecules. 
1.4 Chemical Synthesis of Disulfide-Rich Mini-proteins         
 The in vitro studies of protein folding have given information to develop suitable 
strategies to chemically access disulfide-rich mini proteins. From Anfinsen’s in vitro 
studies, it is accepted that an intrinsic folding code in primary amino acid sequence of a 
protein determines its correct folding pattern.41 This implies that as long as we can 
synthesize the correct primary amino acid sequence, generation of the native 3D structure 
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of protein is possible with suitable folding methods. This concept opened up a huge area 
of chemical synthesis of proteins and several methods have been developed to access 
disulfide-rich mini-proteins.  
 The first chemical synthesis of conotoxins were carried out in early to mid 1980s 
and since then, at least a hundred of conotoxins have been synthesized.57,58,59,60 The 
primary amino acid sequence is made either by Fmoc or Boc chemistry with thiol 
protected cysteines using several thiol-protecting groups (Table 1.2). There are several 
methods used to synthesize disulfide-rich peptides and these methods can be 
categorized into three broad sections based on how the linear peptide or reagents are 
used in the synthetic process; either in solution or on a solid support. They are namely 1) 
solution-phase oxidation 2) on-resin oxidation and 3) oxidation via solid-supported 
oxidants. When performing each of these strategies, a special attention needed to be 
taken to optimize variables in the folding reaction, such as peptide concentration, 
temperature, folding time, folding additives and solvents to increase the folding 
efficiency.61,62,63  
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Table 1.2 The most common thiol protecting groups used in peptide synthesis
Protecting Group Structure Stability Removal
4-methylbenzyl (Bzl(4-Me))
4-methoxybenzyl (Mob)
tert-butyl (tBu)
Acetamidomethyl (Acm)
tert-butylsulfanyl (StBu)
3-nitro-2-pyridylsulfanyl (Npys)
triphenylmethyl, trityl (Trt)
4-methoxytrityl (Mmt)
2,4,6-trimethyoxybenzyl (Tmob)
9H-xanthen-9-yl (Xan)
MeO
O
N
H
S
SN
NO2
MeO
MeO OMe
OMe
O
TFA, Ag(I), base, RSCl
TFA, base, RSCl, I2
TFA, HF (0 ºC),
Ag(I), I2
TFA, HF (0 ºC), base
TFA, HF (partial), base, 
RSCl
HF
base, nucleophiles
base, nucleophiles
base, nucleophiles
base, nucleophiles
HF (0 ºC),Tl(Ii),
Ph2SO/MeSiCl3
HF (0 ºC), Ag(I), Hg(II),
Tl(III), Ph2SO/MeSiCl3
HF (0 ºC), Hg(II), RSCl,
Ph2SO/MeSiCl3
I2, Ag(I), Hg(II), RSCl,
Tl(III), Ph2SO/MeSiCl3
RSH, Bu3P, 
(HOOC-CH2-CH2)P
dil.TFA/scavenger, I2, 
Ag(I), Hg(II), TI(III), RSCl
dil.TFA/scavenger, I2, 
Ag(I), Hg(II), TI(III)
dil.TFA/scavenger, I2, 
TI(III)
dil.TFA/scavenger, I2, 
TI(III)
RSH, Bu3P, 
(HOOC-CH2-CH2)P
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1.4.1 Solution-Phase Synthesis of Disulfide-Rich Peptides  
 Solution-phase oxidation is the most common method to form intramolecular 
disulfide bonds in peptides.51,52,64,65,66 The linear synthesis of the peptide is assembled 
via solid phase peptide synthesis (SPPS), and the peptide folding is performed after 
cleavage of the linear peptide from the resin. Solution-phase disulfide bond formation 
requires highly dilute conditions such as 20 – 50 µM concentrations of peptide solution. 
In solution, there is a competition between intramolecular disulfide bond formation and 
intermolecular disulfide bond formation. At higher peptide concentrations, the effective 
concentration of intermolecular thiol becomes relatively higher, which facilitates 
dimerization and oligomerization of the peptide and lowers the folding yields.67 Numerous 
oxidants have been exployed to perform solution-phase peptide folding.68 Common 
examples of such oxidants are, glutathione, cysteine, cystamine, DMSO, trans-1,2-bis(2-
mercaptoacetamido)cyclohexane (BMC) and molecular oxygen. Glutathione-based redox 
buffers are common in solution-phase disulfide bond formation methods as they are 
hypothesized to better reflect oxidation pathways in vivo.69,70 The folding efficiency and 
extent of oxidation are influenced by the ratio of GS-SG to GSH.71 Dilute dimethyl 
sulfoxide with final concentration of 5 – 10% is another common oxidant, often requiring 
longer folding times.72 The major drawback of DMSO oxidation is the difficulty of removal 
of excess DMSO from the folded  product.  Molecular oxygen is also used to form disulfide 
bonds in peptides and oxygen is drawn from either air or oxygen atmosphere for the 
folding process. Oxygen-mediated peptide folding method relies on low levels of oxygen 
dissolved in solution. Thus, the method is relatively slow.67 When performing multistep 
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folding procedures in solution-phase, in addition to the final product, the intermediate 
products from each step usually need to be purified before the next step. Multiple 
purification steps can diminish the final yield of the folded peptide.           
 1.4.2 On-resin Synthesis of Disulfide-Rich Peptides 
 High dilution conditions in solution-phase folding protocols introduce problems with 
larger scale and high throughput folding. To avoid this issue, peptide disulfide bond 
formation can be performed on solid support, requiring less solvent. After the linear 
synthesis of the target peptide on resin, the folding procedures are carried out while the 
peptide is still attached to the resin. The reagents are easily filtered out after the synthesis 
and the resulting folded product can be cleaved form the resin and purified. Therefore, 
this method does not need time-consuming and wasteful purification steps. When 
disulfide is formed on a resin with medium to low loading, a phenomenon called pseudo-
dilution73 is generated within the reaction core, which ensure that the molecule of peptide 
is isolated. This favors intramolecular disulfide bond formation over intermolecular 
disulfide bond formation, minimizing formation of dimers and oligomers as by products. 
Several methods have been developed to form disulfide bonds in resin-bound peptides 
using suitable cysteine protecting groups and reagents, which are compatible with resin-
based reaction conditions. Few of them are summarized in Scheme 1.2. One of the 
traditional approaches to access disulfide bonds on resin is the iodine oxidation. On-resin 
peptides with Trt, Acm or Mmt protected cysteines (1.1.A) are treated with excess 
iodine.74,75 
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This is a convenient method to form on-resin disulfide linkages, but it cannot always be 
employed as peptides containing Met or Trp amino acids are prone to oxidation and 
peptides on TGT and CTC resins can be cleaved under iodine oxidation condition.76 In 
addition to iodine oxidation, Tl(tfa)3 can be used on peptides 1.1.C with Acm protected 
cysteine to directly yield the product with desired disulfide bond. This approach is not 
orthogonal to other cysteine protecting groups or acid-labile side chain protecting groups, 
and it can induce cleavage of peptides from TGT and CTC resins.77 On-resin oxidation of 
free thiols, 1.1.B, can be achieved using either N-chlorosuccinimide78 or acidic DMSO 
(HX = HCl or HOAc).79 Cysteines with benzyl derived protecting groups, 1.1.D, need 2-
step process to form disulfide bonds. First, low concentration of TFA is used to the remove 
benzyl group, and then, the resulting free thiols are oxidized with CCl4/TFA to form 
corresponding disulfide bond. This method is not compatible with Cys(Mmt), Cys(Trt) or 
TGT and CTC resins as TFA can cause cysteine deprotection and/or peptide cleavage. 
The multistep approach with StBu and Mmt protected cysteines, 1.1.E, was developed to 
S S
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SPG SPG
H
SH SH
H
STmob STmob
H
SAcm SAcm
H
SStBu SMmt
H
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1.1.A
1.1.C
1.1.E
1.1.B
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2) DTNP, CH2Cl2
3) 1% TFA, CH2Cl2
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Scheme 1.2 Known methods for on-resin disulfide formation
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improve the purity of peptides.80 The disulfide bond formation takes place based on the 
sequence of two disulfide exchange reactions and no oxidizing agent is needed. First, the 
on-resin peptide is treated with mercaptoethanol to remove StBu group by reduction to 
expose free thiols. Then, the peptide undergoes first disulfide exchange reaction when 
treated with excess DTNP to activate the free thiol with 5-Npys group. Deprotection of 
Cys(Mmt) group initiates second disulfide exchange reaction, where the nucleophilic 
attack of free thiol on the resin-bound 5-Npys-activated hetero disulfide leads to the 
desired folded product. This approach is very effective and widely used. The reaction can 
also be carried out under microwave heating to decrease the reaction time.81 Current 
limitations in on-resin disulfide bond formation are often poor yield recovery cause by 
undesired polymerization or disulfide interaction with the resin.82  
 1.4.3 Disulfide Bond Formation via Solid-Supported Oxidants  
 Another solution for the issues associated with high dilution conditions in solution-
phase disulfide bond formation is use of solid-supported oxidants. A variety of solid-
supported oxidants have been explored using different types of polymers/resins such as 
hydrocarbon-based resins,83 agarose-bound folding chaperones,84 PEG-PS, Sephadex, 
controlled pore glass85 and cross-linked ethoxylate acrylate resin (CLEAR)86 (Figure 1.3). 
As in on-resin disulfide bond formation, the low loading of the resin takes advantage of 
the pseudo-dilution effect and favors the intramolecular disulfide bond formation. In 
addition, the reagent can be easily filtered off upon completion of disulfide bond formation.  
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Polymer-bound version of Ellman’s reagent (1.2.A) can be made by linking the oxidant to 
a polymer matrix through a lysine residue.86  When a solution of reduced peptide is treated 
with solid-supported Ellman’s reagent, the reduced peptide is temporarily immobilized on 
to the solid-supported disulfide, generating a peptide – resin disulfide intermediate that is 
released again upon intramolecular disulfide-bond formation. The Clear resin preloaded 
with Ellman’s reagent called Clear-OX69 has been successfully utilized in the synthesis of 
many conotoxins.66,87 The drawback of this method is lower yield of recovery due to the 
covalent trapping of the peptide within the resin.  
The solid-supported Met sulfoxide (1.2.B), which is known as Oxyfold, can be 
readily prepared on aminopoly(ethylene glycol)polyacrylamide (PEGA) resin by 
methionine N-carboxyanhydride polymerization initiated by free amine groups on the 
resin.88 The disulfide formation of resin-bound Met sulfoxide is analogous to DMSO 
oxidation, and therefore, it can be used as a substitute of DMSO. As mentioned earlier, 
the major drawback of DMSO oxidation is the difficulty in removal of excess DMSO from 
the oxidized product. The resin-bound Met sulfoxide does not have this disadvantage as 
it can be removed by simple filtration. The efficiency of the resin-bound Met sulfoxide can 
be increased by generating longer Met sulfoxide chains, which increases the number of 
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Met sulfoxide groups per gram of resin.73 Besides the longer reaction time, the resin-
bound Met sulfoxide oxidation shows quantitative formation of the disulfide bonds with no 
dimer formation, and hence, it can be used to get high yields for more complex or valuable 
peptide sequences.89  
N-chlorosuccinimide can also be immobilized on the versatile poly(ethylene 
glycol)-based ChemMatrix resin (1.2.C). The resin-bound NCS can be used in either 
aqueous or organic media and have shown efficient reactivity to form disulfide bonds on 
peptides.90             
1.4.4 Thermodynamically controlled Folding Strategy for Disulfide Bond Formation in 
Peptides 
 The classic work of Anfinsen and co-workers towards in vitro protein folding41 
inspired the development of a thermodynamically controlled oxidative folding strategy to 
access disulfide-rich bioactive mini-proteins. This approach involves random oxidation, 
reduction and reshuffling of the fully deprotected peptide to the native isomer (scheme 
1.3). Disulfide bond formation is performed mainly in solution phase and all the cysteine 
groups are usually protected with a single protecting group during the SPPS. Common 
folding conditions include slightly alkaline aqueous or aqueous/organic buffers, such as 
GSH/GSSG buffer. In addition, DMSO-promoted oxidation is done frequently. Most 
recently, Clear-OX was successfully used in the oxidative folding of three disulfide-
bridged conotoxins such as µ-SIIIA, µ-KIIIA, w-GVIA.72 As the name implies, disulfide 
bond connectivity in this method is not controlled by reagents. Therefore,  the final yield 
and disulfide connectivity is highly dependent on the encoded structure information built-
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in the primary amino acid sequence and thermodynamic stability of the native 
conformation.91,92,93  
 
This can result in many non-native or misfolded products in addition to the native product. 
Although the method requires only one purification step, separation of the native product 
from all the non-native products is very challenging. Despite its disadvantages, this is still 
the most commonly use approach to access peptides, especially when the native 
configuration is substantially thermodynamically favored. 
1.4.5 Regioselective Folding Strategy for Disulfide Bond Formation in Peptides 
 The regioselective folding approach is a step-by-step process to form multiple 
disulfide bonds in desired pattern. The strategy is based on selective deprotection and 
oxidation of each cysteine pair in the peptide. As this is a step-wise process, reshuffling 
of disulfide bonds can take place by the breakage of disulfide bonds that already formed. 
Hence, exposure to alkaline conditions, thiols and other nucleophiles and lengthy reaction 
PeptideH
SPG SPG
SPG SPG
OHPeptideH
SH SH
SH SH
OHPeptideH
S S
S S
Peptide cleavage 
and 
total deprotection
Disulfide bond formation
(Oxidation)
Scheme 1.3 Thermodynamically controlled disulfide bond formation
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times should be avoided to prevent competitive disulfide-bond disproportionation, which 
can lower the product recovery. Most importantly, regioselective folding strategies require 
careful planning and designing of the synthetic route by analyzing the orthogonal behavior 
of cysteine protecting groups. Regioselective disulfide bond formation can be conducted 
either in solution phase, after the peptide been cleaved from the resin, or solid phase, 
while the peptide is still attached to the resin. 
1.4.5.1 In-Solution Regioselective Disulfide Bond Formation in Peptides 
 Nishiuchi and Sakakibara demonstrated the use of Acm protected cysteine in 
combination with Trt protected cysteine to form disulfide bonds in a-conotoxin GI using 
Boc chemistry (Scheme 1. 4).94 Since then, Acm group has been widely used in the 
synthesis of disulfide bonds in peptides. As Acm group is resistant to TFA or HF cleavage, 
the linear peptide can be cleaved form the resin together with all other protecting groups 
without affecting the Acm group. In the synthesis of a-conotoxin GI, the resulting free 
thiols from HF cleavage were oxidized by mild oxidant, ferricyanide, to form the first 
disulfide bond. The second disulfide bond formation was then achieved after Acm group 
removal and oxidation by iodine oxidation.   
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The utility of S-Acm protection strategy to synthesize conotoxins containing three disulfide 
bonds has also been explored. A semi-directed method was used to synthesize w-
conotoxin MVIID using Acm group in combination with Trt group to protect pairs of 
cysteine residues (Scheme 1.5.A).95 During the resin cleavage all the protecting groups 
get cleaved except for the Acm group, forming two pairs of reduced cysteine residues. 
Upon treatment with air, the reduced peptide undergoes a random oxidation to form first 
two disulfide bonds. This step gave predominantly a single isomer which reflects the 
efficiency of the synthetic design. The second disulfide linkage was formed by 
simultaneous Acm group removal and oxidation using iodine-mediated oxidation 
condition.   
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SMeb SMeb
SAcm SAcm
Scheme 1.4 Regioselective folding strategy for synthesis of α-GI 
                     using Cys(Acm) and Cys(Meb)
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The synthesis of w-conotoxin MVIIA, which is a three disulfide bond containing peptide, 
has been done in a more selective approach using Acm, Mob and Trt protected 
cysteines.96 It allows a step-by-step oxidation by selective deprotection and oxidation of 
each pair of cysteine groups. First, selective Cys(Trt) deprotection was achieved together 
with total deprotection by TFA treatment. Then, air oxidation was performed to oxidize the 
free thiols to access the first disulfide bond. Iodine oxidation ensures selective cleavage 
of Acm and oxidation to introduce the second disulfide bond in the peptide. The fully 
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STrt STrt
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Scheme 1.5  A. Semi-directed folding strategy for synthesis of ω-MVIID using Cys(Acm) and Cys(Trt) 
                      B. Regioselective folding strategy for synthesis of ω-MVIIA using Cys(Acm), Cys(Mob) 
                           and Cys(Trt)
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folded peptide was completed by deprotection of Cys(Mob) to get the reduced cysteines 
followed by DMSO oxidation of free thiols. 
 A  method was reported in which DTNP was used to remove several commercially 
available protecting groups.97 In the regioselective synthesis of apamin, no Acm 
protection was applied, StBu and tBu groups were used to protect cysteine residues 
(Scheme 1.6). DTNP was used to deprotect both StBu and tBu groups, and the selectivity 
of one group removal over the other was achieved by the presence or absence of 
thioanisole in the reaction solution. As StBu group was found to be stable in DTNP 
reaction condition without thioanisole, Cys(tBu) deprotection was done first using DTNP 
in absence of thioanisol.  
 
1) DTNP / TFA
2) 1 equiv. DTT
1) DTNP / 2% thioanisole / TFA
2) 1 equiv. DTT
1) Piperidine / DMF
2) TFA / Scavengers
PeptideFmoc
StBu StBu
SStBu SStBu
NH2PeptideH
StBu StBu
SStBu SStBu
NH2PeptideH
S S
SAcm SAcm
NH2PeptideH
S S
S S
Scheme 1.6 Regioselective DTNP-mediated strategy for synthesis of apamin using 
                      Cys(tBu) and Cys(StBu)
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A bis-Npys-protected peptide was made upon removal of tBu group with DTNP, addition 
of DTT facilitated the first disulfide bond formation instantaneously. After purifying the 
mono-cyclic peptide, it was subjected to the same reaction condition, but with thioanisole, 
to deprotect Cys(StBu) and form second disulfide bond in the target peptide. 
Although most of the regioselective folding approaches have multiple disulfide 
formation steps with a distinct set of reagents for each step, one-pot regioselective 
method has been developed to synthesize a-conotoxin SI.98 (Scheme 1.7). In this one-
pot regioselective approach, combination of Meb and tBu protected cysteines were used, 
and synthesis was designed based on the difference temperature dependence of these 
groups towards DMSO / TFA / anisole oxidation.  
 
    
TFA / DMSO / anisole / 25 ºC
TFA / DMSO / anisole / 70 ºC
1) Piperidine / DMF
2) TFA / Scavengers
PeptideFmoc
SMeb SMeb
StBu StBu
Scheme 1.7 Regioselective in-solution folding strategy for synthesis of α-SI 
                     using Cys(Meb) and Cys(tBu)
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At room temperature, tBu protected cysteines rapidly get converted to the corresponding 
disulfide bond without affecting Meb group removal. Subsequent heating of the same 
reaction solution facilitates the deprotection and oxidation of Cys(Meb) groups to form the 
second disulfide bond. 
1.4.5.2 On-resin Regioselective Disulfide Bond Formation in Peptides 
 As an on-resin strategy, the regioselective disulfide formation is done while the 
peptide is still attached to the resin. The specific methods of on-resin disulfide formation 
(see Section 1.4.2) can be combined carefully, based on their orthogonality towards other 
excising cysteine protecting groups, to control formation of each disulfide bond in the 
peptide. One of the examples is use of Cys(Fm) in combination with Cys(Acm) to 
synthesize a-conotoxin GI using Boc chemistry (Scheme 1.8).99  
 
I2 / solvent
HF / Scavengers
1) Mercaptoethanol / DIEA / DMF / 1h
2) Piperidine / DMF
PeptideBoc
SAcm SAcm
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Scheme 1.8 Regioselective on-resin folding strategy for synthesis of α-GI
                     using Cys(Acm) and Cys(Fm)
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In this synthetic route, piperidine in DMF was used to base-labile Fm group and iodine-
mediated oxidation was used for simultaneous Acm removal and oxidation. Final peptide 
cleavage and side group deprotection has to be done using HF condition. This step is 
challenging as disulfide bonds are found to be unstable under highly acidic condition. 
Therefore, careful selection of scavengers is critical for isolation of the native isomer in 
good yields.  
Fmoc chemistry can be carried out as an alternative method to avoid HF conditions 
in the synthesis of disulfide bonds. Two different approaches have been reported to 
synthesize a-conotoxin GI by Fmoc chemistry (Scheme 1.9). The first approach (Scheme 
1.9.A) was done using Tmob group in combination with Acm group for cysteine 
protection.100 The challenging step in this protocol is deprotection of Cys(Tmob) residue, 
as it requires TFA conditions, which can affect the peptide cleavage from resin. Therefore, 
this step needs to be run carefully to avoid peptide loss. The resulting free thiols can be 
oxidized with CCl4-Et3N in NMP to form the first disulfide bond without Acm group 
removal. Second disulfide bond formation can be done by oxidation of Acm group with 
TI(TFA)3 in DMF in presence of anisole as the scavenger.  In the second approach 
(Scheme 1.9.B), the orthogonal combination of Acm and Xan group was used to obtain 
a selective disulfide bond formation.101 The deprotection and selective disulfide bond 
formation conditions were similar to that of approach A in Scheme 1.9. These methods 
illustrate the utility of orthogonal combination of Acm group with various other cysteine 
protecting groups to access multiple disulfide bonds on resin.  
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N-chlorosuccinimide-mediated oxidation can also be used in on-resin 
regioselective disulfide bond formation.79 Regioselective synthesis of a-conotoxin SI is 
reported utilizing NCS as only oxidant to form disulfide bonds (Scheme 1.10.A). 
Orthogonal combination of STmp and Mmt groups were chosen as cysteine protecting 
group for the synthesis, which is an example for an on-resin regioselective synthesis 
without Acm group protection. A solution of 2 equivalents NCS in DMF was needed for 
each oxidation step and each disulfide formation was completed in 15 min.    
TI(TFA)3 in DMF / anisole, 4 ºC
TFA / Scavengers
1) Piperidine / DMF
2) 7% TFA / DCM / Scavenger
3) CC4 / Et3N in NMP
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Scheme 1.9 Regioselective on-resin folding strategy for synthesis of α-SI using; A. Cys(Acm) and Cys(Fm) 
                     B. Cys(Acm) and Cys(Xan)
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A microwave-assisted on-resin regioselective disulfide formation method was reported for 
the synthesis of a-conotoxin MII102 (Scheme 1.10.B). This is a displacement method that 
can be used to form the first intramolecular disulfide bond in a regioselective scheme to 
access peptides with two disulfide bonds. For this method, three cysteine protecting 
groups were used, StBu, Mmt and Acm, and two of them were facilitated the displacement 
process to access first disulfide bond. 30% Mercaptoethanol in DMF was used to remove 
the StBu group under microwave heating. Upon addition of excess DTNP to the resulting 
on-resin peptide, reaction between the free thiol from StBu removal and DTNP forms an 
activated 5-Npys cysteine group. Removal of highly acid sensitive Mmt group under 
microwave heating facilitates the nucleophilic attack of free thiol on to the activated 
1) 2% TFA in DCM 
2) NCS (2 equiv) in DMF
   15min
TFA / Scavengers
1) Piperidine / DMF
2) 0.1M NMMin 5% DTT/DMF
3) NCS (2 equiv) in DMF
   15 min
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SSTmp SSTmp
SMmt SMmt
Scheme 1.10 A. Regioselective on-resin folding strategy for synthesis of α-SI using Cys(STmp) and 
                      Cys(Mmt) B. Regioselective on-resin folding strategy for synthesis of α-MII using Cys(StBu), 
                      Cys(Mmt) and Cys(Acm)
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cysteine to form the first disulfide bond by releasing one molecule of 5-nitropyridine-2-
thione. Neither the deprotection conditions nor activation process in this displacement 
step affects the Cys(Acm) group in the peptide. The second disulfide formation was 
achieved by traditional on-resin Acm removal and oxidation via iodine oxidation. The 
significance of this method is reduction in the time required for disulfide bond formation, 
which highlights the power of microwave heating in combination with a displacement 
method.  
1.4.5.3 On-Resin Oxidants for Regioselective Disulfide Bond Formation in Peptides 
 As described in section 1.4.3, there a several on-resin oxidants available for 
formation of disulfide bonds in peptides. Commercially available Clear-OX resin has been 
successfully applied in regioselective two-step disulfide formation procedure to access a-
conotoxin GI (Scheme 1.11).84 Both Xan and Acm groups were used to protect cysteine 
residues selectively and standard free thiol oxidation methods have been replaced by 
Clear-OX oxidation to form the first disulfide bond.    
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1.5 Objective of the Project 
 Cysteine-rich peptides, including plant derived protease inhibitors, defensins from 
both vertebrates and invertebrates and neurotoxins from spiders, scorpions and mollusks, 
demonstrate high potency and good target specificity, making them useful tool 
compounds in biomedical and pharmaceutical research. The importance of these 
peptides is not limited to exclusively to therapeutic peptides. They can also be used in 
other applications such as bioconjugation,103 b-sheet stabilization,104 siRNA delivery,105 
increasing in vivo stability,106 stabilization of peptide-based nanocarriers, and peptide 
backbone linkers.107,108 Due to their small size, chemical synthesis has been the method 
of choice to access these bioactive targets in large quantities. Although several strategies 
Clear-OX
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2) TFA / Scavengers
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Scheme 1.11 Regioselective on-resin folding strategy for synthesis of α-GI using 
                      solid supported oxidant (Clear-OX)
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have been developed to synthesize cysteine-rich mini-proteins, a convenient and 
straightforward preparation of the native disulfide bond connectivity in these peptides still 
needed to be investigated. The goal of this dissertation is to further explore cysteine 
protecting groups with effective deprotection conditions and develop efficient methods for 
on-resin regioselective disulfide bond formation to access disulfide-rich bioactive 
peptides. 
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CHAPTER 2: DIRECT Pd-MEDIATED ON-RESIN DISULFIDE BOND FORMATION 
FROM ALLOCAM PROTECTED PEPTIDES 
 
 
2.1 Introduction 
 The preparation of disulfide bonds in bioactive peptide is currently limited by the 
lengthy nature of solution-phase folding procedures. On-resin approach for disulfide bond 
formation is advantageous as it avoids multiple purification steps and reaction 
manipulations associated with solution-phase protocols. In addition, it favors 
intramolecular disulfide bond formation.74 Much effort has been devoted to the 
development of new cysteine protecting groups to improve the available toolbox to access 
disulfide-rich bioactive peptides. Although some of these groups are selective in their 
cleavage, several have practical limitations preventing their widespread use. In this 
chapter, we are reintroducing Allocam group as cysteine protecting group with novel Pd-
mediated deprotection-oxidation method to form on-resin disulfide bonds in peptides.   
 2.2 Allyloxycarbonylaminomethyl as Cysteine Protecting Group 
 Kunz and coworkers are the pioneers who introduced the allyl (All) and 
Allyloxycarbonyl (Alloc) protecting groups (Figure 1.1) in to the fields of peptide 
synthesis.109,110 The groups became increasingly popular due to their orthogonality with 
the widely used Boc chemistry and Fmoc chemistry in peptide synthesis.111 They can be 
selectively cleaved under mild condition by catalytic p-allyl palladium chemistry which 
involves combination of a palladium catalyst and a nucleophilic species as an allyl group 
scavenger.112 These groups have been used for a-amino and a-carboxy groups and 
various side chain reactive functionalities such as carboxylic groups of aspartic acid and 
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glutamic acid,113,114 phenolic groups of tyrosine,115 nitrogen functions of lysine116 or 
indole.117  However, neither the allyl nor the Alloc groups are suitable for thiol group 
protection in cysteine residues. The allyl thioesters are not cleaved by palladium and can 
undergo intermolecular nucleophilic attack by neighboring a-amino function under basic 
conditions of Fmoc removal or even during coupling processes.114 
 As an alternative group for allyl-based cysteine protection, the 
allyloxycarbonylaminomethyl (Allocam, Figure 1.1) group was introduced by Loffet and 
co-workers.118,119 It is stable in the basic conditions of Fmoc deprotection but only 
marginally stable under acidic conditions.  
 
Allocam protected thiols can be cleaved by palladium-catalyzed hydrostannolysis with 
Bu3SnH. A nucleophilic species should be in a reaction medium to trap the p-allyl entity 
before any rearrangements take place. Examples of such scavengers are N,N’-
dimethybarbituric acid (NDMBA),120 N-trimethylsilylamines121 and phenylsilane.122 In 
early studies of Allocam deprotection, it was found that the deprotection reaction stops at 
initial stage as a result of catalyst poisoning. The system of PdCl2(PPh3)2/Bu3SnH /AcOH 
was found as the best deprotection conditions to get rapid and complete removal of 
Allocam. The success of the procedure may be due to the combination of very high rate 
of the palladium catalyzed hydrostannolytic cleavage and presence of acetic acid, which 
prevent the catalytic poisoning.120 However, 5-10% of allyl thioether formation was 
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H
O
O
Allyl Alloc Allocam
Figure 2.1 Structure of Allyl, Alloc and Allocam groups
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observed during reaction.  In addition, the hydrostannolytic procedure give a mixture of 
the thiol, its tributylstannyl salt and minor amount of disulfide (Scheme 2.1). 
 
Therefore, isolation of the deprotected product is difficult. In order to characterize the 
product, the solvent and most of the acetic acid were evaporated and the crude reaction 
mixture was treated with iodine until persistence of I2 coloration. Reaction with iodine 
convert all thiols and their tin salts into disulfide. Theses disulfides were then purified from 
the side-products (catalyst and tin compounds) by appropriate extractive procedures 
followed by chromatographic purification.120 The acid lability of Allocam group, use of 
Bu3SnH as an allyl scavenger, and the observation of significant amounts of S-allylated 
side products in the deprotection process have limited the general use of Allocam group. 
To improve the acid stability of Allocam group, two new protecting group, Fsam and 
Fnam,  were introduced by substitution of an electron-withdrawing group on the carbonate 
nitrogen (Figure 2.2).123,124 Both Fnam and Fsam are completely stable to basic and 
acidic conditions used in both Boc and Fmoc based peptide synthesis and can be 
selectively cleaved by palladium-catalyzed allylic cleavage in the presence of 
nucleophiles (Scheme 2.2).124,125   
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Scheme 2.1 Reported cleavage and oxidation condition for Allocam
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However, in the deprotection process, they require additional acidic treatment to convert 
intermediate 2.2.A to the free thiol 2.2.B.  
 
The reported deprotection methods for Allocam, Fnam and Fsam groups result the 
reduced cysteine and a separate oxidation step need to be performed to access disulfide 
bond 2.1.C. 
2.3 Synthesis of Fmoc-Cys(Allocam)-OH 
 Loffet and co-workers have reported synthesis of Allocam protected thiols.120 The 
reported synthesis cannot be reproduced and hence, we developed an alternative 
approach starting from commercially available allyl chloroformate (Scheme 2.3). First, 
ammonia was bubbled through a solution of allyl chloroformate (2.3.A) to access the 
intermediate carbamate in 95% yield. Then, it was treated with paraformaldehyde and 
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Ba(OH)2, which generated hydroxymethyl carbamate (2.3.B) in 48% yield. Next, the 
hydroxymethyl group was activated with trimethylsilyl chloride and addition of Fmoc-
Cys(H)-OtBu produced fully protected cysteine (2.3.C) in 70% yield. Finally, the t-Bu ester 
was removed with 30% TFA to produce Fmoc-Cys(Allocam)-OH (2.3.D) in 99% yield.  
 
This approach can be used to synthesize Fmoc-Cys(Allocam)-OH in larger scale with 
good yields.    
2.4 Optimization of Solid Phase Peptide Synthesis (SPPS) using Fmoc-Cys(Allocam)-OH 
 With a convenient protocol to synthesize Fmoc-Cys(Allocam)-OH in hand, we 
wanted to develop new deprotection conditions and reintroduce Allocam group for 
cysteine protection in peptide synthesis. First, compatibility of Allocam as cysteine 
protecting group in Fmoc-SPPS process was evaluated. For the studies, a model peptide 
derived from the first 9 amino acid residues of islet amylod polypeptide was selected 
(IAPP1-9, Figure 2.3). The main reason for the selection of IAPP1-9 as the model peptide 
was its higher potential in formation of a disulfide linkage between the two cysteine 
residues without any secondary structures.125,126 In addition, linear synthesis of a peptide 
with 9 amino acid residues can be done relatively shorter period of time.  
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Initial SPPS was done on TGT resin using HATU as the coupling agent and DIPEA as 
the base under microwave heating. Single coupling step was sufficient enough to 
incorporate Fmoc-Cys(Allocam)-OH successfully into the linear IAPP1-9 sequence. 
Allocam group is stable to the TGT resin cleavage condition, TFE:AcOH:DCM (1:1:3). 
Moreover, Fmoc-Cys(Allocam)-OH is compatible with SPPS on CTC, Wang and Rink 
amide resins. When cleaving peptides from Wang and Rink amide resins, the Allocam 
group get cleaved with 95% TFA condition. In order to cleave peptides from Wang and 
Rick amide resins, without affecting Allocam removal, a cleavage solution of 30% TFA in 
DCM in presence of a scavenger can be used.     
2.5 Palladium-Mediated On-Resin Disulfide Formation in Peptides using Allocam 
Protected cysteines 
 As mentioned in section 2.2, removal of Allocam group can be done selectively via 
p-allyl palladium chemistry. We envisioned a combination of palladium mediated Allocam 
cleavage and in situ oxidation to access disulfide bonds in a single step (Scheme 2.4). If 
a Pd(II) pre-catalyst 2.4.A is employed to the process, first, in situ reduction would convert 
KCNTATCATH OH
S S
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37
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Figure 2.3 Structure of Islet amyloid polypeptide and the model peptide
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Pd(II) to Pd(0). Then, Pd(0) complex 2.4.B coordinates to the p-allyl system in Allocam 
protected thiol 2.4.C and generate the system 2.4.D.  
 
Next, oxidative addition of Pd(0) complex leads to cationic p-allyl Pd(II) species 2.4.E and 
intermediate 2.4.F. The intermediate 2.4.F can undergo decarboxylation to release an 
equivalent of formimine, and liberates the thiol. The p-allyl Pd(II) species 2.4.E undergoes 
nucleophilic attack to turn over the catalyst (2.4.G then 2.4.B) and release the allylated 
nucleophile. In presence of an oxidant, the thiol can undergo in situ oxidation to form a 
disulfide bond. 
In Albericio and co-workers’ study of cleavage conditions for an allyl aspartate, 
they observed undesired disulfide bond formation when a mixture of DMSO, AcOH, and 
NMM was used in combination with Pd(PPh3)3 complex.127 These conditions were taken 
as the starting point for our investigation and the model peptide IAPP1–9 was subjected to 
different Pd complexes with various solvent systems and additives (Table 2.1). First, 5 
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equivalents of  Pd(PPh3)4  in a DMSO/THF solvent mixture was used in presence of 3% 
NMM and 5% AcOH (entry 1). A mixture of unreacted starting peptide (2.5.B), desired 
disulfide (2.5.C), and the mono-Allocam version of the starting peptide was observed after 
2 hours. When the amount of NMM was increased, an increment in the conversion of 
disulfide was observed. In addition, ∼1% mono-S-allylated product was observed along 
with the mono-Allocam side product (entry 2). With 7 equivalent Pd(PPh3)4, the desired 
disulfide was observed as the major product (80% conversion) in addition to the minor 
amounts of mono-Allocam, reduced, and mono- and bis-allylation products (entry 3). 
Next, the Pd(0) source was switched to Pd(II) complexes due to the practical difficulties 
in handling air sensitive Pd(0) complexes. When Pd(dppf)Cl2·CH2Cl2 was used in 
presence of regular DMSO-AcOH-NMM solvent system, the reaction was completely shut 
down and no disulfide bond formation was observed (entry 4). However, repeating this 
reaction in the presence of 20 equivalent of phenylsilane resulted in nearly complete 
conversion to the desired disulfide bond, and most importantly, with no S-allylation by 
products (entry 5). Beside Pd(dppf)Cl2·CH2Cl2, Pd(OAc)2 was used as the Pd(II) complex 
for this reaction. In the presence of 7 equivalent of Pd(OAc)2, 10% NMM, and 5% AcOH 
in DMSO, about <5% starting material was observed within 2 hours as well as a small 
amount of mono-Allocam peptide (entry 6). Lowering the loading to 5 equivalent and 
increasing the reaction time to 4 hours led to complete disulfide formation with no side 
products (entry 7). However, further reduction in the loading of Pd(OAc)2 to only 1 
equivalent resulted insignificantly reduced conversion and increased side product 
formation (entry 8). Therefore, the loading of Pd(OAc)2 was slightly increased to 1.5 
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equivalent (entry 9), and a nearly complete conversion was observed. When less NMM 
was used the reaction can be pushed towards a 100% conversion of the desired product 
(entry 10). 
 
These were taken as the optimized conditions for the NovaSynTGT resin. As PEG resins 
have superior swelling properties relative to polystyrene resins,128,129,130 we wanted to 
evaluate the reaction conditions on ChemMatrix resin. After linear synthesis of the model 
peptide IAPP1-9 on ChemMatrix resin, the reaction was performed with lower loadings of 
aUnless otherwise noted, reaction was performed using 10 mg of TGT resin (loading 0.2 
mmol/g) and 250 µL total volume (all liquids). LCMS analysis is performed directly on crude 
peptide following removal of solvents from resin cleavage. b NovaSyn PEG-PS copolymer 
resin with TGT linker, preloaded with Fmoc-Thr(OtBu). c Aminomethyl ChemMatrix Resin 
manually functionalized with TGT linker. d 20 equiv PhSiH3 added. e Ratio determined by 
integration of relevant peaks in mass spectra. f 1 Allocam remaining. g 2 Free thiols. h 1 S-
Allyl. i 2 S-Allyls.
Table 2.1 On-resin deprotection/oxidation optimization for model peptide (IAPP1-9)
catalyst equiv
additive (%v/v) time
(h)NMM AcOH
1.b
solvent 2.5.B : 2.5.C : othereentry
Pd(PPh3)4 5.0 2 57 34
2.b
3% 5% DMSO:THF (1:1)
3.b
Pd(PPh3)4 5.0 10% 5% DMSO:THF (1:1) 2 11 71
4.b
Pd(PPh3)4 7.0 10% 5% DMSO:THF (1:1) 2 1 80
5.b,d
Pd(dppf)Cl2 7.0 10% 5% DMSO 2 100 0
6.b
Pd(dppf)Cl2 7.0 10% 5% DMSO 2 2 98
7.b
Pd(OAc)2 7.0 10% 5% DMSO 2 4 93
Pd(OAc)2 5.0 10% 5% DMSO 4 0 100
9f
18f,h
19f-i
0
0
3f
0
8.b
9.b
Pd(OAc)2 1.0 10% 5% DMSO 4 10 63
10.b
Pd(OAc)2 1.5 10% 5% DMSO 4 4 96
11.c
Pd(OAc)2 1.5 3% 5% DMSO 4 0 100
12.c
Pd(OAc)2 0.75 3% 5% DMSO 4 89 11
13.c
Pd(OAc)2 1.0 3% 5% DMSO 4 50 50
Pd(OAc)2 1.5 3% 5% DMSO 2 0 100
27f,g
0
0
0
0
0
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tBu tBu
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Pd(OAc)2 (entries 11 and 12). Upon exposure to 0.75 or 1.0 equiv Pd(OAc)2, only 11 or 
50% conversion was observed after 4 h. However, under the previously optimized 
conditions, complete conversion was observed after 2 h instead of 4 h (entry 13). Overall, 
we were delighted with the low loadings of palladium needed for the transformation.131 
Addition of a Pd scavenger to the rinsing procedure prevents any detectable 
contamination of the cleaved products. Most importantly, neither partially deprotected nor 
S-allylated products were observed with the optimized Allocam deprotection-oxidation 
conditions. 
 Moreover, we were interested in understanding the mechanism of Pd-DMSO 
mediated simultaneous Allocam removal and oxidation. To evaluate the function of each 
component in the reaction system and to understand how each component affects 
reactivity of the reaction, a set optimization were done. In the optimization process 
reactions were done by removing each component from the optimized condition at a time 
to evaluate the role of the component in deprotection-oxidation process. In addition, 
components such as NMM and AcOH were replaced by ionic NH4OAc to understand the 
mechanism of action. Further details are needed to conclude the mechanism of Pd-
DMSO mediated simultaneous Allocam cleavage-oxidation and the investigations are still 
ongoing in our lab     
2.6 Synthesis of Oxytocin using Allocam Protected Cysteine 
 With optimized conditions in hand, we wanted to utilize this direct, on-resin 
disulfide bond formation method to form disulfide bond in oxytocin.132,133,134,135 Oxytocin 
is a neurotransmitter which has 9 amino acid residues and one disulfide bond. Carboxy-
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oxytocin was synthesized in order to facilitate analysis of the disulfide bond forming 
reaction. Linear synthesis of the peptide 2.6.A was done on a TGT-linked ChemMatrix 
resin via Fmoc-SPPS. The resulting fully protected peptide was subjected to Pd-DMSO 
mediated simultaneous Allocam cleavage and oxidation conditions (Table 2.2). First, the 
optimized conditions for IAPP1-9 was used and only ~80% conversion of the product 2.6.C 
was observed after 6 hours (Entry 1). Then, Pd(OAc)2 loading was increased to 3.0 
equivalent and it facilitated a complete conversion of folded peptide 2.X.B (Entry 2).  The 
resulting folded peptide was cleaved from the resin followed by side chain protecting 
groups deprotection. 
 
Fully deprotected carboxy-oxytocin was purified via RP-HPLC and 32% isolated yield was 
obtained.  
2.7 Summary 
 In this study, Allocam group was reintroduced to the field of peptide synthesis as 
a cysteine protecting group with novel Pd-mediated deprotection-oxidation method to 
form disulfide bonds on resin. This is a one-pot approach, which avoids solution-phase 
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manipulations of the peptide and minimizes the number of time consuming purification 
steps. No special equipment is needed and the reaction can be done with bench-stable 
reagents. Reaction conditions were optimized for no trace of Pd or S-allylated byproducts. 
The utility of the method was demonstrated by solid phase synthesis and folding of the 
carboxy-oxytocin, which consist of single disulfide bond. This method can be broadly 
applied in the synthesis of more complex targets with multi-disulfide bonds. Detailed 
investigations into the mechanism of Pd-DMSO mediated simultaneous Allocam removal 
and oxidation are still ongoing.        
2.8 Materials and Methods 
2.8.1 General Information  
 Unless otherwise specified, all commercially available reagents were purchased from 
Sigma-Aldrich and used without further purification. Anhydrous Et2O, MeCN, DMF, 
DMSO, CH2Cl2 were purchased from Fisher. These were passed through a commercial 
solvent purification system (2 columns of alumina) and used without further drying. 
Hünig’s base was distilled over CaH2 immediately prior to use. All amino acids were 
purchased from Chem-Impex Int’l. Inc. unless otherwise noted. HATU were purchased 
from Chem-Impex Int’l. Inc. Unless otherwise noted, all reactions were performed in 2 mL, 
5 mL and 10 mL Biotage reactor vials with PTFE frit (depend on reaction volume) at room 
temperature. All yields refer to chromatographically and spectroscopically pure products. 
All HPLC analyses and purifications were performed on a Custom Reverse Phase 
Shimadzu Liquid Chromatograph Mass Spectrometer (LCMS-2020), which can toggle 
between analytical and semi-preparative columns. This instrument has a photodiode 
 
 
43 
array (PDA) detector (D2 & W lamp), which collects a range of wavelengths, in place of 
a traditional single channel UV detector. RP-HPLC-MS mobile phases (MeCN and H2O) 
contained 0.1% Formic Acid. Analytical HPLC was performed on a Phenomenex Kinetex 
C18 column (5 µm, 250 x 4.6 mm) and a Thermo Scientific Hypersil Gold C8 column (5 
µm, 250 x 4.6 mm). Semi-Preparative HPLC was conducted using a Thermo Scientific 
Hypersil Gold C8 column (5 µm, 150 x 10 mm). All peptide yields are calculated based 
on the final loading. 
Fmoc-SPPS General Information. Solid-phase peptide synthesis was executed on a 
Biotage Isolera+ semi-automated synthesizer with microwave heating. 
•   Reactor Vials [Vial size (Volume range allowed)]: 2 mL reactor vial (0.8-1.1 mL), 5 mL 
reactor vial (1.6-3.2 mL), and 10 mL reactor vial (3.2-6.4 mL) 
•   Swelling + Heat: DMF was added and vortexed at 1200 RPM for 20 m at 70 ºC. The 
solvent was then removed over 1 m followed by two DMF washes (DMF was added 
and the suspension was vortexed at 600 RPM for 45 s, followed by the removal of 
solvent (over 2 m)).  
•   Coupling: A solution of Fmoc-aa-OH (3 equiv), HATU (3 equiv), and DIPEA (6 equiv) 
in DMF was made immediately prior to addition to the reaction vial containing the 
resin. Once the solution was added, the suspension was heated to 75 ºC (except for 
Fmoc-Cys-OH which was heated to 50 ºC) for 5 minutes with a vortex rate of 1200 
RPM. After the reaction, the solution was removed (over 2 m) and the resin was rinsed 
with DMF 4 times (after addition of DMF, the suspension was agitated at a vortex rate 
of 1200 RPM for 1 m, solvent removal was at a rate of 2 m). 
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•   Fmoc Removal (Deprotection): The reactor vial was filled with 20% piperidine in DMF. 
The suspension was vortexed at 1200 RPM for 3 m at RT. The solvent is removed 
followed by addition of 20% piperidine in DMF. The suspension is vortexed again at 
1200 RPM for 10 m at RT. The solvent was removed over 2 m, followed by 4 DMF 
washes (after addition of DMF, the suspension was agitated at a vortex rate of 1200 
RPM for 1 m, solvent removal was at a rate of 2 m). 
•   Wash: DMF was added to the reaction vial and agitated at a vortex rate of 1200 RPM 
for 1 m. The solvent was removed over 1 m and repeated for a total of 4 times. 
•   Final Wash: Resin was rinsed with CH2Cl2 (3 x 1 mL) and MeOH (3 x 1 mL). 
•   Drying for Storage/Weighing: After the final wash, the resin was placed on the 
lyophilizer overnight for drying. 
General Procedure for Capping - First, 25% acetic anhydride in DMF (3 mL) was added 
and agitated for 5 min. Then,1.5 eqiuv. of DIPEA was added to the reaction and agitated 
for 30 min. Finally, the reaction solution was filtered and the resin was washed with DMF 
(5 x 3 mL). 
Procedure for Resin Loading Analysis. Initial and final loading of resin was analyzed 
based on amount of Fmoc group. 
Fmoc Deprotection – 10 mg of the resin was weighed out and swelled in DMF in the 
peptide synthesizer. Then, 1.00 ml of 20% piperidine in DMF was added and it was 
allowed to vortex in the peptide synthesizer at room temperature for 3 min. After 3 min, 
the filtrate was collected in to a separate tube, another 1.00 ml of 20% piperidine in DMF 
was added to it and allowed to vortex in the peptide synthesizer at room temperature for 
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10 min. The resulting filtrate was collected to the same tube and the deprotected resin 
was washed with DMF (4 x 1.75 ml). 
Sample preparation for UV analysis – From the collected ”deprotection solution” above, 
100 µL was transferred in to an eppendorf tube and it was diluted with 900 µl of DMF. 
The resulting diluted sample was used to get the absorbance at 301 nm versus a DMF 
blank using a UV spectrometer with 1 cm cuvette. 
2.8.2 Experimental Procedures and Spectroscopic Data  
 
 
 
 
Synthesis of IAPP1-9 (2.5.A). The standard Fmoc-SPPS protocol described was used to 
synthesize IAPP1-9 on preloaded TGT resin 2.5.A’ using a semi-automated peptide 
synthesizer, in a 10-mL reaction vial. First, the resin was swelled followed by deprotection. 
Then, each amino acid was added accordingly followed by coupling and deprotection 
steps. Finally, the resin + peptide was washed with DCM and Methanol. To analyze the 
peptide, 10 mg of the resin was subjected to 300 µL of the cleavage mixture (1:1:3 
TFE:AcOH:DCM)  for 30 min. The filtrates were collected, concentrated and analyzed by 
RP-HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow 
rate of 1 mL/min with 40-80% MeCN/H2O gradient for 60 minutes. m/z ES calc’d for 
Allocam IAPP (2.5.A) [(C80H121N13O20S2)+1]+: 1648.83; observed: 1649.60; m/z ES calc’d 
for [(C70H105N11O16S2 + 2)/2]+: 824.92; observed: 825.30. 
SPPS
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Figure 2.4 Analytical Column PDA for linear IAPP1-9 2.5.A; Gradient: 40-80% MeCN/H2O + 1% HCOOH  
over 60 min. Retention time 27.26 min 
 
 
Figure 2.5 ES-MS spectrum for linear IAPP1-9 2.5.A  
 
 
 
 
        
Linear IAPP1-9 (2.5.A) [M+1]+ 
 
Linear IAPP1-9 (2.5.A) [(M+2)/2]+ 
 
PDA, 190 nm 
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General Procedure for Allocam Cleavage/Oxidation for IAPP1-9 (Table 2.1). IAPP1-9 
on the stated resin (10 mg, 2.0 µmol) was swelled in DMF (800 µL) on the Biotage Isolera+ 
synthesizer. After removing excess DMF, the cartridge was removed from the synthesizer 
and capped on the bottom. A solution of the stated catalyst in 5% AcOH/DMSO 
solution (250 µL) was added, and then the stated amount of PhSiH3 (if relevant) 
and NMM were added. The cartridge was capped on the top, attached to a 
magnetic stirbar retriever using a rubber band (see image), and agitated for the 
stated amount of time under an atmosphere of ambient air. The reaction was filtered then 
transferred back to the synthesizer, where it was washed successively: 1) 750 µL of DMF 
was added and vortexed 2 min, then filtered (3 total times), 2) 750 µL of CH2Cl2 was 
added and vortexed 2 min, then filtered (3 total times), 3) 800 µL of 0.2 M sodium 
diethyldithiocarbamate in DMF was added and vortexed 15 min, then filtered (3 total 
times). *Note: resin changes from dark orange/brownish to yellowish/tan. 4) 750 µL of 
DMF was added and vortexed 2 min, then filtered (5 total times), 5) 750 µL of CH2Cl2 was 
added and vortexed 2 min. The resin was then subjected to a cleavage mixture of 
TFE:AcOH:DCM (1:1:3, 300 µ ) for 3 x 15 min (not on synthesizer). The filtrates were 
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collected and concentrated with a stream of nitrogen gas. The concentrated solution was 
analyzed directly (with no lyophilization) by analytical HPLC-MS using a Hypersil GOLD 
column (5 µL, 150 x 4.6 mm) at a flow rate of 1 mL/min with 20–80% MeCN/H2O gradient 
for 60 min. The possible expected masses are: 
m/z ES calc’d for Allocam IAPP (2.5.A) [(C80H121N13O20S2)+1]+: 1648.83; observed: 1649.60; m/z 
ES calc’d for [(C70H105N11O16S2 + 2)/2]+: 824.92; observed: 825.30. 
m/z ES calc’d for IAPP Disulfide (2.5.B) [(C70H105N11O16S2)+1]+: 1420.72; observed: 1421.05; m/z 
ES calc’d for [(C70H105N11O16S2 + 2)/2]+: 710.86; observed: 711.100. 
m/z ES calc’d for 1-Allocam (2.5.C) [(C70H105N11O16S2)+1]+: 1535.78; observed: 1535.00; m/z ES 
calc’d for [(C70H105N11O16S2 + 2)/2]+: 768.39; observed: 767.85. 
m/z ES calc’d for free thiols (2.5.D) [(C70H105N11O16S2)+1]+: 1422.73; observed: 1422.25; m/z ES 
calc’d for [(C70H105N11O16S2 + 2)/2]+: 711.86; observed: 712.10. 
m/z ES calc’d for 1 allyl (2.5.E) [(C70H105N11O16S2)+1]+: 1462.77; observed: 1463.15; m/z ES calc’d 
for [(C70H105N11O16S2 + 2)/2]+: 731.88; observed: 732.20. 
m/z ES calc’d for 2 allyls (2.5.F) [(C70H105N11O16S2)+1]+: 1502.80; observed: 1502.25; m/z ES 
calc’d for [(C70H105N11O16S2 + 2)/2]+: 751.90; observed: 752.15. 
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Table 2.1, entry 1. The general procedure was followed. The relevant quantities are: 
Pd(PPh3)4 (11.6 mg, 10 µmol), NMM (6.3 µL, 58 µmol). The reaction mixture was agitated 
in a closed vial at room temperature for 2 hours.  
 
 
Figure 2.6 Analytical Column PDA for determination of conversion; Table 2.1. Entry 1.  
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min. 
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Table 2.1, entry 2. The general procedure was followed. The relevant quantities are: 
Pd(PPh3)4 (11.6 mg, 10 µmol), NMM (25 µL, 227 µmol). The reaction mixture was agitated 
in a closed vial at room temperature for 2 hours.  
 
 
Figure 2.7 Analytical Column PDA for determination of conversion; Table 2.1. Entry 2.  
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min. 
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Table 2.1, entry 3. The general procedure was followed. The relevant quantities are: 
Pd(PPh3)4 (16.2 mg, 14 µmol), NMM (25 µL, 227 µmol). The reaction mixture was agitated 
in a closed vial at room temperature for 2 hours.  
 
 
Figure 2.8 Analytical Column PDA for determination of conversion; Table 2.1. Entry 3.  
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min. 
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Table 2.1, entry 4. The general procedure was followed. The relevant quantities are: 
Pd(dppf)Cl2 (11.4 mg, 14 µmol), NMM (25 µL, 227 µmol). The reaction mixture was 
agitated in a closed vial at room temperature for 2 hours.  
 
 
Figure 2.9 Analytical Column PDA for determination of conversion; Table 2.1. Entry 4.  
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min. 
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Table 2.1, entry 5. The general procedure was followed. The relevant quantities are: 
Pd(PPh3)4 (11.4 mg, 14 µmol), PhSiH3 (5 µL, 40 µmol), NMM (25 µL, 227 µmol). The 
reaction mixture was agitated in a closed vial at room temperature for 2 hours.  
 
 
Figure 2.10 Analytical Column PDA for determination of conversion; Table 2.1. Entry 5.  
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min. 
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Table 2.1, entry 6. The general procedure was followed. The relevant quantities are: 
Pd(OAc)2 (3.1 mg, 14 µmol), NMM (25 µL, 227 µmol). The reaction mixture was agitated 
in a closed vial at room temperature for 2 hours.  
 
 
Figure 2.11 Analytical Column PDA for determination of conversion; Table 2.1. Entry 6.  
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min. 
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Table 2.1, entry 7. The general procedure was followed. The relevant quantities are: 
Pd(OAc)2 (2.2 mg, 10 µmol), NMM (25 µL, 227 µmol). The reaction mixture was agitated 
in a closed vial at room temperature for 4 hours.  
 
 
Figure 2.12 Analytical Column PDA for determination of conversion; Table 2.1. Entry 7.  
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min. 
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Table 2.1, entry 8. The general procedure was followed. The relevant quantities are: 
Pd(OAc)2 (0.45 mg, 2 µmol), NMM (25 µL, 227 µmol). The reaction mixture was agitated 
in a closed vial at room temperature for 4 hours.  
 
 
Figure 2.13 Analytical Column PDA for determination of conversion; Table 2.1. Entry 8.  
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min. 
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Table 2.1, entry 9. The general procedure was followed. The relevant quantities are: 
Pd(OAc)2 (0.67 mg, 3 µmol), NMM (25 µL, 227 µmol). The reaction mixture was agitated 
in a closed vial at room temperature for 4 hours.  
 
 
Figure 2.14 Analytical Column PDA for determination of conversion; Table 2.1. Entry 9.  
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min. 
 
 
 
 
 
 
        
Starting peptide (2.5.B) [M+1]+ 
 
Starting peptide-1Allocam (2.5.D) [M+1]+ 
 
Oxidized Pdt (2.5.C) [M+1]+ 
 
Isotope of Oxi Pdt (2.5.D) [M+1]+ 
 
1 S-Allyl (2.5.E) [M+1]+ 
 
2 S-Allyl (2.5.F) [M+1]+ 
PDA, 214 nm 
 
 
 
 
 
58 
Table 2.1, entry 10. The general procedure was followed. The relevant quantities are: 
Pd(OAc)2 (0.67 mg, 3 µmol), NMM (7.5 µL, 68.4 µmol). The reaction mixture was agitated 
in a closed vial at room temperature for 4 hours.  
 
 
Figure 2.15 Analytical Column PDA for determination of conversion; Table 2.1. Entry 10.  
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min. 
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Table 2.1, entry 11. The general procedure was followed. The relevant quantities are: 
Pd(OAc)2 (0.34 mg, 1.5 µmol), NMM (7.5 µL, 68.4 µmol). The reaction mixture was 
agitated in a closed vial at room temperature for 4 hours.  
 
 
Figure 2.16 Analytical Column PDA for determination of conversion; Table 2.1. Entry 11.  
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min. 
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Table 2.1, entry 12. The general procedure was followed. The relevant quantities are: 
Pd(OAc)2 (0.45 mg, 2 µmol), NMM (7.5 µL, 68.4 µmol). The reaction mixture was agitated 
in a closed vial at room temperature for 4 hours.  
 
 
Figure 2.17 Analytical Column PDA for determination of conversion; Table 2.1. Entry 12.  
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min. 
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Table 2.1, entry 13. The general procedure was followed. The relevant quantities are: 
Pd(OAc)2 (0.67 mg, 3 µmol), NMM (7.5 µL, 68.4 µmol). The reaction mixture was agitated 
in a closed vial at room temperature for 2 hours.  
 
 
Figure 2.18 Analytical Column PDA for determination of conversion; Table 2.1. Entry 13.  
Gradient: 20-80% MeCN/H2O + 1% HCOOH over 60 min. 
 
 
 
 
 
 
 
 
        
Starting peptide (2.5.B) [M+1]+ 
 
Starting peptide-1Allocam (2.5.D) [M+1]+ 
 
Oxidized Pdt (2.5.C) [M+1]+ 
 
Isotope of Oxi Pdt (2.5.D) [M+1]+ 
 
1 S-Allyl (2.5.E) [M+1]+ 
 
2 S-Allyl (2.5.F) [M+1]+ 
 
PDA, 214 nm 
 
 
 
 
 
62 
 
TGT-ChemMatrix Resin. The coupling of 4-(diphenylhydroxy methyl)benzoic acid on to 
the Aminomethyl ChemMatrix resin was done using the semi-automated peptide 
synthesizer, in a 10-mL reaction vial. The general procedure was followed. The relevant 
quantities are: Aminomethyl ChemMatrix resin (200 mg, 0.112 mmol), 4-(diphenylhydroxy 
methyl)benzoic acid (170.4 mg, 0.56 mmol), HATU (212.9 mg, 0.56 mmol), and DIPEA 
(195 µl, 1.12 mmol). After the coupling, the reaction vial with the resin was taken out from 
the synthesizer and 25% acetic anhydride in DMF (3 mL) was added. It was agitated for 
5 min and then DIPEA (30 µl, 0.168 mmol) was added and agitated for another 30 min. 
After the reaction, the solution was removed and the resin was rinsed with DMF 4 times. 
Next, 1M NaOH (3 mL) was added to the resin and agitated for 12 h. At the end of the 
reaction, the solution was removed followed by 4 DMF washes. To the resulting resin in 
a close-sealed vial, 2% SOCl2 in DCM (3 mL) was added and agitated for 12 h. Finally, 
the solution was removed and the resin was rinsed with DCM 5 times and 2% DIPEA in 
DCM 3 times. 
Fmoc-Gly-TGT-ChemMatrix. The resin was swelled in DMF and a solution of the desired 
Fmoc-Gly-OH (5 equiv) with DIPEA (6 equiv) in DMF was added. Then the resulting 
reaction vial was agitated at RT for 12 h. After the reaction, the solution was drained out 
and the resin was rinsed with DMF, DCM and MeOH (3 times each). Finally, the resin 
was dried in the lyophilizer for 12 h. 
CMH2N TGTGlyFmoc
Aminomethyl
ChemMatrix Resin
Fmoc-G-TGT
ChemMatrix Resin
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Synthesis of Linear Oxytocin (2.6.A). The standard Fmoc-SPPS protocol described 
was used to synthesize linear peptide 2.6.A on Fmoc-Gly-TGT-Chemmatric resin 2.6.A’ 
using a semi-automated peptide synthesizer, in a 10-mL reaction vial. First, the resin was 
swelled followed by deprotection. Then, each amino acid was added accordingly followed 
by coupling and deprotection steps. Finally, the resin + peptide was washed with DCM 
and Methanol. To analyze the peptide, 10 mg of the resin was subjected to 300 µL of the 
cleavage mixture (1:1:3 TFE:AcOH:DCM)  for 30 min. The filtrates were collected, 
concentrated and analyzed by RP-HPLC-MS using an analytical Phenomenex column at 
a flow rate of 1 mL/min with 5-95% MeCN/H2O gradient for 30 minutes. Final loading: 
0.13 mmol/g. m/z ES calc’d for linear peptide 2.6.A [(C95H117N13O17S2)+1]+: 1777.18; 
observed: 1776.95. 
 
Figure 2.19 Analytical Column PDA for linear carboxy-oxytocin 2.6.A; Gradient: 2-95% MeCN/H2O + 1% HCOOH  
over 30 min. Retention time 14.92 min 
SPPS
2.6.A’
TGTGlyFmoc
Trt
tBu
Trt
CYIQNCPLGH
S S Allocam
Allocam
2.6.A
TGT
9
        
Linear peptide (2.6.A); [M+1]+ 
 
PDA 214 nm 
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Figure 2.20 ES-MS spectrum for linear carboxy-oxytocin 2.6.A at retention time 14.92 min  
 
 
 
 
 
Optimized Conditions for On-Resin Folding of Oxytocin-OH (2.6.A ® 2.6.C). The 
IAPP standard protocol was followed. The relevant quantities are: Pd(OAc)2 (1.34 mg, 6 
µmol, 3 equiv), NMM (7.5 µL, 68.4 µmol). The reaction mixture was agitated in a closed 
vial at room temperature for 6 hours. The resin was then subjected to a cleavage mixture 
of TFE:AcOH:DCM (1:1:3, 300 µ ) for 3 x 1 h. The resin was then subjected to a cleavage 
mixture of TFE:AcOH:DCM (1:1:3, 300 µ ) for 3 x 1 h. The filtrates were collected and 
analyzed directly (with no lyophilization) by analytical HPLC-MS using a Phenomenex 
column (5 µL, 250 x 4.6 mm) at a flow rate of 1 mL/min with 50–90% MeCN/H2O gradient 
for 30 min. The side chain protecting groups were then cleaved with 95:2.5:2.5 
TFA:TIPS:H2O,, the peptide was crashed out with cold ether, redissolved in 1:1 MeCN/H-
OH
Trt
tBu
Trt
Trt
tBu
Trt
CYIQNCPLGH
S S Allocam
Allocam
CYIQNCPLGH
S S
1) 3.0 equiv. Pd(OAc)2, 
    DMSO-AcOH-NMM, 6 h
  
2) TFE:AcOH:CH2Cl2 
    (1:1:3), 3 x 1 h
2.6.C2.6.A
CYIQNCPLGH
S S
Trt
tBu
Trt
Allocam
Allocam
2.6.B
OHTGT
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2O, and lyophilized. The resulting white solid was purified on a Hypersil GOLD column (5 
µL, 150 x 10 mm) at a flow rate 5 mL/min with 10–50% MeCN/H2O gradient for 30 min. 
The purified product was analyzed by analytical HPLC-MS using a Phenomenex column 
(5 µL, 250 x 4.6 mm) at a flow rate of 1 mL/min with 10–50% MeCN/H2O gradient for 30 
min. m/z ES calc’d for carboxy-oxytocin [(C43H66N12O12S2)+1]+: 1007.19; observed: 
1008.25. 
 
 
 
Figure 2.21 Analytical Column PDA for crude carboxy-oxytocin 2.6.C. Gradient: 10-50% MeCN/H2O + 1% HCOOH 
over 30 min. Retention time 17.67 min 
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Figure 2.22 Analytical Column PDA for pure carboxy-oxytocin 2.6.C. Gradient: 10-50% MeCN/H2O + 1% HCOOH 
 over 30 min. Retention time 17.67 min 
 
 
 
 
 
Figure 2.23 ES-MS spectrum for pure carboxy-oxytocin 2.6.C at retention time 17.67 min  
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CHAPTER 3: ASSESSING ALLOCAM: 
ON-RESIN SYNTHESIS AND CONTROLLED FOLDING OF a-CONOTOXIN LvIA 
 
 
3.1 Introduction  
   Conotoxins are a group of neuroactive peptides with multiple disulfide linkages 
and have considerable potential as both therapeutics and biochemical probes.136,137 The 
synthesis of conotoxins would enable both biological studies and evaluation of both the 
ion-gated and ligand-gated structures as lead target for therapeutics.138,139 The success 
in  synthesis of oxytocin using Allocam-protected cysteine led us to discover the potential 
of our Pd0/II - DMSO based Allocam cleavage-oxidation strategy to generate two disulfide 
linkages in peptides with their desired pattern. This chapter details two on-resin synthetic 
approaches to access a4/7-conotoxin LvIA using Allocam in combination with other 
cysteine protecting groups.  
3.2 a4/7-Conotoxin LvIA 
3.2.1 a4/7-Conotoxin LvIA: Structure and Bioactivity 
 a4/7-conotoxin LvIA is a C-terminally amidated mini-peptide from C. lividus with 
16 amino acid residues. It is the first a-conotoxin isolated from C. lividus and has 4 
cysteine residues, resulting two disulfide bridges with constrained conformation.140 These 
disulfide bridges lie between Cys2-Cys8 and Cys3-Cys16 (Figure 3.1). The first loop or 
bridge contains 4 amino acid residues, and the second loop consists of 7 amino acid 
residues. 
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Being an a-conotoxin, a4/7-conotoxin LvIA has unique selectivity on nicotinic 
acetylcholine receptors (nAChRs) subtypes and mainly block mammalian neuronal 
nAChRs.141 Neuronal nAChRs consists of combinations of a (a2-a10) and b (b2-b4) 
subunits and exit as a complex family of heteromeric and homooligomeric pentameric 
proteins.142 These subtypes are important in normal physiology and in a wide range of 
disease states such as pain, addiction, Alzheimer’s disease, myasthenia gravis, 
schizophrenia, epilepsy, and breast and lung carcinoma.143,144 a-conotoxins are valuable 
tools for identifying and probing the composition and roles of nAChR subtypes.145 
Interestingly, a4/7-conotoxins have the ability to discriminate between diverse neuronal 
a-b nAChR subunit combinations. a4/7-conotoxin LvIA is selective for the a3b2 nAChR, 
and it is the first a-conotoxin that blocks human a3b2 with high selectivity over a6b2* 
nAChRs.146 The receptor residues involved in its binding have been identified, and an 
analog has been generated that selectively targets a3b2 and a3b6 nAChRs. This analog 
also facilitated the identification of a3b4* receptors as the major subtype present in human 
adrenal chromafinn cells.147 
 
 
NH2GCCSHPACNVDHPEICH
S S
S S
Gly1-Cys2-Cys3-Ser4-His5-Pro6-Ala7-Cys8-Asn9-Val10-Asp11-His12-Pro13-Glu14-Ile15-Cys16H NH2
S S
S S
16
A.
B.
Figure 3.1 A. Structure of α4/7-conotoxin LvIA B. Graphical represtation of α4/7-conotoxin LvIA structure
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3.2.2 a4/7-Conotoxin LvIA: Published Chemical Synthesis 
 Walker and co-workers have reported a solution phase chemical synthesis of a4/7-
Conotoxin LvIA (Scheme 3.1).148 In their synthesis protocol, they used Trt and Acm 
groups to protect cysteine thiols. After linear synthesis of the peptide 3.1.A using Fmoc-
SPPS on rink amide resin, the peptide was removed from the resin and purified. The first 
disulfide bond was formed in solution using 20 mM potassium ferricyanide in a Tris buffer 
(pH 7.5). The resulting monocyclic peptide 3.1.C was purified by RP-HPLC before the 
next folding step. Then, a simultaneous Acm group removal and oxidation was done using 
iodine oxidation to close the second disulfide linkage. To perform iodine oxidation, they 
dripped the monocyclic peptide and HPLC eluent into a solution of 
iodine:H2O:trifluroacetic acid (78:2:20 by volume) and used ascorbic acid diluted 20-fold 
with 0.1% TFA to quench the reaction. Finally, a third purification step had to be performed 
using RP-HPLC to get a pure bicyclic product 3.1.D.  
 
The above synthetic process contains total of three purifications steps, which consume 
more time and diminish the yield. In addition, there are two in-solution manipulations of 
the peptide, which introduces possibility of solubility and/or aggregation issues. 
  
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
STrt STrt
SAcm SAcm
RA
3.1.A
16 1) TFA in DCM
2) HPLC purification
OHGCCSHPACNVDHPEICH
SH SH
SAcm SAcm
3.1.B
16
3.1.C
1) I2:H2O:TFA 
2) HPLC purification
OHGCCSHPACNVDHPEICH
S S
S S
3.1.D
161) Potssium ferricyanide  
2) HPLC purification
OHGCCSHPACNVDHPEICH
S S
SAcm SAcm
16
Scheme 3.1 Published in-solution synthesis of α4/7-conotoxin LvIA
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3.3 Orthogonality of Other Cysteine Protecting Groups Towards Pd-based Allocam 
removal  
 In order to access two disulfide systems like a4/7-conotoxin LvIA, in addition to 
Allocam group, another cysteine protecting group is needed for the regioselective 
synthesis. The suitable candidate must have stability towards Pd0/II - DMSO based 
cleavage-oxidation condition. Therefore, the orthogonality of common cysteine protecting 
groups such as Trt, Acm, Mmt and tBu towards Pd-based Allocam removal condition was 
evaluated using the model peptide IAPP1-9 (Table 3.1) 
 
 
Four batches of the model peptide IAPP1-9 were made using Cys(Trt), Cys(Mmt), 
Cys(Acm) and Cys(tBu). Each peptide was subjected to the optimized Pd0/II - DMSO 
based Allocam removal condition discussed in Chapter 2. Peptides with Trt and tBu 
protected cysteines remained unreacted (entry 1 and entry 4) while peptide with Mmt and 
Acm protected cysteines gave 20% (entry 2) and 90% (entry 3) of the expected oxidized 
product 3.2.B respectively, compared to the starting peptide . This experiment concluded 
PG 3.2.B 3.2.C
Trt
Mmt
Acm
Table 3.1 Stability of cysteine protecting groups towards Pd-based Allocam removal condition
TrtBoc
tBu
tBu tBu
KCNTATCATH
SPG SPG
KCNTATCATH OH
S S
1) 1.5 equiv Pd(OAc)2
    DMSO - 5% AcOH - 3% NMM, 4 h
    
2) TFE:AcOH:DCM (1:1:3), 30 min
TrttBu
tBu
tBu tBu
3.2.A 3.2.B
TGT
tBu
:
TrtBoc
tBu
tBu tBu
KCNTATCATH OH
SPG SPG
3.2.C
20 80
00 100
00 100
90 10
9 9 9
Entry
1.
2.
3.
4.
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that both Cys(Trt) and Cys(tBu) are stable to the Pd0/II - DMSO based cleavage-oxidation 
condition and both Cys(Mmt) and Cys(Acm) groups can be cleaved during the Allocam 
removal process.  
3.4 Stability of Allocam Group Towards Other On-Resin oxidants 
 After evaluating the orthogonality of other cysteine protecting groups towards Pd-
based Allocam removal condition, next, the stability of Allocam group towards other on-
resin oxidants was examined. Iodine149 and NCS150 are commonly used oxidants for on-
resin disulfide formation. Therefore, the model peptide IAPP1-9 with Allocam protected 
cysteines was subjected to iodine and NCS oxidation condition separately (Scheme 3.2). 
 
It was observed that Allocam is not stable under both iodine and NCS oxidation 
conditions. The model peptide 3.3.A on Wang resin was subjected to general iodine-
mediated oxidation conditions (Scheme 3.2.A). Interestingly, simultaneous Allocam 
cleavage and oxidation was observed.  With Albericio conditions79, 2 equivalents of NCS 
in DMF for 15 min (Scheme 3.2.B), 50% conversion of the oxidized product 3.3.B’ was 
observed. 
 
TrtBoc
tBu
tBu tBu
KCNTATCATH
S S
KCNTATCATH OH
S S
1) 8 equv I2 in DCM, 1 h
    
2) TFA:TIPS:DCM (30:5:65), 30 min
Allocam Allocam
TrtBoc
tBu
tBu tBu
KCNTATCATH
S S
KCNTATCATH OH
S S
1) 2 equv NCS in DMF, 15 min
    
2) TFE:AcOH:DCM (1:1:3), 30 min
TrttBu
tBu
tBu tBu
Allocam Allocam
Scheme 3.2 IAPP1-9 under A. I2 oxidation and B. NCS oxidation condition
A.
B.
3.3.A 3.3.B
3.3.A’ 3.3.B’
9 9
9 9
Wang
TGT
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3.5 On-Resin Synthesis of a4/7-Conotoxin LvIA 
3.5.1 Synthesis of a4/7-Conotoxin LvIA using Cys(Allocam) and Cys(Trt) on CTC Resin 
 Considering results from both the experiments discussed in sections 3.1 and 3.2, 
our first attempt for on-resin synthesis of a4/7-conotoxin LvIA was use of Trt group as the 
second cysteine protecting group along with Cys(Allocam). In the synthesis procedure, 
simultaneous removal of Allocam and oxidation followed by Trt group removal and 
oxidation using I2 in DCM can be done to obtain the two disulfide linkages selectively 
(Scheme 3.3). Stability of Trt group towards Pd0/II - DMSO based cleavage-oxidation 
condition allowed us to use it for the second disulfide bond formation. But, it cannot be 
used to form the first disulfide linkage since Allocam group is unstable to I2 oxidation.  
 
To evaluate feasibility of the proposed synthesis, linear synthesis of the peptide with 
Cys(Allocam) and Cys(Trt) was done on CTC resin. Although C-terminal end of a4/7-
conotoxin LvIA is an amide, CTC resin, which gives C-terminal carboxylic acid after 
peptide cleavage, was used to facilitate analysis of the reaction. CTC resin cleavage 
requires mild acid condition such as TFE:AcOH:DCM (1:1:8), which results peptides with 
side chain protecting groups including Cys(Allocam) and Cys(Trt). This helps in reaction 
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SAllocam
SAllocam
STrt STrt
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
S S
S S
Pd(OAc)2 in
DMSO-AcOH-NMM
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
S S
STrt STrt
I2 in DCM
Scheme 3.3 On-Resin Synthesis of α4/7—Conotoxin LvIA using Cys(Allocam) 
                     and Cys(Trt)
16 16
16
3.4.A 3.4.B
3.4.C
 
 
73 
optimization for each step of the synthesis. Reactions were monitored via analytical RP-
HPLC-MS. The ratio of starting material to product was monitored and optimization was 
done until complete disappearance of the starting material in the system.  
 First, optimization of step one was done, which is Allocam removal and oxidation 
using Pd0/II - DMSO based cleavage-oxidation condition (Table 3.2). 
 
The linear peptide 3.5.A was subjected to the optimized Pd0/II - DMSO based Allocam 
cleavage condition for IAPP 1-9 described on chapter 2. A ratio of 80:20, the desired folded 
product 3.5.B and the starting peptide 3.5.C was observed (entry 1). When the reaction 
time was increased from 4 hours to 6 hours, keeping equivalents of Pd the same, the 
reaction can be pushed towards 100% conversion of the product with desired disulfide 
bond 3.5.B (entry 2). After optimizing the first step of the synthesis, the reaction was 
scaled up and the resulting solid supported peptide 3.5.D was forward to the second step. 
Traditional I2 oxidation was done using 8 equivalents of iodine in DCM to form the second 
disulfide bond. Here, Trt group removal and oxidation occur in a single step (Scheme 
3.4).  
1) 1.5 equiv  Pd(OAc)2 
      DMSO - 5% AcOH - 3% NMM, t h
2) TFE:AcOH:DCM (1:1:8), 30 min
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SAllocam
SAllocam
STrt STrt
OHGCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
S S
STrt STrt
Rxn time (h)
4
6
CTC
OHGCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SAllocam
SAllocam
STrt STrt
3.5.A
3.5.B
3.5.C
3.X.B 3.X.C:
100 00
80 20
Table 3.2 Optimization for Pd-mediated Allocam cleavage and oxidation
16
16
16
Entry
1.
2.
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After each step, the resin was washed thoroughly to remove all the reagents used. The 
final peptide was cleaved from the resin using TFA:AcOH:DCM (1:1:8) mixture and all the 
remaining side chain protecting groups were cleaved with 95% TFA to obtain fully 
deprotected carboxy-a4/7-conotoxin LvIA 3.5.E with desired folding pattern. This 
illustrated the potential of orthogonal combination of Allocam and Trt groups for cysteine 
protection to form on-resin selective disulfide bonds to access carboxy-a4/7-conotoxin 
LvIA. 
3.5.2 Synthesis of a4/7-Conotoxin LvIA using Cys(Allocam) and Cys(Trt) on MeDbz-G-
ChemMatrix Resin 
 With the optimized conditions on hand, we wanted to synthesize a4/7-conotoxin 
LvIA on a resin which gives C-terminal carboxamide after cleavage. Our first choice was 
rink amide resin. Due to the failure in linear synthesis of the peptide on rink amide resin, 
we had to select another suitable resin for the synthesis. This problem let to development 
of a novel method for C-terminal modification of peptides,151,152,153 while we employed as 
shown in Figure 3.2. ChemMatrix resin with MeDbz linker154,155,156 (Figure 3.2.A) was 
employed to synthesize a4/7-conotoxin LvIA. Peptides on MeDbz linker found to be 
cleaved with a balloon of NH3, after activating the linker, to achieve peptide 
carboxamide.152  
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
S S
STrt STrt
OHGCCSHPACNVDHPEICH
S S
S S
1) 8 equiv I2 in DCM, 1 h
2) TFE:AcOH:DCM (1:1:8)
3) TFA:TIPS:H2O (95:2.5:2.5)
CTC
3.5.D 3.5.E
Scheme 3.4 I2 oxidation for second disulfide formation
16 16
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When peptides are cleaved from MeDbz linker, the N-terminal needs to be protected to 
prevent acylation during linker activation.153 On the other hand, for Pd-mediated Allocam 
removal process, the N-terminal of the peptide should be free in order to use less Pd 
loading.157 Therefore, in the synthesis of a4/7-conotoxin LvIA on MeDbz linker-G-
ChemMatrix resin, an additional step needed to be done to protect N-terminal of the 
peptide before cleavage from the resin (Scheme 3.5).     
 
After success in the linear synthesis of the peptide 3.6.A on MeDbz-G-ChemMatrix resin, 
it was first subjected to optimized Pd0/II - DMSO based Allocam cleavage condition to form 
on-resin peptide 3.6.B with first S-S bond. With 1.5 equivalences of Pd in DMSO-AcOH-
NMM solvent system for 6 hours, 100% of the desired product 3.6.B was obtained as 
CMGFmocHN MeDbz
CM
O
N
H
O
H
N
HN
Me
Fmoc
A. B.
Figure 3.2 A. Structure of MeDbz linker-Gly-ChemMatrix Resin B. Graphical representation of 
                       MeDbz linker-Gly-ChemMatrix Resin
Fmoc-MeDbz-Gly-ChemMatrix Resin
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SAllocam
SAllocam
STrt STrt
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
BocHN
S S
S S
Pd(OAc)2 in
DMSO-AcOH-NMM
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
S S
STrt STrt
Boc
Protection
Scheme 3.5 On-Resin Synthesis of α4/7-Conotoxin LvIA on MeDbz-G-ChemMatrix Resin
MeDbz CMG MeDbz CMG
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
S S
S S
MeDbz CMG
I2 
DCM
MeDbz CMG
NH2GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
BocHN
S S
S S
1) 4-nitrophenyl 
    chloroformate 
    then DIPEA/DMF
2) NH3, DMF
NH2GCCSHPACNVDHPEICH
S S
S S
TFA:TIPS:H2O (95:2.5:2.5)
3.6.A 3.6.B
3.6.C 3.6.D
3.6.E 3.6.F
16 16
16 16
16 16
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expected. The mono-cyclic peptide 3.6.B was then exposed to I2 oxidation for 1 hour to 
form the second S-S bond 3.6.C. Before cleaving the peptide from resin, Boc protection 
was done to the N-teminal using (Boc)2O in DCM along with DIPEA as the base. Next, 
MeDbz linker was activated with 4-nitrophenyl chloroformate followed by bubbling NH3 in 
to a solution of peptide in DMF to result Boc-protected and side chain protected peptide 
3.6.E. Finally, 95% TFA cleavage was done to obtain fully deprotected peptide 3.6.F with 
desired disulfide bonds. All the steps in the synthesis proceeded as expected except the 
last step, the Boc group proved resistant to acidic cleavage. Even though the final product 
was subjected to 95% TFA for longer exposer time, Boc group deprotection was 
unsuccessful.     
3.5.3 Synthesis of a4/7-Conotoxin LvIA using Cys(Allocam) and Cys(Trt) on Rink Amide 
Resin 
 After several attempts, we were able to optimize Fmoc-SPPS condition for the 
linear synthesis of a4/7-conotoxin LvIA with Cys(Allocam) and Cys(Trt) on rink amide 
resin. This led us to evaluate all the optimized on-resin folding steps on rink amide resin 
and synthesize a4/7-conotoxin LvIA with carboxyamide functionality (Scheme 3.6). First, 
the linear peptide 3.7.A was subjected to the optimized Pd0/II - DMSO mediated Allocam 
cleavage condition for CTC resin. The reaction didn’t go to completion with 1.5 equivalent 
of Pd(OAc)2 loading. The reaction was repeated with 3.0 equivalent of Pd(OAc)2 loading 
for 6 hours and complete disappearance of starting peptide was observed along with the 
product 3.7.B with desired disulfide bond. Next, the resulting solid supported mono cyclic 
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peptide 3.7.C was subjected to traditional I2 oxidation to obtain the second disulfide bond 
3.7.D. 
 
Treatment of 95% TFA followed by RP-HPLC purification gave the fully deprotected a4/7-
conotoxin LvIA 3.7.E in ~1% isolated yield. 
3.5.4 Synthesis of a4/7-Conotoxin LvIA using Cys(StBu), Cys(Mmt) and Cys(Allocam) on 
Rink Amide Resin 
 After accessing a4/7-conotoxin LvIA with Cys(Allocam) and Cys(Trt), where 
simultaneous Allocam removal and oxidation followed by Trt group removal and oxidation 
was done on solid support, we wanted to evaluate the utility of Pd-based Allocam removal 
and oxidation method to generate a second S-S bond selectively in mono cyclic peptides. 
To form the first disulfide linkage, the method reported by Tung and co-workers was 
selected.81  According to their method, StBu and Mmt was used as cysteine protecting 
groups, which facilitate on-resin disulfide bond formation without an oxidant. As the first 
step, the Cys(StBu) deprotection can be done using 20% mrecaptoethanol in DMF and 
the resulting free SH 3.8.B can be activated with 10-fold excess of DTNP in DCM to form 
5-Npys-activated disulfide 3.8.C. Removal of Mmt group with mild TFA condition in 
RAGCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SAllocam
SAllocam
STrt STrt
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
S S
S S
Pd(OAc)2 in
DMSO-AcOH-NMM
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
S S
STrt STrt
I2 in DCM
Scheme 3.6 On-Resin Synthesis of α4/7—Conotoxin LvIA using Cys(Allocam) 
                     and Cys(Trt) on Rink Amide Resin
16 16
16
RA
RA
3.7.A 3.7.B
3.7.C
NH2GCCSHPACNVDHPEICH
S S
S S
3.7.D
16TFA:TIPS:H2O 
(95:2.5:2.5)
 
 
78 
presence of TIPS facilitates the disulfide bond formation in the peptide 3.8.D. After 
formation of first disulfide bond, our Pd-based simultaneous removal of Allocam and 
oxidation method can be done to form the second disulfide bond (3.8.E) (Scheme 3.7).  
 
Linear synthesis of a4/7-conotoxin LvIA with Cys(StBu), Cys(Mmt) and Cys(Allocam) was 
successfully done using optimized Fmoc-SPPS conditions. Optimization of each step was 
then begun starting with thiol exchange of the StBu group (Table 3.3). Linear a4/7-
conotoxin LvIA on rink amide resin 3.8.A was first subjected to 20% mercaptoethanol at 
room temperature for different time intervals. In 3 hours, it gave 40% conversion of the 
desired product 3.8.F (entry 1). When increase the time to 6 hours, 80% product 
conversion was observed (entry 2). More than 95% of product was observed when the 
reaction run for 12 hours (entry 3). Grøtli and co-workers have reported microwave 
conditions for StBu – Mmt mediated on-resin non-oxidative disulfide bond formation 
strategy.82    
Mercaptoethanol
DMF
DTNP
DCM
Scheme 3.7 On-Resin Synthesis of α4/7-Conotoxin LvIA with Cys(StBu), Cys(Mmt) 
                     and Cys(Allocam)
1% TFA
DCM
3.8.A 3.8.B
3.8.C 3.8.D
3.8.E
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SMmt SStBu
SAllocam SAllocam
RA GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SMmt SH
SAllocam SAllocam
RA
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SMmt S
SAllocam SAllocam
RA
Npys
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
S S
SAllocam SAllocam
RA
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
S S
S S
RA
Pd(OAc)2
DMSO-AcOH-NMM
16 16
16
16
16
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For Cys(StBu) deprotection, they used microwave heating at 60 ºC with 30% 
mercaptoethanol. In order to lower the reaction time for Cys(StBU) deprotection, a 
reaction with 30% mercaptoethanol at 60 ºC under microwave heating was set up for 2 
hours. This reaction gave 95% conversion of product (entry 4), while heating for 3 hours 
gave more than 98% of product conversion (entry 5). Therefore, it was concluded that 
30% mercaptoethanol at 60 ºC under microwave heating for 3 hours is the optimal 
Cys(StBu) deprotection condition for the substrate 3.8.A.    
According to Tung and co-workers’ displacement method for on-resin disulfide 
bond formation, the resulting free SH, after Cys(StBu) deprotection, needs to be activated 
using 10-fold excess of DTNP in DCM. Optimization for DTNP activation was done for 
Cys(StBu) deprotected peptide 3.8.B. In terms of monitoring the reaction, we analyzed 
ratio of the desired folded product 3.8.H and the fully reduced product 3.8.I. If the reaction 
goes to 100% conversion, only desired folded product 3.8.H should be observed in MS 
1) X% HSCH2CH2OH in DMF, t h
2) TFA:TIPS:H2O (95:2.5:2.5), 30 min
X% time (h)
20 3
20 6
R.T.
R.T.
20 12R.T.
30 60 ºC, MW 2
Temperature
30 60 ºC, MW 3
3.8.A
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SMmt SStBu
SAllocam SAllocam
RA
NH2GCCSHPACNVDHPEICH
SH SH
SAllocam SAllocam
3.8.F
3.8.G
NH2GCCSHPACNVDHPEICH
SH SStBu
SAllocam SAllocam
3.8.F 3.8.G:
Table 3.3 Reaction optimization for Cys(StBu) deprotection
16
16
16
40 60
80 20
>95 <5
>95 <5
>98 <2
Entry
1.
2.
3.
4.
5.
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after 95% TFA cleavage. Partially activated resins give mixture of folded and reduced 
products since, only peptides with 5-Npys-activated thiol group facilitates disulfide bond 
formation. First, reactions were done at room temperature for different time intervals 
(Table 3.4). Reactions which run for 1 hour (entry 1) and 3 hour (entry 2) time intervals 
gave about 50% and 65% of folded product respectively while 6 hour reaction (entry 3) 
gave 100% folded product, indicating all the thiol groups on the resin have been activated 
with 5-Npys group.        
 
In addition, microwave condition was tried similar to Grøtli and co-workers have reported 
in their studies. Under microwave heating at 60 ºC, 100% activation of free SH from DTNP 
can be achieved within an hour (entry 4). When scaling up the reaction, microwave 
conditions didn’t give consistent results. Hence, we concluded 6 hour room temperature 
conditions as the optimal conditions for this reaction.  
According to the synthetic procedure, next step is to remove Mmt group using mild 
TFA condition to facilitate S-S bond formation. Although commonly used Cys(Mmt) 
1) 10 equiv DTNP in DCM, t1 h
2) TFA:TIPS:H2O (95:2.5:2.5), 30 min
3.8.B
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SMmt SH
SAllocam SAllocam
RA
NH2GCCSHPACNVDHPEICH
S S
SAllocam SAllocam
3.8.H
3.8.I
NH2GCCSHPACNVDHPEICH
SH SH
SAllocam SAllocam
Table 3.4 Reaction optimization for activation of free thiol using DTNP
time (h)Temperature 3.8.H 3.8.I:
1
3
R.T.
R.T.
6R.T.
60 ºC, MW 1
100 00
100 00
16
16
16
50 50
65 35
Entry
1.
2.
3.
4.
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cleavage condition is 1% TFA in DCM, in our system, Mmt group is found to be not labile 
to such mild TFA condition. Therefore, reaction optimization had to be done to Mmt group 
removal and a4/7-conotoxin LvIA was synthesized on CTC resin as the substrate for the 
optimization. After the success in linear synthesis of a4/7-conotoxin LvIA on CTC, the 
peptide 3.8.J was subjected to various percentages of TFA solutions in DCM with 5% 
TIPS for different time intervals (Table 3.5).  
 
As CTC resin is sensitive to mild acidic conditions, the peptide cleavage can also be 
achieved in the same TFA condition as the reaction condition. The resulting peptides are 
immediately precipitated using cold diethyl ether, centrifuged, the ether layer was 
decanted, resulting precipitate was dissolved in 1:1 MeCN:H2O and analyzed by MS 
directly for 100% product 3.8.K peaks. With increased TFA concentration, Cys(Mmt) 
removal can be seen in shorter period of time. In order to have a minimal percentage of 
X% TFA: 5% TIPS: in DCM
t min
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SMmt SStBu
SAllocam SAllocam
CTC
OHGCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SH SStBu
SAllocam SAllocam
OHGCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SMmt SStBu
SAllocam SAllocam
3.8.K
3.8.L
3.8.J
time (min)X% 3.8.K 3.8.L:
302
602
3 15
4 10
4 5
5 5
Table 3.5 Reaction optimization for Cys(Mmt) deprotection
16
16
16
Entry
1.
2.
3.
4.
5.
6.
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TFA to remove Mmt group, 3% TFA condition was selected as the optimal reaction 
condition for this substrate (entry 3). For peptides with 5-Npys-activated disulfide group, 
3% TFA treatment was done for 2 x 15 min to ensure total Mmt group cleavage and it 
was then subjected to DCM wash for 3 x 30 min until no yellow color in the washings. As 
the byproduct 5-nitropyridine-2-thione has an absorbance at 386 nm,14 disappearance of 
yellow color in the washings indicates completion of disulfide bond formation. In addition, 
Ellman’s reagent was used to analyze unreacted free thiol groups in the system. These 
steps led to the first folding of a4/7-conotoxin LvIA. The resulting peptide was then 
subjected to Pd-DMSO Allocam removal condition to obtain the second folding of the 
peptide (Table 3.6). For an incomplete reaction, in addition to the desired peptide 3.8.M, 
starting peptide with both Allocam group on, 3.8.N, and starting peptides with partial 
Allocam cleavage, 3.8.O, were observed by MS. Therefore, when monitoring the reaction 
for completion, all the above structures were evaluated. Optimization was started with 
previously optimized conditions for caboxy-a4/7-conotoxin LvIA. With 1.5 equivalences 
of Pd(OAc)2 at room temperature for 6 hours, reaction didn’t go to completion as expected 
(enrty 1). Neither increased time nor increased Pd loading at room temperature pushed 
the reaction for 100% product conversion (entry 2 – entry 4). Assuming additional energy 
might improve reactivity of the reaction, microwave heating was applied to the system 
(entry 5 – entry 9). Various Pd loadings and reaction times were tried, but none of them 
led to complete disappearance of starting material in MS. In addition to the Pd-based 
Allocam removal condition, NCS oxidation condition was also used to achieve a complete 
conversion of the desired product. Different equivalencies of NCS and reaction times 
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were tried (Table 3.7), and no complete conversion of the reaction was observed. 
Interestingly, in most of these reaction conditions tried, major substrate observed was the 
peptide with one Allocam cleavage 3.8.O.  
 
 
1) X equiv  Pd(OAc)2 
     DMSO - 5% AcOH - 3% NMM, T ºC, t h
2) TFA:TIPS:H2O (95:2.5:2.5), 2 x 30 min
3.8.D
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
S S
SAllocam SAllocam
RA
NH2GCCSHPACNVDHPEICH
S S
SAllocam SAllocam
NH2GCCSHPACNVDHPEICH
S S
SH SAllocam
NH2GCCSHPACNVDHPEICH
S S
S S
NH2GCCSHPACNVDHPEICH
S S
SAllocam SH
NH2GCCSHPACNVDHPEICH
S S
SH SH
3.8.M
3.8.N
3.8.P 3.8.O
Table 3.6 Reaction optimization for Pd-based Allocam removal and oxidation
X equiv. time (h)
1.5 6
1.5 12
R.T.
R.T.
3.0 R.T.
Temperature
6
3.0 60 ºC MW 6
3.0, 1.5 60 ºC MW 6, 3
3.0 60 ºC MW 7
3.0 60 ºC MW 6
5.0 60 ºC MW 6
7.0 R.T. 6
3.8.M 3.8.N 3.8.O 3.8.P
16
16
16
16
16
16
05 00 95 00
: : :
n.d. n.d. n.d. n.d.
05 00 95 00
15 00 85 00
55 00 45 00
n.d. n.d. n.d. n.d.
50 00 50 00
45 00 55 00
20 00 80 00
Entry
1.
2.
3.
4.
5.
6.
7.
8.
9.
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The results of these reactions indicate that removal of one of the Allocam groups’ is 
difficult. If we analyze the peptide structure, one of the Allocam protected cysteines is 
closer to the resin and sterically more hindered. Due to the fact Cys16(Allocam) is closer 
to the resin, deprotection might be challenging.                     
3.5.5 Synthesis of a4/7-Conotoxin LvIA using Cys(StBu), Cys(Mmt) and Cys(Allocam) on 
Rink Amide Linker-GGG-ChemMatrix Resin 
 In order to overcome the challenge of terminal Cys16(Allocam) removal we 
hypothesized that the steric hindrance around the peptide needed to be minimized. 
Therefore, we endeavor to increase the distance between the resin and the peptide by 
introducing a long linker in between them (Figure 3.3).   
 
The linker (A. Figure 3.3) was synthesized successfully on ChemMatrix resin and then, 
linear synthesis of the peptide 3.9.A was done, using optimized Fmoc-SPPS conditions, 
on the linker. Thereafter, reaction conditions for each step was evaluated. First, the 
Table 3.7 Reaction optimization for NCS-mediated Allocam removal and oxidation
X equiv. time (h)
5.0 6
5.0 10
7.0 6
02 00 95 00
60 00 40 00
85 00 15 00
3.8.M 3.8.N 3.8.O 3.8.P: : :Entry
1.
2.
3.
CM
O
N
H
O
Fmoc—Rink amide linker-Gly-Gly-Gly-ChemMatric Resin
H
N
O
N
H
O
O
H
N
CMGGGRA LinkerFmocHN
O
O
Fmoc
A. B.
Figure 3.3 A. Structure of RA linker-Gly—Gly-Gly-ChemMatrix Resin 
                  B. Graphical representation of RA linker-Gly-Gly-Gly-ChemMatrix Resin
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peptide 3.9.A was subjected to microwave assisted optimized Cys(StBu) deprotection 
conditions described in section 3.6 (Table 3.8). With 3 hours, a total deprotection was 
observed as expected (entry 1). In chapter 02, we evaluated that PEG based ChemMatrix 
resin can proceed reactions faster than polystyrene based resins due to their superior 
swelling power. Therefore, we set up reactions with lower reaction times leaving 
microwave heating conditions the same. Interestingly, complete StBu removal was 
observed in 1.5 hours for our new system (entry 2). 
 
After StBu removal, the resulting free SH needed to be activated by DTNP. The reaction 
optimization was done for the peptide 3.9.D with 10 equivalences of DTNP in DCM for 
different time intervals (Table 3.9). Even though it took 6 hours for the peptide on rink 
amide resin to get fully activated, for the same peptide on rink amide linker-Gly-Gly-Gly 
1) 30% HSCH2CH2OH in DMF
    60 ºC MW, t h
2) TFA:TIPS:H2O (95:2.5:2.5), 30 min
time (h)
3
1.5
3.9.A
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SMmt SStBu
SAllocam SAllocam
NH2GCCSHPACNVDHPEICH
SH SH
SAllocam SAllocam
3.9.B 3.9.C
NH2GCCSHPACNVDHPEICH
SH SStBu
SAllocam SAllocam
3.9.B 3.9.C
Table 3.8 Reaction optimization for Cys(StBu) deprotection
100 00
100 00
RA Linker CMGGG
16
16 16
:
1 95 05
Entry
1.
2.
3.
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ChemMatrix resin, it only took 1 hour (entry 3). Remarkably, the reaction time dropped 
drastically for this reaction.  
 
After activating the free thiol group on the peptide, Mmt removal needed to be done to 
form the first disulfide bond after release of Npys group. In section 3.6, the selected 
condition for Mmt removal was 3% TFA in DCM for 15 min. Due to a significant peptide 
cleavage observed with longer exposer time, we switched the condition for shorter time 
by using 5% TFA in DCM for 5 x 1 min. After TFA treatment, the resin was allowed to 
agitate with DCM wash an hour to ensure  complete displacement of 5-Npys group. 
Additionally, DCM wash for 3 x 30 min was done until no yellow color was observed in 
the washings. Furthermore, absence of free thiol groups was tested with Ellman’s reagent 
to confirm complete folding of first S-S bond.   
Table 3.9 Reaction optimization for Activation of free thiol using DTNP
time (h) 3.9.E 3.9.F:
6
3
1 100 00
100 00
100 00
1) 10 equiv DTNP in DCM, t h
2) TFA:TIPS:H2O (95:2.5:2.5), 30 min
3.9.D
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SMmt SH
SAllocam SAllocam
NH2GCCSHPACNVDHPEICH
S S
SAllocam SAllocam
3.9.E 3.9.F
NH2GCCSHPACNVDHPEICH
SH SH
SAllocam SAllocam
RA Linker CMGGG
16
16 16
Entry
1.
2.
3.
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Three different procedures were tried simultaneously to form the second on-resin disulfide 
bond (Table 3.10). Previously optimized Pd-DMSO Allocam removal and oxidation 
condition gave about 95% conversion of desired product with 7% overall yield and 
significantly less partial Allocam cleavage substrate 3.9.J (entry 1). The NCS condition 
also worked well for the new design where about 98% conversion was achieved with 5.0 
equivalences of NCS in 6 hours reaction time (entry 2). This is a great improvement from 
what we observed in section 3.6. For the first time, we tried iodine condition for Allocam 
removal and oxidation. With 5.0 equivalences of iodine in DCM for 6 hours, about 50% 
oxidized product formation was observed (entry 3). When increase the iodine loading from 
1) Reaction condition, t h
2) TFA:TIPS:H2O (95:2.5:2.5), 2 x 30 min
3.9.G
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
S S
SAllocam SAllocam
NH2GCCSHPACNVDHPEICH
S S
SAllocam SAllocam
NH2GCCSHPACNVDHPEICH
S S
SH SAllocam
NH2GCCSHPACNVDHPEICH
S S
S S
NH2GCCSHPACNVDHPEICH
S S
SAllocam SH
NH2GCCSHPACNVDHPEICH
S S
SH SH
3.9.H
3.9.I
3.9.K 3.9.J
Table 3.10 Reaction optimization for Allocam removal and oxidation
Rxn condition time (h)
3.0 equiv Pd(OAc)2
DMSO-5%AcOH-3%NMM 6
5.0 equiv NCS in DMF 6
3.9.H (Yield%) 3.9.I 3.9.J 3.9.K
5.0 equiv I2 in DCM 6
8.0 equiv I2 in DCM 6
>95       (7) 00 <5 00
: : :
>99     (n.d.) 00 <1 00
50 00 00 50
RA Linker CMGGG
16
16
16
16
16
16
>99      (18) 00 <1 00
Entry
1.
2.
3.
4.
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5.0 to 8.0 equivalences the reaction went to 100% conversion of the product with desired 
S-S pattern in 18% overall yield (entry 4). 
3.5.6 Synthesis of a4/7-Conotoxin LvIA using Cys(Allocam) and Cys(Trt) on Rink Amide 
Linker-GGG-ChemMatrix Resin 
 After the success in the synthesis of a-Conotoxin LvIA on Rink amide linker-GGG-
ChemMatrix resin (see section 3.5.5), we wanted to revisit the synthesis protocol 
discussed in section 3.5.3 on Rink amide linker-GGG-ChemMatrix resin.  
 
The linear synthesis of the peptide was done using Cys(Allocam) and Cys(Trt) on Rink 
amide linker-GGG-ChemMatrix resin and the optimized conditions for each step were 
rerun for the new system (Scheme 3.8). Similar to what we observed in section 3.5.5, an 
increment in the reaction rates was observed. First disulfide bond formation can be 
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Scheme 3.8 Synthesis of of α4/7—Conotoxin LvIA using Cys(Allocam) 
                     and Cys(Trt) on Rink Amide Linker-GGG-ChemMatrix Resin
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obtained in 3 hours with 3.0 equivalent of Pd(OAc)2 in DMSO-AcOH-NMM solvent 
system, which required 6 hours for rink amide resin without the linker. An iodine oxidation 
was done to achieve the formation of second disulfide bond. Final TFA cleavage was 
done to access the fully deprotected a-Conotoxin LvIA, 3.10.C with desired disulfide 
bonds.   
3.6 Summary 
In this chapter, we demonstrated the utility of Allocam group to access a4/7-conotoxin 
LvIA in combination with other cysteine protecting groups such as Trt, StBu and Mmt. 
Two routes were introduced based on position of the Allocam protected cysteines and 
selection of compatible other cysteine protecting groups for each of the synthetic routes. 
The linear synthesis of the a4/7-conotoxin LvIA and its reactivity towards folding were 
improved by using a three glycine linker in between the resin and the peptide. In addition 
to Pd-DMSO based simultaneous on-resin Allocam removal and oxidation condition, both 
I2 oxidation and NCS oxidation can be used in on-resin Allocam removal and oxidation. 
Among the three deprotection-oxidation conditions, I2 mediated simultaneous Allocam 
removal and oxidation gave the highest yield for selective on-resin synthesis of a4/7-
conotoxin LvIA. The utility of Allocam group can be extended to synthesize peptides with 
more than two disulfide bonds by careful selection of orthogonally compatible other 
cysteine protecting groups.   
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3.6 Materials and methods 
3.6.1 General Information 
 Unless otherwise specified, all commercially available reagents were purchased from 
Sigma-Aldrich and used without further purification. Anhydrous Et2O, MeCN, DMF, 
DMSO, CH2Cl2 were purchased from Fisher. These were passed through a commercial 
solvent purification system (2 columns of alumina) and used without further drying. 
Hünig’s base was distilled over CaH2 immediately prior to use. All amino acids were 
purchased from Chem-Impex Int’l. Inc. unless otherwise noted. HATU were purchased 
from Chem-Impex Int’l. Inc. Unless otherwise noted, all reactions were performed in 2 mL, 
5 mL and 10 mL Biotage reactor vials with PTFE frit (depend on reaction volume) at room 
temperature. All yields refer to chromatographically and spectroscopically pure products. 
All HPLC analyses and purifications were performed on a Custom Reverse Phase 
Shimadzu Liquid Chromatograph Mass Spectrometer (LCMS-2020), which can toggle 
between analytical and semi-preparative columns. This instrument has a photodiode 
array (PDA) detector (D2 & W lamp), which collects a range of wavelengths, in place of 
a traditional single channel UV detector. RP-HPLC-MS mobile phases (MeCN and H2O) 
contained 0.1% Formic Acid. Analytical HPLC was performed on a Phenomenex Kinetex 
C18 column (5 µm, 250 x 4.6 mm) and a Thermo Scientific Hypersil Gold C8 column (5 
µm, 250 x 4.6 mm). Semi-Preparative HPLC was conducted using a Thermo Scientific 
Hypersil Gold C8 column (5 µm, 150 x 10 mm). All peptide yields are calculated based 
on the final loading. 
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SPPS General Information. Solid-phase peptide synthesis was executed on a Biotage 
Isolera+ semi-automated synthesizer with microwave heating. 
•   Reactor Vials [Vial size (Volume range allowed)]: 2 mL reactor vial (0.8-1.1 mL), 5 mL 
reactor vial (1.6-3.2 mL), and 10 mL reactor vial (3.2-6.4 mL) 
•   Swelling + Heat: DMF was added and vortexed at 1200 RPM for 20 m at 70 ºC. The 
solvent was then removed over 1 m followed by two DMF washes (DMF was added 
and the suspension was vortexed at 600 RPM for 45 s, followed by the removal of 
solvent (over 2 m)).  
•   Coupling: A solution of Fmoc-aa-OH (3 equiv), HATU (3 equiv), and DIPEA (6 equiv) 
in DMF was made immediately prior to addition to the reaction vial containing the 
resin. Once the solution was added, the suspension was heated to 75 ºC (except for 
Fmoc-Cys-OH which was heated to 50 ºC) for 5 minutes with a vortex rate of 1200 
RPM. After the reaction, the solution was removed (over 2 m) and the resin was rinsed 
with DMF 4 times (after addition of DMF, the suspension was agitated at a vortex rate 
of 1200 RPM for 1 m, solvent removal was at a rate of 2 m). 
•   Fmoc Removal (Deprotection): The reactor vial was filled with 20% piperidine in DMF. 
The suspension was vortexed at 1200 RPM for 3 m at RT. The solvent is removed 
followed by addition of 20% piperidine in DMF. The suspension is vortexed again at 
1200 RPM for 10 m at RT. The solvent was removed over 2 m, followed by 4 DMF 
washes (after addition of DMF, the suspension was agitated at a vortex rate of 1200 
RPM for 1 m, solvent removal was at a rate of 2 m). 
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•   Wash: DMF was added to the reaction vial and agitated at a vortex rate of 1200 RPM 
for 1 m. The solvent was removed over 1 m and repeated for a total of 4 times. 
•   Final Wash: Resin was rinsed with CH2Cl2 (3 x 1 mL) and MeOH (3 x 1 mL). 
•   Drying for Storage/Weighing: After the final wash, the resin was placed on the 
lyophilizer overnight for drying. 
General Procedure for Capping - First, 25% acetic anhydride in DMF (3 mL) was added 
and agitated for 5 min. Then,1.5 eqiuv. of DIPEA was added to the reaction and agitated 
for 30 min. Finally, the reaction solution was filtered and the resin was washed with DMF 
(5 x 3 mL). 
Procedure for Resin Loading Analysis. Initial and final loading of resin was analyzed 
based on amount of Fmoc group. 
Fmoc Deprotection – 10 mg of the resin was weighed out and swelled in DMF in the 
peptide synthesizer. Then, 1.00 ml of 20% piperidine in DMF was added and it was 
allowed to vortex in the peptide synthesizer at room temperature for 3 min. After 3 min, 
the filtrate was collected in to a separate tube, another 1.00 ml of 20% piperidine in DMF 
was added to it and allowed to vortex in the peptide synthesizer at room temperature for 
10 min. The resulting filtrate was collected to the same tube and the deprotected resin 
was washed with DMF (4 x 1.75 ml). 
Sample preparation for UV analysis – From the collected ”deprotection solution” above, 
100 µL was transferred in to an eppendorf tube and it was diluted with 900 µl of DMF. 
The resulting diluted sample was used to get the absorbance at 301 nm versus a DMF 
blank using a UV spectrometer with 1 cm cuvette. 
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General Procedure for Pd-DMSO Cleavage/Oxidation. The peptide on the stated resin 
(10 mg) was swelled in DMF at room temperature for 30 minutes. After removing excess 
DMF, the cartridge was capped on the bottom. A solution of Pd(OAc)2 in 5% AcOH/DMSO 
solution was added, and then the stated amount of NMM was added. The cartridge was 
capped on the top, attached to a magnetic stirbar retriever using a rubber band, and 
agitated for the stated amount of time. The reaction was filtered, and the resin was 
washed successively with with DMF (3 x 2 min), CH2Cl2 (3 x 2 min), 0.2 M sodium 
diethyldithiocarbamate in DMF (3 x 30 min), MeOH (3 x 1 min), DMF (5 x 1 min) and 
CH2Cl2 (3 x 1 min). *Note: resin changes from dark orange/brownish to yellowish/tan. The 
resin was then subjected to a stated cleavage mixture for 30 minutes.  
Product analysis was done directly (with no lyophilization) by analytical RP-HPLC-MS 
using a Hypersil GOLD column (5 L, 150 x 4.6 mm) at a flow rate of 1 mL/min with stated 
gradient and time. 
Ammonia Cleavage of Peptides on Resin: The stated amount of the peptide on resin 
(dry) was weighed out into a fritted reaction vial with an attached needle and rubber 
stopper (suggested selection of SPPS vial: 10-40 mg of peptide on resin goes into the 2 
mL reaction vial, 40-200 mg in the 5 mL reaction vial and ³200 mg goes into the 10 mL 
reaction vial). The resin was swelled in DCM (500 µL – 4 mL) for 0.5-1 h. The MeDbz 
linker was activated by a previously established protocol., Next, 500 µL of DMF was added 
and the reaction vial was closed off with a septum (needle and stopper still attached at 
the bottom). A double balloon was made and filled with ammonia. A hypodermic needle 
was attached to the balloon and inserted into the septum and submerged into the DMF 
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solution. The smallest (blue) gauge needle was placed into the septum to allow for the 
slow exiting of gas. The ammonia gas was bubbled into DMF for 1.5 h. Then the solvent 
was removed and collected. Additional rinsing was required to completely remove the 
desired peptide from resin. DCM (3 x 1 mL) was used to rinse the resin, followed by MeCN 
(3 x 1 mL), and lastly DCM (3 x 1 mL). The washes were combined with the initial DMF 
solution, blown down with air, subjected to 1:1 MeCN:H2O, frozen (LN2), and lyophilized 
to yield the crude product. 
3.6.2 Experimental Procedures and Spectroscopic Data 
 
 
General Procedure for Table 3.1. The general procedure for Pd-DMSO cleavage-
oxidation was followed. The reaction mixture was agitated in a closed vial at room 
temperature for 4 hours. After the wash, the dried resin was subjected to 300 µL of the 
cleavage mixture (1:1:3 TFE:AcOH:DCM) for 30 min. The filtrates were collected, 
concentrated and analyzed by RP-HPLC-MS using an analytical Thermo Scientific 
Hypersil Gold C8 column at a flow rate of 1 mL/min. 
 
Entry 1. The IAPP1-9 with Cys(Trt) was used. The relevant quantities are: Resin 3.2.A (10 
mg, 2 µmol), Pd(OAc)2 (0.67 mg, 3 µmol), NMM (7.5 µL, 68.4 µmol) and DMSO-5% AcOH 
(250 µL). The reaction was analyzed by RP-HPLC-MS using an analytical Thermo 
Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 50-90% MeCN/H2O 
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gradient for 30 minutes. m/z ES calc’d for peptide 3.2.C [C108H135N11O16S2 + 1]+: 
1907.45; observed: 1908.40. m/z ES calc’d for peptide 3.2.C-Trt [C89H121N11O16S2 + 1]+: 
1665.13; observed: 1665.70.  
 
Figure 3.4 Analytical Column PDA for Table 3.1 – Entry 1  
 
 
 
Entry 2. The IAPP1-9 with Cys(Mmt) was used. The relevant quantities are: Resin 3.2.A 
(10 mg, 2 µmol), Pd(OAc)2 (0.67 mg, 3 µmol), NMM (7.5 µL, 68.4 µmol) and DMSO-5% 
AcOH (250 µL). The reaction was analyzed by RP-HPLC-MS using an analytical Thermo 
Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 50-80% MeCN/H2O 
gradient for 30 minutes. m/z ES calc’d for peptide 3.2.C [C110H139N11O18S2 + 1]+: 
1967.50; observed: 1968.40. m/z ES calc’d for peptide 3.2.C-Mmt [C90H123N11O17S2 + 
        
Starting peptide (3.2.C); [(M+2)/2]+ 
 
Starting peptide-Trt; [(M+2)/2]+ 
 
Product (3.2.B); [(M+2)/2]+ 
 
PDA 214 nm 
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1]+: 1695.15; observed: 1695.75. m/z ES calc’d for peptide 3.2.B [(C70H105N11O16S2 + 
2)/2]+: 711.40; observed: 711.25.  
  
Figure 3.5 Analytical Column PDA for Table 3.1 – Entry 2  
 
 
Entry 3. The IAPP1-9 with Cys(Acm) was used. The relevant quantities are: Resin 3.2.A 
(10 mg, 2 µmol), Pd(OAc)2 (0.67 mg, 3 µmol), NMM (7.5 µL, 68.4 µmol) and DMSO-5% 
AcOH (250 µL). The reaction was analyzed by analytical Thermo Scientific Hypersil Gold 
C8 column at a flow rate of 1 mL/min with 50-80% MeCN/H2O gradient for 30 minutes. 
m/z ES calc’d for peptide 3.2.C [(C76H117N13O18S2 + 2)/2]+: 783.48; observed: 783.20. 
m/z ES calc’d for peptide 3.2.8 [(C70H105N11O16S2 + 2)/2]+: 711.40; observed: 711.20.  
        
Starting peptide (3.2.C); [(M+2)/2]+ 
Starting peptide-Mmt; [(M+2)/2]+ 
Oxidized Product (3.2.B); [(M+2)/2]+ 
PDA 214 nm 
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Figure 3.6 Analytical Column PDA for Table 3.1 – Entry 2  
 
 
Entry 4. The IAPP1-9 with Cys(tBu) was used. The relevant quantities are: Resin 3.2.A 
(10 mg, 2 µmol), Pd(OAc)2 (0.67 mg, 3 µmol), NMM (7.5 µL, 68.4 µmol) and DMSO-5% 
AcOH (250 µL).  The reaction was analyzed by RP-HPLC-MS using an analytical Thermo 
Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 50-90% MeCN/H2O 
gradient for 30 minutes. m/z ES calc’d for peptide 4.X.B [C78H123N11O16S2 + 1]+: 1535.02; 
observed: 1535.65. m/z ES calc’d for [(C78H123N11O16S2 + 2)/2]+: 768.51; observed: 
768.25. 
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Figure 3.7 Analytical Column PDA for Table 3.1 – Entry 4  
 
 
 
 
 
Test Reaction (Scheme 3.2.B). The resin 3.3.A’ (10 mg, 2 µmol) was swelled in DMF 
(300 µL). Then, a solution of NCS (0.5 mg, 4 µmol) in DMF (200 µL) was added and it 
was agitated at room temperature for 15 min. The reaction solution was filtered and the 
resin was rinsed with DMF (3 x 1 mL) and DCM (3 x 1 mL). The resulting resin was 
subjected to 300 µL of the cleavage mixture (1:1:3 TFE:AcOH:DCM) for 30 min. The 
resulting solution was collected, concentrated and analyzed by RP-HPLC-MS using an 
analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 10-
50% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 3.3.A’ 
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[(C80H121N13O20S2 + 2)/2]+: 825.52; observed: 824.90. m/z ES calc’d for peptide 3.3.B’ 
[(C70H105N11O16S2 + 2)/2]+: 711.40; observed: 711.15.  
  
Figure 3.8 Analytical Column PDA for Scheme 3.2 Reaction B  
 
 
 
 
 
 
 
SPPS of Peptide 3.5.A. The standard Fmoc-SPPS protocol was used to synthesize 
peptide 3.5.A on CTC resin, except no HATU was used in the first amino acid coupling. 
To analyze the peptide, 10 mg of the resin was subjected to 300 µL of the cleavage 
mixture (1:1:8 TFE:AcOH:DCM)  for 30 min. The filtrates were collected, concentrated 
and analyzed by RP-HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 
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column at a flow rate of 1 mL/min with 50-75-95% MeCN/H2O gradient for 30 minutes. 
m/z ES calc’d for peptide 4.X.B [(C183H209N23O27S4 + 2)/2]+: 1645.23; observed: 1645.35.  
 
Figure 3.9 Analytical Column PDA for linear peptide 3.5.A; Gradient: 10-50% MeCN/H2O + 1% HCOOH  
over 30 min. Retention time 16.81 min 
 
 
Figure 3.10 ES-MS spectrum for linear peptide 3.5.A at retention time 16.81 min 
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PDA 214 nm 
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General Procedure for Table 3.2. For each of the reaction, the general procedure for 
Pd-DMSO cleavage-oxidation was followed using the peptide 3.5.A (10 mg, 4 µmol), 
Pd(OAc)2 (1.4 mg, 6 µmol), NMM (15.0 µL, 68.4 µmol) and DMSO-5% AcOH (500 µL). 
The reaction mixture was then agitated in a closed vial at room temperature for stated 
amount of time. After the wash, the dried resin was subjected to 300 µL of the cleavage 
mixture (1:1:8 TFE:AcOH:DCM)  for 30 min. The filtrates were collected, concentrated 
and analyzed by RP-HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 
column at a flow rate of 1 mL/min with 50-75-95% MeCN/H2O gradient for 30 minutes.  
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Entry 1. The reaction was agitated for 4 h. m/z ES calc’d for peptide 3.5.C 
[(C183H209N23O27S4 + 2)/2]+: 1645.23; observed: 1646.00. m/z ES calc’d for peptide 3.5.B 
[(C173H193N21O23S4 + 23 + 2)/2]+: 1543.41; observed: 1544.41  
 
 
Figure 3.11 Analytical Column PDA for determination of conversion; Table 3.2. Entry 1.  
Gradient: 50-95% MeCN/H2O + 1% HCOOH over 40 min. 
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Entry 2. The reaction was agitated for 6 h. m/z ES calc’d for peptide 3.5.B 
[(C173H193N21O23S4 + 23 + 2)/2]+: 1532.41; observed: 1531.45  
 
 
Figure 3.12 Analytical Column PDA for determination of conversion; Table 3.2. Entry 2.  
Gradient: 50-75-95% MeCN/H2O + 1% HCOOH over 30 min. 
 
 
 
 
 
 
 
 
 
        
Starting peptide (3.5.C); [(M+2)/2]+ 
 
Product (3.5.B); [(M+2)/2]+ 
 
PDA 214 nm 
 
 
 
 
 
104 
 
Carboxy a4/7-Conotoxin LvIA (3.5.E). The resin 3.5.D (30 mg, 12 µmol) was swelled in 
DMF (500 µL). Then, Iodine (24.4 mg, 96 µmol) in DCM (360 µL) was added and the 
reaction mixture was agitated at room temperature for 1 hour. Next, the reaction mixture 
was filtered out and few drops of saturated ascorbic acid in water was added until the 
purple color of iodine disappeared. The resulting resin was washed with saturated 
ascorbic acid in water. After that, 300 µL of the cleavage mixture (1:1:8 TFE:AcOH:DCM) 
was introduced and kept for 2 x 15 min. The filtrates were collected, concentrated and 
subjected to TFA:TIPS:H2O (95:2.5:2.5) cleavage mixture for 1 hour. Finally, the resulting 
solution was concentrated under a constant stream of air, crashed out with cold diethyl 
ether, centrifuged, and decanted to yield the crude peptide. The peptide was dissolved in 
5% MeCN:Water in presence of 0.05%TFA and analyzed via RP-HPLC-MS using an 
analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 5-
95% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 3.5.E 
[(C66H97N21O23S4 +  2)/2]+: 841.44; observed: 840.90 
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Figure 3.13 Analytical Column PDA for crude product 3.5.E; Gradient: 5-95% MeCN/H2O + 1% HCOOH  
over 30 min. Retention time 10.34 min 
 
 
 
 
 
 Figure 3.14 ES-MS spectrum for crude product 3.5.E at retention time 10.34 min 
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MeDbz Linker-Gly-ChemMatrix Resin. The standard Fmoc-SPPS protocol described 
was used to synthesize the linker on ChemMatrix resin. The loading of MeDbz linker: 0.3 
mmol/g.  
 
 
Linear Peptide 3.6.A. The standard Fmoc-SPPS protocol described was used to 
synthesize peptide 3.6.A on MeDbz linker-Gly-ChemMatrix resin. The peptide was 
capped before the last coupling step. To analyze the peptide, 10 mg of the resin was 
subjected general ammonia cleavage protocol and the resulting crude product was 
dissolved in 50% MeCN:Water in presence of 0.05%TFA and analyzed via direct ES-MS. 
Final loading of the resin: 0.01 mmol/g. m/z ES calc’d for peptide 3.6.A 
[(C183H210N24O26S4 +  2)/2]+: 1646.04; observed: 1645.30. 
 
Figure 3.15 ES-MS spectrum for linear peptide 3.6.A  
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Mono Cyclic Peptide 3.6.C. The general procedure for Pd-DMSO cleavage-oxidation 
was followed. The relevant quantities are: Resin 3.6.A 50 mg, 15 µmol), Pd(OAc)2 (5.1 
mg, 22.5 µmol), NMM (56.5 µL, 513 µmol) and DMSO-5% AcOH (1.875 mL). The reaction 
mixture was agitated in a closed vial at room temperature for 6 hours. To analyze the 
peptide, first, 10 mg of the peptide (3 µmol) was treated with di-tert-butyl dicarbonate 
(32.7 mg, 150 µmol) in DCM (300 µL). Then DIPEA (1.5 µL, 9 µmol) was added to the 
reaction mixture and agitated for 12 hours. Thereafter, the resin was washed with DCM 
(3 x 1 mL) and DMF (3 x 1 mL). After Boc protection step, the resulting peptide was 
subjected to the general procedure for ammonia cleavage of peptide on resin. The 
resulting crude product was then treated with TFA:TIPS:H2O (95:2.5.2.5) for 2 hours. 
Finally, the TFA solution was concentrated under a constant stream of air, crashed out 
with cold diethyl ether, centrifuged, and decanted to yield the crude peptide. The peptide 
was dissolved in 50% MeCN:Water in presence of 0.05%TFA and analyzed via RP-
HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow rate 
of 1 mL/min with 50-90% MeCN/H2O gradient for 30 minutes. Final loading of the resin: 
0.01 mmol/g. m/z ES calc’d for peptide 3.6.C+Boc-Trt [(C159H188N22O24S4 +  2)/2]+: 
1460.81; observed: 1460.40. m/z ES calc’d for peptide 3.6.C+Boc-2Trt 
[(C140H174N22O24S4 +  2)/2]+: 1339.65; observed: 1339.15. 
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Figure 3.16 Analytical Column PDA for determination of conversion. Gradient: 50-90% MeCN/H2O + 1% HCOOH 
over 30 min.  
 
 
 
a4/7-conotoxin LvIA 3.6.F. First, the peptide 3.6.C (50 mg, 15 µmol) was swelled in DMF 
(500 µL). Then, Iodine (30.5 mg, 120 µmol) in DCM (400 µL) was added and the reaction 
mixture was agitated at room temperature for 1 hour. Then, the reaction mixture was 
filtered out and few drops of saturated ascorbic acid in water was added until the purple 
color of iodine disappeared. The resulting resin was washed with saturated ascorbic acid 
in water. Next, the peptide was treated with di-tert-butyl dicarbonate (163.5 mg, 750 µmol)  
in DCM (1.5 mL). Then DIPEA (8.0 µL, 45 µmol) was added to the reaction mixture and 
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agitated for 12 hours. After Boc protection step, the resulting peptide was subjected the 
general procedure for ammonia cleavage of peptide on resin. The resulting crude product 
was then treated with TFA:TIPS:H2O (95:2.5.2.5) for 2 hours. Finally, the TFA solution 
was concentrated under a constant stream of air, crashed out with cold diethyl ether, 
centrifuged, and decanted to yield the crude peptide. The peptide was dissolved in 50% 
MeCN:Water in presence of 0.05%TFA and analyzed via RP-HPLC-MS using an 
analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 20-
90% MeCN/H2O gradient for 30 minutes. Final loading of the resin: 0.01 mmol/g. m/z ES 
calc’d for peptide 3.6.F+Boc [(C71H106N22O24S4 +  2)/2]+: 891.00; observed: 890.20. m/z 
ES calc’d for [(C140H174N22O24S4 +  3)/3]+: 594.33; observed: 593.80. 
  
Figure 3.17 Analytical Column PDA for crude product 3.6.F; Gradient: 20-90% MeCN/H2O + 1% HCOOH  
over 30 min. Retention time 15.26 min 
 
 a4/7-conotoxin LvIA (3.6.F); [(M+2)/2]+ 
 
PDA 214 nm 
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Figure 3.18 ES-MS spectrum for crude product 3.6.F at retention time 15.26 min 
 
 
 
 
 
 
 
SPPS of Linear Peptide 3.8.A. The standard Fmoc-SPPS protocol described was used 
to synthesize peptide 3.8.A on rink amide resin. The peptide was capped before the last 
coupling step. To analyze the final peptide, 10 mg of the resin was subjected to cleavage 
solution of TFA:TIPS:H2O (95:2.5.2.5) for 30 min. Finally, the TFA solution was 
concentrated under a constant stream of air, crashed out with cold diethyl ether, 
centrifuged, and decanted to yield the crude peptide. The peptide was dissolved in 10% 
MeCN:Water in presence of 0.05%TFA and analyzed via RP-HPLC-MS using an 
analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 10-
50% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 3.8.A 
[(C80H124N24O26S5 +  2)/2]+: 1000.15; observed: 999.90. m/z ES calc’d for 
[(C74H116N24O26S5 +  3)/3]+: 667.10; observed: 667.00. 
SPPS
FmocHN RA
3.8.A
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SMmt SStBu
SAllocam SAllocam
RA
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Figure 3.19 Analytical Column PDA for linear peptide 3.8.A; Gradient: 10-50% MeCN/H2O + 1% HCOOH  
over 30 min. Retention time 21.87 min 
 
 
 
 
 
 
Figure 3.20 ES-MS spectrum for linear peptide 3.8.A at retention time 21.87 min 
 
 
   
Linear peptide (3.8.A); [(M+3)/3]+ 
Linear peptide (3.8.A); [(M+3)/3]+ 
Linear peptide – 1Allocam; [(M+2)/2]+ 
PDA 214 nm 
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General Procedure for Reaction Optimization Table 3.3. For each of the reactions, the 
peptide 3.8.A (10 mg, 4 µmol) was first swelled in DMF (500 µL). Then, a solution of 20% 
mercaptoethanol in DMF (1.0 mL) was added and agitated for stated amount of time either 
at room temperature or at 60 ºC under microwave heating. The reaction solution was then 
filtered and the resin was washed with DMF (5 x 1 mL). The resulting resin was subjected 
to 300 µL of the cleavage mixture (95:2.5:2.5 TFA:TIPS:H2O) for 30 min. The resulting 
TFA solution was collected, concentrated, and the peptide was crashed out with cold 
diethyl ether. The precipitate was centrifuged, ether discarded, and the pellet was 
dissolved in 10% MeCN:Water in presence of 0.05%TFA. This solution was analyzed via 
RP-HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow 
rate of 1 mL/min with 10-50% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for 
peptide 3.8.G [(C80H124N24O26S5 +  2)/2]+: 1000.15; observed: 999.80. m/z ES calc’d for 
[(C80H124N24O26S5 +  3)/3]+: 667.10; observed: 666.95. m/z ES calc’d for peptide 3.8.F 
[(C76H116N24O26S4 +  2)/2]+: 956.08; observed: 955.70. m/z ES calc’d for 
[(C76H116N24O26S4 +  3)/3]+: 637.72; observed: 637.55. 
  
 
1) X% HSCH2CH2OH in DMF, t h
2) TFA:TIPS:H2O (95:2.5:2.5), 30 min
3.8.A
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SMmt SStBu
SAllocam SAllocam
RA
NH2GCCSHPACNVDHPEICH
SH SH
SAllocam SAllocam
3.8.F
3.8.G
NH2GCCSHPACNVDHPEICH
SH SStBu
SAllocam SAllocam
16
16
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Entry 1. The reaction was agitated at room temperature for 3 hours.  
 
Figure 3.21 Analytical Column PDA for Table 3.3. Entry 1.  
 
 
Entry 2. The reaction was agitated at room temperature for 6 hours.  
Figure 3.22 Analytical Column PDA for Table 3.3. Entry 2. 
Starting peptide (3.8.G); [(M+2)/2]+ 
 
Product (3.8.F); [(M+2)/2]+ 
 
PDA 214 nm 
 
 
 
Starting peptide (3.8.G); [(M+2)/2]+ 
 
Product (3.8.F); [(M+2)/2]+ 
 
PDA 214 nm 
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Entry 3. The reaction was agitated at room temperature for 12 hours.  
 
Figure 3.23 Analytical Column PDA for Table 3.3. Entry 3. 
 
Entry 4. The reaction was agitated in a microwave at 60 ºC for 2 hours.  
 
Figure 3.24 Analytical Column PDA for Table 3.3. Entry 4. 
Starting peptide (3.8.G); [(M+2)/2]+ 
Product (3.8.F); [(M+2)/2]+ 
PDA 214 nm 
 
 
 
Starting peptide (3.8.G); [(M+2)/2]+ 
Product (3.8.F); [(M+2)/2]+ 
PDA 214 nm 
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Entry 5. The reaction was agitated in a microwave at 60 ºC for 3 hours.  
 
Figure 3.25 Analytical Column PDA for Table 3.3. Entry 5. 
 
 
 
 
 
General Procedure for Reaction Optimization Table 3.4. For each of the reactions, the 
resin 3.8.B (10 mg, 4 µmol) was first swelled in DMF (500 µL). Then, a solution of DTNP 
(12.4 mg, 40 µmol) in DCM (1.0 mL) was added and allowed to agitate the stated amount 
of time either at room temperature or at 60 ºC under microwave heating. The reaction 
solution was filtered and the resin was washed with DCM (5 x 1 mL). The resulting resin 
1) 10 equiv DTNP in DCM, t1 h
2) TFA:TIPS:H2O (95:2.5:2.5), 30 min
3.8.B
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S S
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SH SH
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16
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Starting peptide (3.8.G); [(M+2)/2]+  
 
Product (3.8.F); [(M+2)/2]+ 
 
Product – 1Allocam; [(M+2)/2]+ 
PDA 214 nm 
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was subjected to 300 µL of the cleavage mixture (95:2.5:2.5 TFA:TIPS:H2O) for 30 min. 
The resulting TFA solution was collected, concentrated, and the peptide was crashed out 
with cold diethyl ether. The precipitate was centrifuged, ether discarded, and the pellet 
was dissolved in 10% MeCN:Water in presence of 0.05%TFA. This solution was analyzed 
via RP-HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow 
rate of 1 mL/min with 10-50% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for 
peptide 3.8.H [(C76H116N24O26S4 +  2)/2]+: 956.08; observed: 955.75. m/z ES calc’d for 
[(C76H116N24O26S4 +  3)/3]+: 637.72; observed: 637.45. m/z ES calc’d for peptide 3.8.I 
[(C76H114N24O26S4 +  2)/2]+: 955.06; observed: 954.85. m/z ES calc’d for 
[(C76H114N24O26S4 +  3)/3]+: 637.04; observed: 636.95. 
  
Entry 1. The reaction was agitated at room temperature for 1 hour.  
 
Figure 3.26 Analytical Column PDA for Table 3.4. Entry 1. 
 
Starting peptide (3.8.I); [(M+3)/3]+   
 
Product (3.8.H); [(M+2)/2]+ 
 
PDA 214 nm 
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Entry 2. The reaction was agitated at room temperature for 3 hours.  
 
Figure 3.27 Analytical Column PDA for Table 3.4. Entry 2. 
 
Entry 3. The reaction was agitated at room temperature for 6 hours.  
 
Figure 3.28. Analytical Column PDA for Table 3.4. Entry 3. 
Product (3.8.H); [(M+3)/3]+    
 
Product isotope; [(M+3)/3]+    
 
Product – 1Allocam; [(M+3)/3]+   
 
PDA 214 nm 
 
 
 
Starting peptide (3.8.I); [(M+2)/2]+   
 
Product (3.8.H); [(M+2)/2]+ 
 
PDA 214 nm 
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Entry 4. The reaction was agitated in a microwave at 60 ºC for 1 hour.  
 
Figure 3.29 Analytical Column PDA for Table 3.4. Entry  
 
 
 
 
 
 
 
SPPS of Peptide 3.8.J. The standard Fmoc-SPPS protocol described was used to 
synthesize peptide 3.8.J on CTC resin, except no HATU was used in the first amino acid 
coupling. To analyze the peptide, 10 mg of the resin was subjected to 300 µL of the 
cleavage mixture (1:1:8 TFE:AcOH:DCM)  for 30 min. The filtrates were collected, 
concentrated and analyzed via RP-HPLC-MS using an analytical Thermo Scientific 
Hypersil Gold C8 column at a flow rate of 1 mL/min with 50-75-95% MeCN/H2O gradient 
SPPS
HO CTC GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SMmt SStBu
SAllocam SAllocam
CTC
3.8.J
16
Product (3.8.H); [(M+3)/3]+   
 
Product isotope; [(M+3)/3]+   
 
PDA 214 nm 
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for 30 minutes. . m/z ES calc’d for peptide 3.X.B [(C169H206N24O27S5 +  2)/2]+: 1583.97; 
observed: 1584.35. m/z ES calc’d for [(C169H206N24O27S5 +  3)/3]+: 1056.32; observed: 
1056.55. 
 
Figure 3.30 ES-MS spectrum for linear peptide 3.8.J  
 
 
 
 
General Procedure for Reaction Optimization Table 3.5. For each of the reactions, the 
peptide 3.8.J (10 mg, 4 µmol) was first swelled in DCM (500 µL). A freshly prepared stated 
percentage of TFA solution in DCM  was added and the reaction mixture was agitated at 
stated amount of time. About 2 – 3 drops of TIPS were added during the reaction until the 
orange-yellow color disappeared in the reaction mixture. The resulting reaction solution 
X% TFA: 5% TIPS: in DCM
t min
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was filtered in to a tube. The peptide was immediately crashed out with cold diethyl ether 
and centrifuged, ether discarded, and the pellet was dissolved in 50% MeCN:Water in 
presence of 0.05%TFA. This solution was analyzed directly by MS. m/z ES calc’d for 
peptide 3.8.L [(C169H206N24O27S5 +  2)/2]+: 1583.97; observed: 1584.30. m/z ES calc’d 
for peptide 3.8.K [(C149H190N24O26S5 +  2)/2]+: 1447.80; observed: 1448.05. 
  
Entry 1. A freshly prepared solution of TFA:TIPS:DCM (2:5:93, 300 µL) was added and 
the reaction mixture was agitated at room temperature for 30 min.  
 
Figure 3.31 ES-MS spectrum for direct injection. Table 3.5. Entry 1 
 
Entry 2. A freshly prepared solution of TFA:TIPS:DCM (2:5:93, 300 µL) was added and 
the reaction mixture was agitated at room temperature for 60 min.  
 
Figure 3.32 ES-MS spectrum for direct injection. Table 3.5. Entry 2 
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Entry 3. A freshly prepared solution of TFA:TIPS:DCM (3:5:92, 300 µL) was added and 
the reaction mixture was agitated at room temperature for 15 min.  
 
Figure 3.33 ES-MS spectrum for direct injection. Table 3.5. Entry 3 
 
 
 
Entry 4. A freshly prepared solution of TFA:TIPS:DCM (4:5:91, 300 µL) was added and 
the reaction mixture was agitated at room temperature for 10 min.  
 
Figure 3.34 MS spectrum for direct injection. Table 3.5. Entry 4 
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Entry 5. A freshly prepared solution of TFA:TIPS:DCM (4:5:91, 300 µL) was added and 
the reaction mixture was agitated at room temperature for 5 min.  
 
Figure 3.35 ES-MS spectrum for direct injection. Table 3.5. Entry 5 
 
 
 
Entry 6. A freshly prepared solution of TFA:TIPS:DCM (5:5:90, 300 µL) was added and 
the reaction mixture was agitated at room temperature for 5 min.  
 
Figure 3.36 ES-MS spectrum for direct injection. Table 3.5. Entry 5 
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General Procedure for Reaction Optimization Table 3.6. For each of the reactions, the 
general procedure for Pd-DMSO cleavage-oxidation was followed. The stated amount of 
the resin 3.8.D was subjected to the stated amount of Pd(OAc)2 , NMM and DMSO-5% 
AcOH. The reaction mixture was agitated in a 5 mL closed vial at room temperature for 
stated amount of time. After the wash, the dried resin was subjected to 300 µL of the 
cleavage mixture TFA:TIPS:H2O (95:2.5.2.5) for 2 x 30 min. Finally, the TFA solution was 
concentrated under a constant stream of air, crashed out with cold diethyl ether, 
centrifuged, and decanted to yield the crude peptide. The peptide was dissolved in 10% 
MeCN:Water in presence of 0.05%TFA and analyzed via RP-HPLC-MS using an 
analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 10-
50% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 3.8.N 
[(C76H114N24O26S4 +  3)/3]+: 637.04; observed: 637.20. m/z ES calc’d for peptide 3.8.O 
1) X equiv  Pd(OAc)2 
     DMSO - 5% AcOH - 3% NMM, T ºC, t h
2) TFA:TIPS:H2O (95:2.5:2.5), 2 x 30 min
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[(C71H107N23O24S4 +  3)/3]+: 599.54; observed: 598.50. m/z ES calc’d for peptide 3.8.M 
[(C66H98N22O22S4 +  3)/3]+: 560.96; observed: 560.65. 
 
Entry 1. The relevant quantities are: Peptide 3.X.A (30 mg, 9 µmol), Pd(OAc)2 (3.0 mg, 
13.5 µmol), NMM (34.0 µL, 68.4 µmol) and DMSO-5% AcOH (1125 µL). The reaction 
mixture was agitated at room temperature for 6 hours.  
 
 
Figure 3.37 Analytical Column PDA for Table 3.6. Entry 1 
 
 
 
 
 
Starting peptide (3.8.N); [(M+3)/3]+ 
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+ 
Product isotope (3.8.P); [(M+3)/3]+ 
Oxidized Product (3.8.M); [(M+3)/3]+ 
PDA 214 nm 
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Entry 2. The relevant quantities are: Peptide 3.X.A (30 mg, 9 µmol), Pd(OAc)2 (3.0 mg, 
13.5 µmol), NMM (34.0 µL, 68.4 µmol) and DMSO-5% AcOH (1125 µL). The reaction 
mixture was agitated  at room temperature for 12 hours.  
 
 
Figure 3.38 Analytical Column PDA for Table 3.6. Entry 2 
 
 
 
 
 
 
Starting peptide (3.8.N); [(M+3)/3]+ 
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+ 
Product isotope (3.8.P); [(M+3)/3]+ 
Oxidized Product (3.8.M); [(M+3)/3]+ 
PDA 214 nm 
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Entry 3. The relevant quantities are: Peptide 3.X.A (30 mg, 9 µmol), Pd(OAc)2 (6.1 mg, 
27.0 µmol), NMM (34.0 µL, 68.4 µmol) and DMSO-5% AcOH (1125 µL). The reaction 
mixture was agitated at room temperature for 6 hours  
 
 
Figure 3.39 Analytical Column PDA for Table 3.6. Entry 3 
 
 
 
 
 
 
 
Starting peptide (3.8.N); [(M+3)/3]+ 
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+ 
Product isotope (3.8.P); [(M+3)/3]+ 
Oxidized Product (3.8.M); [(M+3)/3]+ 
PDA 214 nm 
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Entry 4. The relevant quantities are: Peptide 3.X.A (30 mg, 9 µmol), Pd(OAc)2 (14.1 mg, 
63.0 µmol), NMM (34.0 µL, 68.4 µmol) and DMSO-5% AcOH (1125 µL). The reaction 
mixture was agitated at room temperature for 6 hours.  
 
 
Figure 3.40 Analytical Column PDA for Table 3.6. Entry 4 
 
 
 
 
 
 
 
Starting peptide (3.8.N); [(M+3)/3]+ 
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+ 
Product isotope (3.8.P); [(M+3)/3]+ 
Oxidized Product (3.8.M); [(M+3)/3]+ 
PDA 214 nm 
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Entry 5. The relevant quantities are: Peptide 3.X.A (50 mg, 15 µmol), Pd(OAc)2 (10.1 mg, 
45.0 µmol), NMM (56.0 µL, 513.0 µmol) and DMSO-5% AcOH (1875 µL). The reaction 
mixture was agitated at 60 ºC in a microwave for 6 hours.  
 
 
Figure 3.41 Analytical Column PDA for Table 3.6. Entry 5 
 
 
 
 
 
 
 
Starting peptide (3.8.N); [(M+3)/3]+ 
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+ 
Product isotope (3.8.P); [(M+3)/3]+ 
Oxidized Product (3.8.M); [(M+3)/3]+ 
PDA 214 nm 
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Entry 6. The relevant quantities are: Peptide 3.X.A (22 mg, 6.6 µmol), Pd(OAc)2 (4.4 mg, 
19.8 µmol), NMM (25.0 µL, 225.72 µmol) and DMSO-5% AcOH (825 µL). The reaction 
mixture was agitated at 60 ºC in a microwave for 6 hours. Next, the reaction solution was 
then filtered and the resin was subjected again to Pd(OAc)2 (2.2 mg, 9.9 µmol), NMM 
(25.0 µL, 225.72 µmol) and DMSO-5% AcOH (825 µL) and agitated again at 60 ºC in a 
microwave for 3 hours. 
 
 
Figure 3.42 Analytical Column PDA for Table 3.6. Entry 6 
 
 
 
 
 
Starting peptide (3.8.N); [(M+3)/3]+ 
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+ 
Product isotope (3.8.P); [(M+3)/3]+ 
Oxidized Product (3.8.M); [(M+3)/3]+ 
PDA 214 nm 
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Entry 7. The relevant quantities are: Peptide 3.X.A (50 mg, 15 µmol), Pd(OAc)2 (10.1 mg, 
45.0 µmol), NMM (56.0 µL, 513.0 µmol) and DMSO-5% AcOH (1875 µL). The reaction 
mixture was agitated at 60 ºC in a microwave for 7 hours.  
 
 
Figure 3.43 Analytical Column PDA for Table 3.6. Entry 7 
 
 
 
 
 
 
 
Starting peptide (3.8.N); [(M+3)/3]+ 
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+ 
Product isotope (3.8.P); [(M+3)/3]+ 
Oxidized Product (3.8.M); [(M+3)/3]+ 
PDA 214 nm 
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Entry 8. The relevant quantities are: Resin (50 mg, 15 µmol), Pd(OAc)2 (10.1 mg, 45.0 
µmol), NMM (56.0 µL, 513.0 µmol) and DMSO-5% AcOH (1875 µL). The reaction mixture 
was agitated in a 10 mL closed vial at 60 ºC in a microwave for 6 hours.  
 
  
Figure 3.44 Analytical Column PDA for Table 3.6. Entry 8 
 
 
 
 
 
 
 
Starting peptide (3.8.N); [(M+3)/3]+ 
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+ 
Product isotope (3.8.P); [(M+3)/3]+ 
Oxidized Product (3.8.M); [(M+3)/3]+ 
PDA 214 nm 
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Entry 9. The relevant quantities are: Peptide 3.X.A (50 mg, 15 µmol), Pd(OAc)2 (16.8 mg, 
75.0 µmol), NMM (56.0 µL, 513.0 µmol) and DMSO-5% AcOH (1875 µL). The reaction 
mixture was agitated at 60 ºC in a microwave for 6 hours.  
 
 
Figure 3.45 Analytical Column PDA for Table 3.6. Entry 9 
 
 
 
 
Starting peptide (3.8.N); [(M+3)/3]+ 
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+ 
Product isotope (3.8.P); [(M+3)/3]+ 
Oxidized Product (3.8.M); [(M+3)/3]+ 
PDA 214 nm 
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General Procedure for Reaction Optimization Table 3.7. For each of the reactions, the 
peptide 3.8.D (20 mg, 6 µmol) was first swelled in DMF (500 µL). Then, the sated amount 
of NCS in DMF was added and allowed to agitate at room temperature for stated amount 
of time. The reaction solution was filtered and the resin was washed with DMF (5 x 1 mL) 
and DCM (5 x 1 mL).  The resulting resin was subjected to 300 µL of the cleavage mixture 
TFA:TIPS:H2O (95:2.5.2.5) for 2 x 30 min. Finally, the TFA solution was concentrated 
under a constant stream of air, crashed out with cold diethyl ether, centrifuged, and 
decanted to yield the crude peptide. The peptide was dissolved in 10% MeCN:Water in 
presence of 0.05%TFA and analyzed via RP-HPLC-MS using an analytical Thermo 
Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 10-50% MeCN/H2O 
gradient for 30 minutes. m/z ES calc’d for peptide 3.8.N [(C76H114N24O26S4 +  3)/3]+: 
637.04; observed: 637.20. m/z ES calc’d for peptide 3.8.O [(C71H107N23O24S4 +  3)/3]+: 
1) X equiv  Pd(OAc)2 
     DMSO - 5% AcOH - 3% NMM, T ºC, t h
2) TFA:TIPS:H2O (95:2.5:2.5), 2 x 30 min
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599.54; observed: 598.50. m/z ES calc’d for peptide 3.8.M [(C66H98N22O22S4 +  3)/3]+: 
560.96; observed: 560.65. 
 
 Entry 1. A solution of NCS (4.0 mg, 30 µmol) in DMF (400 µL) was added and the 
reaction was allowed to agitate at room temperature for 6 hours.  
 
 
Figure 3.46 Analytical Column PDA for Table 3.7. Entry 1 
 
 
 
 
 
 
Starting peptide (3.8.N); [(M+3)/3]+ 
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+ 
Product isotope (3.8.P); [(M+3)/3]+ 
Oxidized Product (3.8.M); [(M+3)/3]+ 
PDA 214 nm 
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Entry 2. A solution of NCS (4.0 mg, 30 µmol) in DMF (400 µL) was added and the reaction 
was allowed to agitate at room temperature for 10 hours.  
 
 
Figure 3.47 Analytical Column PDA for Table 3.7. Entry 2 
 
 
 
 
 
 
 
 
 
Starting peptide (3.8.N); [(M+3)/3]+ 
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+ 
Product isotope (3.8.P); [(M+3)/3]+ 
Oxidized Product (3.8.M); [(M+3)/3]+ 
PDA 214 nm 
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Entry 3. A solution of NCS (5.6 mg, 42 µmol) in DMF (400 µL) was added and the reaction 
was allowed to agitate at room temperature for 6 hours.  
 
 
Figure 3.48 Analytical Column PDA for Table 3.7. Entry 3 
 
 
 
 
 
 
 
 
Starting peptide (3.8.N); [(M+3)/3]+ 
Starting peptide – 1Allocam (3.8.O); [(M+3)/3]+ 
Product isotope (3.8.P); [(M+3)/3]+ 
Oxidized Product (3.8.M); [(M+3)/3]+ 
PDA 214 nm 
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Rink Amide Linker-Gly-Gly-Gly-ChemMatrix Resin 3.X.A. The standard Fmoc-SPPS 
protocol described was used to synthesize Rink amide linker-Gly-Gly-Gly-ChemMatrix 
Resin, except a special swelling method was performed to swell ChemMatrix resin before 
coupling the first amino acid to get efficient loading. Here, First, MeOH (3 mL) was added 
and agitated for 1 min at RT. The solvent was then removed and the treatment was 
repeated with MeOH. In a similar manner, the resin was washed with DMF (2 x 1 min), 
DCM (3 x 1 min), TFA-DCM (1:99) (3 x 1 min), DIEA-DCM (1:19) (3 x 1 min), DCM (3 x 1 
min) and DMF (3 x 1 min). The linker was capped after the synthesis. Loading of the linker 
on resin: 0.3 – 0.35 mmol/g  
 
 
 
SPPS of Peptide 3.9.A. The standard Fmoc-SPPS protocol described was used to 
synthesize peptide 3.9.A on Rink amide linker-Gly-Gly-Gly-ChemMatrix resin. The 
peptide was capped before the last coupling step. To analyze the final peptide, 10 mg of 
the resin was subjected to cleavage solution of TFA:TIPS:H2O (95:2.5.2.5) for 30 min. 
Finally, the TFA solution was concentrated under a constant stream of air, crashed out 
with cold diethyl ether, centrifuged, and decanted to yield the crude peptide. The peptide 
HO CM
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CMGGGRA LinkerFmocHN
Fmoc—Rink amide linker-Gly-Gly-Gly
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3.9.A
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SMmt SStBu
SAllocam SAllocam
RA Linker CMGGG
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was dissolved in 10% MeCN:Water in presence of 0.05%TFA and analyzed via RP-
HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow rate 
of 1 mL/min with 10-50% MeCN/H2O gradient for 30 minutes. Final loading of the resin: 
0.14 mmol/g. m/z ES calc’d for peptide 3.9.A [(C80H124N24O26S5 +  2)/2]+: 1000.15; 
observed: 999.80. m/z ES calc’d for [(C74H116N24O26S5 +  3)/3]+: 667.10; observed: 
666.90. 
 
Figure 3.49 Analytical Column PDA for linear peptide 3.9.A; Gradient: 10-50% MeCN/H2O + 1% HCOOH  
over 30 min. Retention time 20.62 min 
 
 
 
Figure 3.50 ES-MS spectrum for linear peptide 3.9.A at retention time 20.62 min  
Linear peptide (3.9.A); [(M+2/2]+ 
Linear peptide (3.9.A); [(M+3/3]+ 
PDA 214 nm 
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General Procedure for Reaction Optimization Table 3.8. For each of the reactions, the 
peptide 3.9.A (10 mg, 3 µmol) was first swelled in DMF (500 µL). Then, a solution of 30% 
mercaptoethanol in DMF (1.0 mL) was added and agitated for stated amount of time. The 
reaction solution was filtered and the resin was washed with DMF (5 x 1 mL). The resulting 
resin was subjected to 300 µL of the cleavage mixture (95:2.5:2.5 TFA:TIPS:H2O) for 30 
min. The resulting TFA solution was collected, concentrated, and the peptide was crashed 
out with cold diethyl ether. The precipitate was centrifuged, ether discarded, and the pellet 
was dissolved in 10% MeCN:Water in presence of 0.05%TFA. This solution was analyzed 
via RP-HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow 
rate of 1 mL/min with 10-50% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for 
peptide 3.X.A [(C80H124N24O26S5 +  2)/2]+: 1000.15; observed: 999.80. m/z ES calc’d for 
[(C74H116N24O26S5 +  3)/3]+: 667.10; observed: 666.95. m/z ES calc’d for peptide 3.X.C 
[(C76H116N24O26S4 +  2)/2]+: 956.08; observed: 955.85. m/z ES calc’d for 
[(C76H116N24O26S4 +  3)/3]+: 637.72; observed: 637.60. 
 
1) 30% HSCH2CH2OH in DMF
    60 ºC MW, t h
2) TFA:TIPS:H2O (95:2.5:2.5), 30 min
3.9.A
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SMmt SStBu
SAllocam SAllocam
NH2GCCSHPACNVDHPEICH
SH SH
SAllocam SAllocam
3.9.B 3.9.C
NH2GCCSHPACNVDHPEICH
SH SStBu
SAllocam SAllocam
RA Linker CMGGG
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Entry 1. The reaction was agitated for 3 hours.  
 
Figure 3.51. Analytical Column PDA for Table 3.8. Entry 1 
 
Entry 2. The reaction was agitated for 1.5 hours.  
 
Figure 3.52 Analytical Column PDA for Table 3.8. Entry 2 
Starting peptide (3.9.C); [(M+3)/3]+ 
Product (3.9.B); [(M+3)/3]+ 
Product – 1Allocam; [(M+3)/3]+ 
Product – 2Allocam; [(M+3)/3]+ 
PDA 214 nm 
 
 
 
Starting peptide (3.9.C); [(M+3)/3]+ 
Product (3.9.B); [(M+3)/3]+ 
Product – 1Allocam; [(M+3)/3]+ 
Product – 2Allocam; [(M+3)/3]+ 
PDA 214 nm 
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Entry 3. The reaction was agitated for 1 hour.  
 
Figure 3.53 Analytical Column PDA for Table 3.8. Entry 3 
 
 
 
 
 
 
Starting peptide (3.9.C); [(M+3)/3]+ 
Product (3.9.B); [(M+3)/3]+ 
Product – 1Allocam; [(M+3)/3]+ 
Product – 2Allocam; [(M+3)/3]+ 
PDA 214 nm 
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General Procedure for Reaction Optimization Table 3.9. For each of the reactions, 
The resin 3.9.D (10 mg, 3 µmol) was first swelled in DMF (500 µL). Then, a solution of 
DTNP (9.3 mg, 30 µmol) in DCM (1.0 mL) was added and allowed to stated amount of 
time. The reaction solution was filtered and the resin was washed with DCM (5 x 1 mL). 
The resulting resin was subjected to 300 µL of the cleavage mixture (95:2.5:2.5 
TFA:TIPS:H2O) for 30 min. The resulting TFA solution was collected, concentrated, and 
the peptide was crashed out with cold diethyl ether. The precipitate was centrifuged, ether 
discarded, and the pellet was dissolved in 10% MeCN:Water in presence of 0.05%TFA. 
This solution was analyzed via RP-HPLC-MS using an analytical Thermo Scientific 
Hypersil Gold C8 column at a flow rate of 1 mL/min with 10-50% MeCN/H2O gradient for 
30 minutes. m/z ES calc’d for peptide 3.X.B [(C76H114N24O26S4 +  2)/2]+: 955.06; 
observed: 954.90. m/z ES calc’d for [(C76H114N24O26S4 +  3)/3]+: 637.04; observed: 
636.95. 
 
 
1) 10 equiv DTNP in DCM, t1 h
2) TFA:TIPS:H2O (95:2.5:2.5), 30 min
3.9.D
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
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SMmt SH
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NH2GCCSHPACNVDHPEICH
S S
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3.9.E 3.9.F
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SAllocam SAllocam
RA Linker CMGGG
16
16 16
 
 
143 
Entry 1. The reaction was agitated for 6 hour.  
 
Figure 3.54 Analytical Column PDA for Table 3.9. Entry 1 
 
Entry 2. The reaction was agitated for 3 hours.  
 
Figure 3.55 Analytical Column PDA for Table 3.9. Entry 2 
Product (3.9.E); [(M+3)/3]+  
Product isotope; [(M+3)/3]+ 
PDA 214 nm 
 
 
 
Product (3.9.E); [(M+3)/3]+  
Product isotope; [(M+3)/3]+ 
PDA 214 nm 
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Entry 3. The reaction was agitated for 1 hour.  
 
Figure 3.56 Analytical Column PDA for Table 3.9. Entry 3 
 
 
 
 
 
 
 
 
 
Product (3.9.E); [(M+3)/3]+ 
Product isotope; [(M+3)/3]+ 
PDA 214 nm 
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Procedure for Table 3.10, Entry 1. The general procedure for Pd-DMSO cleavage-
oxidation was followed. The relevant quantities are: Resin 3.9.G (130 mg, 39 µmol), 
Pd(OAc)2 (26.3 mg, 117.0 µmol), NMM (147.0 µL, 1333.8 µmol) and DMSO-5% AcOH 
(4875 µL). The reaction mixture was agitated in a 10 mL closed vial at room temperature 
for 6 hours. After the wash, the dried resin was subjected to 1 mL of the cleavage mixture 
TFA:TIPS:H2O (95:2.5.2.5) for 2 x 3 hours. Finally, the TFA solutions were collected, 
concentrated under a constant stream of air, crashed out with cold diethyl ether, 
centrifuged, and decanted to yield the crude peptide. The peptide was dissolved in 10% 
MeCN:Water in presence of 0.05%TFA and analyzed via RP-HPLC-MS using an 
analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 10-
50% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 3.8.I 
[(C76H114N24O26S4 +  3)/3]+: 637.04; observed: 637.20. m/z ES calc’d for peptide 3.8.J 
1) Reaction condition, t h
2) TFA:TIPS:H2O (95:2.5:2.5), 2 x 30 min
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[(C71H107N23O24S4 +  3)/3]+: 599.54; observed: 598.50. m/z ES calc’d for peptide 3.8.H 
[(C66H98N22O22S4 +  3)/3]+: 560.96; observed: 560.65. 
 
. 
Figure 3.57 Analytical Column PDA for crude product 3.9.H. Table 3.10. Entry 1 
 
 
 
 
The crude peptide was purified via RP-HPLC-MS using an analytical Thermo Scientific 
Hypersil Gold C8 column at a flow rate of 1 mL/min to afford a4/7-conotoxin LvIA in 7% 
yield (~1.6 mg). 
 
 
Starting peptide (3.9.J) – 1Allocam); [(M+3)/3]+   
Reduced peptide (3.9.K); [(M+3)/3]+ 
Oxidized peptide (3.9.H); [(M+3)/3]+ 
PDA 214 nm 
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Figure 3.58 Analytical Column PDA for pure product 3.9.H. Table 3.10. Entry 1 
Gradient: 10-50% MeCN/H2O + 1% HCOOH over 15 min. Retention time 6.91 min 
 
 
 
 
 
 
Figure 3.59 ES-MS spectrum for pure product 3.9.H at retention time 6.91 min. Table 3.10. Entry 1 
 
 
 
 
 
 
 
a4/7-conotoxin LvIA (3.9.H); [(M+3)/3]+   
PDA 214 nm 
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Procedure for Table 3.10, Entry 2. The resin 3.9.G (150 mg, 45 µmol) was first swelled 
in DMF (3 mL). Then, a solution of NCS (30.0 mg, 225 µmol) in DMF (1.0 mL) was added 
and allowed to agitate in a 10-mL closed vial at room temperature for 5 hours. The 
reaction solution was filtered and the resin was washed with DMF (5 x 3 mL) and DCM 
(5 x 3 mL).  The resulting resin was subjected to 1 mL of the cleavage mixture 
TFA:TIPS:H2O (95:2.5.2.5) for 2 x 3 hours. Finally, the TFA solutions were collected, 
concentrated under a constant stream of air, crashed out with cold diethyl ether, 
centrifuged, and decanted to yield the crude peptide. The peptide was dissolved in 10% 
MeCN:Water in presence of 0.05%TFA and analyzed via RP-HPLC-MS using an 
analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 10-
50% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 3.8.H 
[(C66H98N22O22S4 +  3)/3]+: 560.96; observed: 560.65. 
 
Figure 3.60 Analytical Column PDA for crude product 3.9.H. Table 3.10. Entry 2 
Starting peptide (3.9.J) – 1Allocam); [(M+3)/3]+   
Reduced peptide (3.9.K); [(M+3)/3]+ 
Oxidized peptide (3.9.H); [(M+3)/3]+ 
PDA 214 nm 
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Procedure for Table 3.10, Entry 3. The resin 3.9.G (20 mg, 6 µmol) was first swelled in 
DMF (500 µL). Then, a solution of iodine (7.6 mg, 30 µmol) in DCM (400 µL) was added 
and allowed to agitate in a 2 mL vial at room temperature for 5 hours. The reaction solution 
was filtered and the resin was washed with DMF (10 x 1 mL) and DCM (10 x 1 mL).  The 
resulting resin was subjected to 300 µL of the cleavage mixture TFA:TIPS:H2O 
(95:2.5.2.5) for 2 x 30 min. Finally, the TFA solutions were collected, concentrated under 
a constant stream of air, crashed out with cold diethyl ether, centrifuged, and decanted to 
yield the crude peptide. The peptide was dissolved in 10% MeCN:Water in presence of 
0.05%TFA and analyzed via RP-HPLC-MS using an analytical Thermo Scientific Hypersil 
Gold C8 column at a flow rate of 1 mL/min with 10-50% MeCN/H2O gradient for 30 
minutes. m/z ES calc’d for peptide 3.8.H [(C66H98N22O22S4 +  3)/3]+: 560.96; observed: 
560.65. m/z ES calc’d for peptide 3.8.K [(C66H100N22O22S4 +  3)/3]+: 561.96; observed: 
561.40. 
 
Figure 3.61 Analytical Column PDA for Table 3.10. Entry 3 
Starting peptide (3.9.J) – 1Allocam); [(M+3)/3]+   
Reduced peptide (3.9.K); [(M+3)/3]+ 
Oxidized peptide (3.9.H); [(M+3)/3]+ 
PDA 214 nm 
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Procedure for Table 3.10, Entry 4. The resin 3.9.G (150 mg, 45 µmol) was first swelled 
in DMF (3 mL). Then, a solution of iodine (91.3 mg, 360 µmol) in DCM (2 mL) was added 
and allowed to agitate in a 10-mL closed vial at room temperature for 5 hours. The 
reaction solution was filtered and the resin was washed with DMF (10 x 3 mL) and DCM 
(10 x 3 mL).  The resulting resin was subjected to 1 mL of the cleavage mixture 
TFA:TIPS:H2O (95:2.5.2.5) for 2 x 3 hours. Finally, the TFA solutions were collected, 
concentrated under a constant stream of air, crashed out with cold diethyl ether, 
centrifuged, and decanted to yield the crude peptide. The peptide was dissolved in 10% 
MeCN:Water in presence of 0.05%TFA and analyzed via RP-HPLC-MS using an 
analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 10-
50% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 3.X.B 
[(C66H98N22O22S4 +  2)/2]+: 840.94; observed: 840.70. m/z ES calc’d for 
[(C66H98N22O22S4 +  3)/3]+: 560.96; observed: 560.80. 
 
Figure 3.62 Analytical Column PDA for crude product 3.9.H. Table 3.10. Entry 4 
Starting peptide (3.9.J) – 1Allocam); [(M+3)/3]+   
Reduced peptide (3.9.K); [(M+3)/3]+ 
Oxidized peptide (3.9.H); [(M+3)/3]+ 
PDA 214 nm 
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The crude peptide was purified via RP-HPLC-MS using an analytical Thermo Scientific 
Hypersil Gold C8 column at a flow rate of 1 mL/min to afford a4/7-conotoxin LvIA in 18% 
yield (4.2 mg). 
 
Figure 3.63 Analytical Column PDA for pure product 3.9.H. Table 3.10. Entry 4 
Gradient: 10-50% MeCN/H2O + 1% HCOOH over 15 min. Retention time 6.97 min 
 
 
 
 
 
Figure 3.64 ES-MS spectrum for pure product 3.9.H at retention time 6.97 min.  
 
 
 
 
  
a4/7-conotoxin LvIA (3.9.H); [(M+3)/3]+   
PDA 214 nm 
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CHAPTER 4: ELLMAN’S REAGENT  
AS A COLORIMETRIC AND MILD OXIDIZING AGENT FOR ON-RESIN FOLDING OF 
CYSTEINE CONTAINING PEPTIDES 
 
 
4.1 Introduction  
 Ellman’s reagent has been the most popular reagent for spectrometric 
measurement of protein sulfhydryls for over four decades. It is then been adapted 
successfully in to a solid phase mode to mediate intramolecular disulfide bond formation 
in solution. However, there were no reports for its potential as a solution phase oxidizing 
agent to form on-resin disulfide bonds in peptides. In this chapter we are introducing a 
new application of Ellman’s reagent, which can mediate on-resin disulfide bond formation 
while offering colorimetric method to monitor the reaction.  
4.2 Ellman’s Reagent for Free Thiol Analysis 
 The compound 5,5'-dithiobis-(2-nitrobenzoic acid) which is known as Ellman’s 
reagent or DTNB was introduced in 1959 by George L. Ellman to quantify the amount and 
concentration of thiols groups in a sample under physiological conditions.158,159 Since 
then it has been widely used in both qualitative and quantitative assays to measure 
protein sulfhydryls. Reaction between a thiol group and 5,5'-dithiobis-(2-nitrobenzoic acid) 
cleaves off the homo-disulfide bond in DTNB to give a mixed disulfide (R-S-TNB) and 
release one equivalent of 5-thio-2-nitrobenzoic acid (TNB) (Scheme 4.1).  
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Scheme 4.1 Reaction of Ellman’s reagent with thiol groups
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The resulting TNB ionizes to the TNB2− dianion at neutral to alkaline pH and generate a 
yellow color as a result of intense light absorption at 412 nm. Base on this phenomena, 
the standard procedure for colorimetric analysis of thiols is done using a dilute solution of 
Ellman’s reagent in basic aqueous buffer (pH 8). The measurement of absorbance values 
at 412 nm allows to quantify the concentration of thiols using Beer-lambert law. The 
method has been used to analyze sulfhydryl group content in wide range of substrates 
such as cereal proteins,160 blood samples, urine, tissues, purified proteins, etc159. and 
slight modifications in the standard procedure has been done based on stability, solubility 
and pH of the substrate.  
 With rapid development in the solid-phase peptide synthesis, simple laboratory 
methods for analysis of on-resin functionality needed to be developed. Most importantly 
a readily accessible method for on-resin thiol group analysis. Steel and coworkers have 
reported their investigation of adopting Ellman’s reagent to analyze resin bound thiol 
groups.161 According to their findings, for highly-crosslinked polystyrene resins which are 
compatible with range of aqueous and non-aqueous solvent systems, standard thiol 
analysis conditions with aqueous solution of the Ellman’s reagent failed to give 
reproducible results. For peptides on polystyrene based resins, Ellman’s reagent in 
methanol, basified with DIPEA, gave excellent results. TentaGel resins, which can 
tolerate aqueous-organic solvent systems, react efficiently with Ellman’s reagent in a 
THF:methanol (1:1) solvent mixture, basified with DIPEA. This is a simple and cheap 
method to analyze free macroporous or PEG graft resin bound thiols. Further 
enhancement to the procedure can be done by retreating the resin with dithiothreitol to 
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cleave the disulfide bond which releases a second equivalent of TNB. Colorimetric 
analysis of the second TNB allows to get a duplicate value for the same sample.161 
4.3 Supported Ellman’s Reagent for Cysteine Disulfide Formation 
 As discussed in Section 4.2, Ellman’s reagent was originally developed for a 
colorimetric method to measure free thiol concentration under physiological conditions. It 
is then found to be an effective mild oxidizing agent to generate disulfides, when bound 
to a suitable solid support.85 Solid supports such as polyethylene glycol-polystyrene 
(PEG-PS), modified Sephadex supports, controlled-pore glass (CPG) and Cross-Linked 
Ethoxylate Acrylate Resin (CLEAR) can be used to attach Ellman’s reagent through two 
sites and promote cysteine disulfide bond formation in solution.86 In the oxidation process 
(Scheme 4.2), first, one of the peptidyl-thiol groups 4.1.A react with the solid-supported 
oxidant to generate solid-bound activated intermediate 4.1.B.  
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Scheme 4.2 Proposed mechanism for resin-bound Ellman’s reagent mediated intramolecular disulfide  
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Then, the intermediate 4.1.B undergoes intramolecular nucleophilic attack by the other 
peptidyl-thiol group to form the desired disulfide linkage, detached from the solid support 
and release the oxidized product 4.1.C back in to the solution. Simple filtration allows the 
isolation of desired disulfide products and the solid support reagent can be recycled and 
reused.162 Resin-bound Ellman’s oxidation offers a quick and straightforward tool to 
obtain disulfide bonds in peptides. Most significantly, it can function at a wide range of pH 
values and give relatively higher yields and purity over other solution phase oxidation 
methods such as Glutathione-based oxidation and DMSO mediated oxidation.162 
Furthermore, it can be used in orthogonal synthesis schemes (see Chapter 1) and offers 
high selectivity.163 The major drawback of this system is covalent binding of the substrate 
to the solid support, which diminish the overall yield of the product obtained in solution. 
However, the byproduct, the covalently bound peptide can be separated from the product 
easily by filtration at the end of oxidation, along with the resin-bound reduced reagent. 
The covalently bound peptide can be then released from the solid support by treatment 
with dithiothreitol to give the reduced from of the peptide.162,164   
4.4 Potential of Ellman’s Reagent as Mild Oxidizing Agent for On-Resin Cysteine Disulfide 
Formation 
 After understanding the potential of resin bound Ellman’s reagent as an oxidant to 
facilitate cysteine disulfide formation in solution, we were curious to examine its oxidation 
potential to form on-resin cysteine disulfide bonds when Ellman’s reagent is used as a 
solution. Preliminary test reactions were done using the model peptide IAPP1-9 (Table 
4.1).  
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For these experiments, linear synthesis of IAPP1-9 4.2.A was done on TGT resin using 
StBu as the cysteine protecting group. First, Deprotection of Cys(StBu) was done under 
microwave conditions at 60 ºC with 30% mercaptoethanol for an hour to get IAPP1-9 with 
reduced cysteines. Next, 1.0 equivalence of Ellman’s reagent in DMF was added to the 
on-resin reduced peptide and allowed to agitate in an open vial at room temperature. An  
interesting color changing effect was observed during this reaction. At the beginning when 
the resin was treated with Ellman’s reagent, the resin color turned to dark peach-orange 
Table 4.1 On-resin disulfide formation on model peptide IAPP1-9 using Ellman’s reagent
TrtBoc
tBu
tBu tBu
KCNTATCATH
SStBu SStBu
KCNTATCATH OH
SH SH
1) 30% Mercaptoethanol
    60 ºC µW, 1 h
2) 1.0 equiv. Ellman’s Reagent
    in DMF, t min
3) TFE:AcOH:DCM (1:1:3)
    30 min
TrttBu
tBu
tBu tBu
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S S
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Figure 4.1 Color change of the resin during on-resin Ellman’s reagent-mediated oxidation in DMF
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color (B. Figure 4.1). With time, intensity of the peach-orange color decreased (C. Figure 
4.1) and eventually the resin color turned to yellow (D. Figure 4.1). For our curiosity, the 
peptide was cleaved from the resin at different time interval related to each color change 
and the peptide was analyzed by RP-HPLC-MS to evaluate the status of the reaction at 
each time interval (Table 4.1). After 10 min, when the resin color is still dark peach-
orange, about 45% starting peptide 4.2.A was observed with 65% oxidized product 4.2.D 
(entry 1). At 50 min, when the initial resin color get faded to light peach color, hardly any 
starting peptide 4.2.A was observed and formation of a S-Sthionitrobenzoic double 
adduct on peptide 4.2.E was observed along with oxidized peptide 4.2.D (entry 2). When 
the resin color changed to yellow, at 60 min reaction time, fully oxidized product 4.2.D 
was observed as the major product with 30% of the peptide adduct 4.2.E (entry 3). with 
S-Sthionitrobenzoic double adduct. This is an interesting observation which demonstrate 
the colorimetric behavior of Ellman’s reagent to indicate on-resin cysteine disulfide bond 
formation while acting as the mild oxidant for the reaction. 
The mechanism of Ellman’s reagent-mediated on-resin disulfide formation can be 
related to that of solid-bound Ellman’s reagent-mediated solution phase oxidation 
described in Section 4.3 (Scheme 4.3). In this method the peptide containing reduced 
cysteines is attached to a resin instead of the oxidant been attached to a solid support. 
When the resin-bound peptide 4.3.A is treated with a solution of Ellman’s reagent in DMF, 
one of the peptidyl-thiol groups react with Ellman’s reagent and break the homo S-S bond 
to generate solid-bound activated intermediate 4.3.B.   
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This result release of one equivalent of 5-thio-2-nitrobenzoic acid, which gives a yellow 
color to the reaction system.   Formation of the intermediate 4.3.B may be indicated by 
the intense peach-orange color during the reaction, which diminishes the yellow 
coloration of 5-thio-2-nitrobenzoic acid in the reaction solution. As the peptide is attached 
to a resin, due the pseudo-dilution effect, an intramolecular disulfide bond formation is 
favored by the nucleophilic attack of other peptidyl-thiol group. The intramolecular 
reaction breaks the hetero-disulfide bond in the on-resin activated intermediate 4.3.B, 
which may results the disappearance of initial intense peach-orange color. The 
intramolecular reaction facilitates release of another 5-thio-2-nitrobenzoic acid. Hence, 
when the reaction goes to completion, the yellow color of 5-thio-2-nitrobenzoic acid 
becomes the dominant color in the reaction. Beside an intramolecular reaction, the 
second free thiol group of solid-bound activated intermediate can react with another 
molecule of Ellman’s reagent to form S-Sthionitrobenzoic double adduct on peptide 
(Scheme 4.4). This competitive intermolecular reaction forms a byproduct 4.3.D which 
can diminish the yield of the final folded product. Therefore, this Ellman’s reagent-
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Scheme 4.3 Suggested mechanism for on-resin intramolecular disulfide formation via Ellman’s reagent
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mediated on-resin disulfide formation reaction needed to be optimized for minimum 
intermolecular byproduct formation. 
 
In order to minimize the byproduct formation, a test experiment was performed using 
reduced IAPP1-9 4.4.A with different loadings of Ellman’s reagent in DMF (Table 4.2).   
 
Each test reaction was run until the color of the resin changed from dark peach-orange 
to yellow. A relationship was observed between the loading of Ellman’s reagent and the 
amount of byproduct 4.4.C formed. As the loading of Ellman’s reagent is lowered a 
decrement in the byproduct 4.4.C formation was observed along with an increment in the 
reaction time (entry 1 – entry 3). For IAPP1-9 4.4.A, 0.25 equivalent of Ellman’s reagent 
gave the oxidized product with zero byproduct in 3 hours (entry 3).  
PEPTIDE
S SH
H
NO2
HO
O
S
4.3.B
S
S
NO2
O2N
OH
O
O
HO
PEPTIDE
S S
H
NO2
HO
O
S
4.3.D
S
NO2
OH
O
Scheme 4.4 Proposed mechanism for formation of S-Sthionitrobenzoic double adduct on peptide
X equiv. of
Ellman’s R.
Time for 
color change (h) 4.4.B     :    4.4.C
1.00 1.0 60 40
0.50 2.5 90 10
0.25 3.0 100 00
TrtBoc
tBu
tBu tBu
KCNTATCATH
SH SH
4.4.A
TGT
9 1) X equiv. Ellman’s Reagent in DMF, t h
3) TFE:AcOH:DCM (1:1:3), 30 min
KCNTATCATH OH
S S
TrttBu
tBu
tBu tBu
4.4.B
TrtBoc
tBu
tBu tBu
KCNTATCATH OH
S S
4.4.C
9 9
TNB TNB
Table 4.2 Optimization for Ellman’s reagent loading to minimize byproduct formation
Entry
1.
2.
3.
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 Sensitive amino acid side chains of Met, Typ and Tyr can undergo various 
modifications in presence of an oxidant.164,165,166  Therefore a test reaction to determine 
the stability of methionine towards Ellman’s reagent oxidation was evaluated. For the test 
reaction, methionine incorporated model peptide IAPP1-9 4.5.A was used as the substrate 
(Scheme 4.5). The resin-bound peptide 4.5.A was subjected to Ellman’s reagent in DMF 
and the reaction was run until the color of the resin changes from dark peach-orange to 
yellow. The reaction was analyzed by analytical RP-HPLC and neither sulfoxide nor 
sulfone byproducts was observed. The desired oxidized product 4.5.B was observed with 
clean analytical trace. 
 
The stability of Typ and Tyr amino acids towards Ellman’s oxidation were also evaluated 
and the results will be discussed later in this chapter. 
4.5 On-Resin Disulfide Bond Formation in Peptides using Ellman’s Reagent in DMF  
4.5.1 On-Resin Synthesis of Oxytocin  
 After evaluating the potential of Ellman’s reagent to oxidize resin-bound free thiols 
in a model peptide, we wanted to apply this method to a real system. One of the common 
targets, oxytocin, was chosen and the peptide folding was achieved using Ellman’s 
reagent in DMF on rink amide resin (Scheme 4.6). The linear synthesis of the peptide 
4.6.A was done on rink amide resin via Fmoc-SPPS and it was subjected to 5% TFA in 
DCM in presence of TIPS to deprotect Cys(Trt) group. The resulting reduced peptide was 
Trt
tBu
tBu tBu
AMCNTATCATH
SH SH
4.5.A
TGT
9 1) 1.0 equiv. Ellman’s Reagent in DMF, 1 h
2) TFE:AcOH:DCM (1:1:3), 30 min
4.5.B
Trt
tBu
tBu tBu
AMCNTATCATH OH
S S
9
Scheme 4.5 Determination of Met stability toward Ellman’s reagent oxidation condition
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then treated with 0.25 equivalent of Ellman’s reagent to access the disulfide bond in 
oxytocin 4.6.B. The color change of the resin was used to monitor the reaction.   
 
No byproduct of S-Sthionitrobenzoic double adduct on peptide was observed during the 
reaction. Moreover, the Tyr group has not been affected by Ellman’s reagent-mediated 
oxidation condition. The reaction was clean according to the analytical RP-HPLC-MS 
data.  
4.5.2 On-Resin Synthesis of a-Conotoxin ImI  
 The success in the synthesis of oxytocin, which contains single disulfide linkage, 
led us to evaluate the Ellman’s reagent – mediated oxidation method for more advanced 
systems. One of such systems we selected was the C-terminal carboxamide a-conotoxin 
ImI, a sub-type selective nicotinic acetylcholine receptor antagonist167,168,169 isolated from 
the venom of Conus imperialis marine snails.170,171,172 It has two disulfide linkages lie 
between Cys2-Cys8 and Cys3-Cys12 (Figure 4.3)173. 
 
  
NH2
Trt
tBu
Trt
CYIQNCPLGH
STrt STrt
CYIQNCPLGH
S S
1) TFA:TIPS:CH2Cl2 (5:5:90), 5 x 1 min
2) Ellman’s Reagent in DMF
3) TFA:TIPS:H2O (95:2.5:2.5), 2 h
Scheme 4.6 On-resin synthesis of oxytocin
4.6.A 4.6.B
9
RA
9
Gly1-Cys2-Cys3-Ser4-Asp5-Pro6-Arg7-Cys8-Ala9-Trp10-Arg11-Cys12H NH2
S S
S S
A.
B.
Figure 4.2 A. Structure of α-conotoxin ImI B. Graphical represtation of α-conotoxin ImI structure
NH2GCCSDPRCAWRC
S
H
S
S
S
12
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The on-resin synthetic pathway for a-conotoxin ImI was designed in two steps using 
Cys(Acm) and Cys(Trt) groups (Scheme 4.7). The linear synthesis of the starting peptide 
4.7.A was done on rink amide linker-Gly-Gly-Gly-ChemMatric resin. The synthesis 
protocol for a-conotoxin ImI was designed such that the larger loop between Cys3-Cys12 
is made first followed by the small loop between Cys2-Cys8. To achieve the larger loop, 
first, Cys(Trt) deprotection can be done with 5% TFA in DCM in presence of TIPS as the 
scavenger. The resulting free thiol can then be oxidized using Ellman’s reagent in DMF.  
 
Before start the synthesis, the loading of Ellman’s reagent was optimized to get zero 
byproduct during reaction (Table 4.3). 
1) TFA:TIPS:CH2Cl2 (5:5:90)
2) Ellman’s Reagent in DMF
GCCSDPRCAWRC
tBu Pbf
Boc
SAcm
PbfTrt
H
STrt
RA Linker CMGGG
SAcm
STrt
GCCSDPRCAWRC
tBu Pbf
Boc
SAcm
PbfTrt
H
S
SAcm
S
NH2GCCSDPRCAWRC
S
H
S
S
S
RA Linker CMGGG
Scheme 4.7 Synthetic design for on-resin synthesis of α-Conotoxin ImI
1) I2 in DCM
2) TFA:TIPS:H2O (95:2.5:2.5)
12
12
12
4.7.A
4.7.B
4.7.C
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The loadings of Ellman’s reagent was varied from 1.0 equivalent to 0.125 equivalent and 
each of the reactions were run until the color of the resin changes from dark peach-orange 
to yellow. With 1.0 equivalent of Ellman’s reagent, 70% conversion of the desired product 
4.7.D was observed in 3 hours with 30% conversion of the byproduct 4.7.E (entry 1). 
About 90% conversion of the desired oxidized product was observed in 12 hours when 
the loading of Ellman’s reagent was 0.25 equivalent (entry 2). For the larger loop of a-
conotoxin ImI, zero byproduct formation can be achieved with 0.125 equivalent of 
Ellman’s reagent in DMF in 24 hours (entry 3). Hence, the first step of the synthesis was 
scaled up using the optimized condition for Ellman’s reagent in DMF. Then, the resulting 
mono cyclized peptide 4.7.B was treated with 8 equivalent of iodine in DCM for 2 hours 
to remove Acm group and oxidize the free thiol groups, which result the fully folded 
peptide 4.7.C on resin. The a-conotoxin ImI has Trp amino acid residue and no side chain 
modification was observed during the Ellman’s reagent-mediated oxidation process. Only 
GCCSDPRCAWRC
tBu Pbf
Boc
SAcm
PbfTrt
H
STrt
RA Linker CMGGG
SAcm
STrt
12
NH2GCCSDPRCAWRC
SAcm
H
S
SAcm
S
12
NH2GCCSDPRCAWRC
SAcm
H
S
SAcm
S
12
TNB TNB
1) TFA:TIPS:DCM (5:5:90)
    5 x 1 min
2) X equiv. Ellman’s Reagent
    in DMF, t h
3) TFA:TIPS:H2O (95:2.5:2.5)
    3 h
4.7.A
4.7.D
4.7.E
Table 4.3 Optimization of the loading of Ellman’s reagent for minimum byproduct formation
X equiv. of
Ellman’s R.
Time for 
color change (h) 4.7.D    :    4.7.E
1.000 3 70 30
0.250 12 90 10
0.125 24 100 00
Entry
1.
2.
3.
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the fully folded product with desired disulfide bond pattern was observed  in 59% overall 
yield.   
4.5.3 On-Resin Synthesis of a4/7-conotoxin LvIA  
 One of the suggested synthetic routes to access a4/7-conotoxin LvIA (see Chapter 
03) was use Cys(Trt) to form small loop first, either by iodine oxidation or NCS oxidation, 
followed by Cys(Allocam) deprotection and oxidation with Pd-DMSO based cleavage-
oxidation condition to fold the larger loop (Scheme 4.8). Sensitivity of the Allocam group 
towards both iodine oxidation and NCS oxidation failed this synthetic path (4.8.A – 4.8.B) 
and we had to select another method to access first disulfide bond formation, which 
described in chapter 03.  
 
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
STrt STrt
SAllocam SAllocam
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
S S
SAllocam SAllocam
1) TFA:TIPS:DCM (5:5:90), 5 x 1 min
2) NCS in DMF
RA Linker CMGGG
RA Linker CMGGG
1) 3.0 Pd(OAc)2 in
    5%AcOH-DMSO-3%NMM, 6 h
2) TFA:TIPS:H2O (95:2.5:2.5), 2 h
NH2GCCSHPACNVDHPEICH
S S
S S
Scheme 4.8 Suggested on-resin synthesis of α4/7-Conotoxin LvIA with 
                      Cys(Trt) and Cys(Allocam)
4.8.A
4.8.B
4.8.C
16
16
16
I2 in DCM
OR
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After the discovery of Ellman’s reagent as a mild oxidant for on-resin cysteine disulfide 
bond formation, we wanted to revisit the synthesis of a4/7-conotoxin LvIA using Ellman’s 
reagent to form the first S-S bond.  
After the linear synthesis of the peptide 4.8.A, it was subjected to screening the 
best loading condition for Ellman’s reagent to get 100% conversion of the desired mono 
cyclic product 4.8.B. with zero byproduct formation (Table 4.4). 
 
From the optimization data, it was found that 0.125 equivalent of Ellman’s reagent is the 
best condition for this target peptide to form its first disulfide linkage without any byproduct 
made during the oxidation step (entry 3). With the optimized data in hand, the reaction 
was scaled up. Next, the resulting mono cyclic peptide 4.8.B was subjected to I2 oxidation 
for simultaneous Allocam removal and oxidize to get the bicyclic peptide 4.8.C with 
desired disulfide pattern (Scheme 4.9). From chapter 03, it was identified that iodine 
oxidation gives better conversion with good yield compared to Pd-DMSO based Allocam 
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
STrt STrt
SAllocam SAllocam
RA Linker CMGGG
4.8.A
16
1) TFA:TIPS:DCM (5:5:90)
    5 x 1 min
2) X equiv. Ellman’s Reagent
    in DMF, t h
3) TFA:TIPS:H2O (95:2.5:2.5)
    1 h
Table 4.4 Optimization of the loading of Ellman’s reagent for minimum byproduct formation
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
S S
SAllocam SAllocam
4.8.D
16
NH2
GCCSHPACNVDHPEIC
tBu tBu
Trt
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H
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4.8.E
16
NH2
TNB TNB
X equiv. of
Ellman’s R.
Time for 
color change (h) 4.8.D    :    4.8.E
1.000 2 95 05
0.250 10 97 03
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removal and oxidation condition. Therefore, in this synthesis protocol, iodine oxidation 
was chosen over the Pd-DMSO based Allocam removal and oxidation condition to make 
the second disulfide bond. From this method, we were able to synthesize a4/7-conotoxin 
LvIA in 24% overall yield. 
 
Interestingly, Ellman’s reagent-mediated oxidation of on-resin free thiols give access to 
combine Allocam with Trt as the cysteine protecting group to generate disulfides in 
peptides in either order, which was not possible before. This permits the formation of 
disulfides on-resin in either order from a single linear sequence/substrate 4.9.A (Scheme 
4.10). This strategic flexibility can be applied to any peptide containing two disulfide 
linkages. 
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
STrt STrt
SAllocam SAllocam
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
S S
SAllocam SAllocam
1) TFA:TIPS:DCM (5:5:90), 5 x 1 min
2) 0.125 equiv. Ellman’s Reagent in DMF, 16 h
RA Linker CMGGG
RA Linker CMGGG
1) 8 equiv. I2 in DCM, 6 h
2) TFA:TIPS:H2O (95:2.5:2.5), 2 h
NH2GCCSHPACNVDHPEICH
S S
S S
Scheme 4.9 On-resin synthesis of α4/7-Conotoxin LvIA with Cys(Trt)  
                      and Cys(Allocam)
4.8.A
4.8.B
4.8.C
16
16
16
Overall yield - 24%
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4.6 On-Resin Folding of Peptides using Ellman’s Reagent as the Only Oxidizing Agent 
 After investigating the potential of Ellman’s reagent as a colorimetric and mild 
oxidizing agent, we were curious to take advantage of its potential to form all the disulfide 
bonds in a peptide selectively using Ellman’s reagent as the only oxidizing agent. As we 
have seen in previous synthetic procedures, Ellman’s reagent react on free thiols and 
oxidize them to S-S bonds. Therefore, in order to perform oxidation with Ellman’s reagent, 
the cysteine pairs in the target peptide needed to be protected with protecting groups 
which have  deprotecting condition to get free thiol groups. Examples for such protecting 
groups are StBu, which can be cleaved with mercaptoethanol to get free thiol, Trt and 
Mmt, which result the reduced cysteine with mild TFA conditions. To evaluate the method, 
a4/7-conotoxin LvIA was chosen as the target. 
4.6.1 Synthesis of a4/7-Conotoxin LvIA using Ellman’s Reagent in DMF  
 For the synthesis of a4/7-conotoxin LvIA using Ellman’s reagent as the only 
oxidant, StBu and Trt were chosen to protect each pair of cysteines in the peptide. The 
linear synthesis of the peptide 4.10.A was first done on rink amide linker-Gly-Gly-Gly-
TrtTrtTrt
tBu tButBu
TrtTrtTrt
tBu tButBu
TrtTrtTrt
tBu tButBu
GCCSHPACNVDHPEICH
S
S S
NH2
S
GCCSHPACNVDHPEICH
SPG1
S S
NH2
SPG1
GCCSHPACNVDHPEICH
S
SPG2 SPG2
NH2
S
ORGCCSHPACNVDHPEICH
SPG1
SPG2 SPG2
NH2
SPG1
3.0 equiv Pd(OAc)2
NMM, AcOH, DMSO
Scheme 4.10 Strategic flexibility in the controlled folding of α4/7-Conotoxin LVIA.
PG1 = Allocam
PG2 = Trt
PG1 = Trt
PG2 = Allocam 1) 5% TFA, CH2Cl2
2) Ellman’s Reagent
1) 3.0 equiv Pd(OAc)2
NMM, AcOH, DMSO
2) TFE, CH2Cl2, AcOH
3) TFA, H2O, TIPS
1) 5% TFA, CH2Cl2
2) Ellman’s Reagent
2) TFE, CH2Cl2, AcOH
3) TFA, H2O, TIPS
16
16
16
16
4.9.A
4.9.B
4.9.B’
4.9.C
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Chemmatrix resin using Cys(StBu) and Cys(Trt). Selective folding methods were then 
proceeded on the linear peptide to get the desired folding pattern (Scheme 4.11). The 
linear peptide was first treated with 30% mercaptoethanol for 3 hours under microwave 
heating at 60 ºC to remove StBu groups.  
 
The resulting free thiols in the peptide 4.10.B was then oxidized using previously 
optimized condition (see Table 4.4) for Ellman’s reagent – mediated oxidation. The 
reaction was run until the color of the resin changes from dark peach-orange to yellow. 
This step formed the small loop selectively. Next, Cys(Trt) deprotection of the mono cyclic 
Scheme 4.11 On-resin formation of disulfide bonds in α4/7-Conotoxin LvIA      
                        using Ellman’s Reagent in DMF
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2) 0.125 equiv. Ellman’s Reagent, ~ 28 h
3) TFA:TIPS:H2O (95:2.5:2.5), 2 h
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S S
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peptide 4.10.C was done using 5% TFA in DCM in presence of TIPS for 5 x 1 min. The 
resulting free thiol was then oxidized again with Ellman’s reagent in DMF and the reaction 
was monitored by the color change of the resin. It took about 28 hours to form the larger 
loop of the peptide in DMF. The 5% TFA treatment was done several times followed by 
addition of Ellman’s reagent during the reaction in order to ensure completion of the 
reaction (see experimental procedures for more details). When no color change was 
observed after addition of Ellman’s reagent, the reaction was terminated by filtering off 
the solution of Ellman’s reagent followed by several DMF wash. The total deprotection 
and resin cleavage was done to collect the resulting peptide and analytical RP-HPLC was 
performed to confirm the product 4.10.D formation. Surprisingly in the analytical HPLC 
trace the fully folded product 4.10.D was observed in very minor amount whereas the 
mono-cyclic peptide 4.10.C was observed as the major product. The last step of the 
synthesis was revisited with longer TFA treatment with 10% TFA in DCM for 10 x 2 min, 
followed by Ellman’s reagent – mediated oxidation. The resulting peptide was cleaved 
after color change of the resin and analyzed again via analytical RP-HPLC. This slight 
modification in the last step of the synthesis facilitated formation of the desired fully folded 
product 4.10.D. This experiment illustrates that removal of Trt group from the mono cyclic 
system is difficult and longer exposer time or higher TFA concentration is needed to 
improve the synthesis.  
4.6.2 Synthesis of a4/7-Conotoxin LvIA using Ellman’s Reagent in NMP  
 When considering all the synthesis protocols we performed using Ellman’s reagent 
in DMF to form disulfide bonds, the only drawback is longer reaction time. In addition to 
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DMF as the solvent, the reaction was done with 1.0 equivalent of Ellman’s reagent in 
methanol, DMSO and NMP to evaluate their colorimetric behavior. The test experiments 
were done using reduced IAPP1-9 as the model peptide. The color of the resin changed 
to intense yellow color with the addition of Ellman’s reagent in methanol (A. Figure 4.3) 
whereas  with DMSO (B. Figure 4.3) and NMP (C. Figure 4.3), the color of the resin 
changed to dark peach-orange color similar to that in DMF. The reactions were then eft 
for few hours to observe any other changes. Even after two hours, no color change was 
observed in the reactions with methanol and DMSO. Interestingly, in the reaction with 
NMP, the color of the resin changed from dark peach-orange to yellow in 20 min instead 
of an hour with DMF. Analytical RP-HPLC-MS analysis were performed for all of the 
peptides and it confirmed disulfide bond formation during the reaction. In the reaction with 
NMP, no S-Sthionitrobenzoic double adduct on peptide was observed, which was 
significant in the reaction with DMF.  
 
 
  
 
 
 
 
After investigation of faster reaction rates in NMP solvent, the method described in section 
4.6.2 was revisited with Cys(StBu) and Cys(Mmt) to synthesize a4/7-conotoxin LvIA using 
A
Ellman’s in MeOH
B
Ellman’s in DMSO
C
Ellman’s in NMP
Figure 4.3 Color of the resin with Ellman’s reagent in different solvents
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Ellman’s reagent in NMP (Scheme 4.12). First, the linear peptide 4.10.A was subjected 
to 30% mercaptoethanol for 3 hours under microwave heating at 60 ºC to deprotect 
Cys(StBu). Then, the resulting reduced peptide 4.10.B was treated with Ellman’s reagent 
in NMP.  
 
Completion of the first disulfide bond formation was monitored by color change of the 
resin and it required only 30 min. The resulting mono cyclic peptide 4.10.C was treated 
with 5% TFA in DCM in presence of TIPS as a scavenger for 5 x 1 min to ensure Mmt 
group removal in the system. Another solution of Ellman’s reagent in NMP was added to 
Scheme 4.12 On-resin formation of disulfide bonds in α4/7-Conotoxin LvIA      
                        using Ellman’s Reagent in NMP
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the resin with free thiols at Cys3 and Cys16 to form the second disulfide bond. Color 
changed from dark orange to yellow in 90 min for this step. Finally, Ellman’s reagent was 
filtered off and the resin was washed thoroughly with NMP. Analytical RP-HPLC-MS was 
performed to the cleaved peptide and ES-MS confirmed the fully folded peptide 4.2.D.  
After purification, a4/7-conotoxin LvIA was isolated in 76% overall yield. Disulfide bond 
formation using Ellman’s reagent in NMP shows greater improvement in reaction rates 
compared to that of in DMF.  
4.7 Summary 
 We demonstrated the potential of Ellman’s reagent as a colorimetric and mild 
oxidizing agent to form on-resin disulfide bonds in peptides. The reaction procedure is 
simple, no complex time consuming reaction set up is needed. Most importantly, the 
reaction can be monitored easily by observing the color change of the resin, which is 
advantageous over time consuming lengthy reaction analysis protocols. The colorimetric 
behavior of Ellman’s reagent can be seen both in DMF and NMP. Ellman’s reagent – 
mediated disulfide bond formation in DMF is relatively slower and the yield-diminishing 
intermolecular side reaction involving formation of S-Sthionitrobenzoic double adduct on 
peptide can be addressed by optimizing the loading of Ellman’s reagent for each 
substrate. Therefore, DMF is best in formation of smaller disulfide linkages in peptides. 
In contrast, Ellman’s reagent – mediated disulfide bond formation in NMP has faster 
reaction rates and no S-Sthionitrobenzoic double adduct on peptide was observed even 
with 1.0 equivalent of Ellman’s reagent. The insight of colorimetric behavior of Ellman’s 
reagent in disulfide bond formation process needed to be further investigated. However, 
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on-resin disulfide bond formation using Ellman’s reagent introduces a simple and an 
efficient synthetic route to access disulfide rich bioactive peptides.  
4.8 Methods and Material 
4.8.1 General Information 
 Unless otherwise specified, all commercially available reagents were purchased from 
Sigma-Aldrich and used without further purification. Anhydrous Et2O, MeCN, DMF, 
DMSO, CH2Cl2 were purchased from Fisher. These were passed through a commercial 
solvent purification system (2 columns of alumina) and used without further drying. 
Hünig’s base was distilled over CaH2 immediately prior to use. All amino acids were 
purchased from Chem-Impex Int’l. Inc. unless otherwise noted. HATU were purchased 
from Chem-Impex Int’l. Inc. Unless otherwise noted, all reactions were performed in 2 mL, 
5 mL and 10 mL Biotage reactor vials with PTFE frit (depend on reaction volume) at room 
temperature. All yields refer to chromatographically and spectroscopically pure products. 
All HPLC analyses and purifications were performed on a Custom Reverse Phase 
Shimadzu Liquid Chromatograph Mass Spectrometer (LCMS-2020), which can toggle 
between analytical and semi-preparative columns. This instrument has a photodiode 
array (PDA) detector (D2 & W lamp), which collects a range of wavelengths, in place of 
a traditional single channel UV detector. RP-HPLC-MS mobile phases (MeCN and H2O) 
contained 0.1% Formic Acid. Analytical HPLC was performed on a Phenomenex Kinetex 
C18 column (5 µm, 250 x 4.6 mm) and a Thermo Scientific Hypersil Gold C8 column (5 
µm, 250 x 4.6 mm). Semi-Preparative HPLC was conducted using a Thermo Scientific 
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Hypersil Gold C8 column (5 µm, 150 x 10 mm). All peptide yields are calculated based 
on the final loading. 
SPPS General Information. Solid-phase peptide synthesis was executed on a Biotage 
Isolera+ semi-automated synthesizer with microwave heating. 
•   Reactor Vials [Vial size (Volume range allowed)]: 2 mL reactor vial (0.8-1.1 mL), 5 mL 
reactor vial (1.6-3.2 mL), and 10 mL reactor vial (3.2-6.4 mL) 
•   Swelling + Heat: DMF was added and vortexed at 1200 RPM for 20 m at 70 ºC. The 
solvent was then removed over 1 m followed by two DMF washes (DMF was added 
and the suspension was vortexed at 600 RPM for 45 s, followed by the removal of 
solvent (over 2 m)).  
•   Coupling: A solution of Fmoc-aa-OH (3 equiv), HATU (3 equiv), and DIPEA (6 equiv) 
in DMF was made immediately prior to addition to the reaction vial containing the 
resin. Once the solution was added, the suspension was heated to 75 ºC (except for 
Fmoc-Cys-OH which was heated to 50 ºC) for 5 minutes with a vortex rate of 1200 
RPM. After the reaction, the solution was removed (over 2 m) and the resin was rinsed 
with DMF 4 times (after addition of DMF, the suspension was agitated at a vortex rate 
of 1200 RPM for 1 m, solvent removal was at a rate of 2 m). 
•   Fmoc Removal (Deprotection): The reactor vial was filled with 20% piperidine in DMF. 
The suspension was vortexed at 1200 RPM for 3 m at RT. The solvent is removed 
followed by addition of 20% piperidine in DMF. The suspension is vortexed again at 
1200 RPM for 10 m at RT. The solvent was removed over 2 m, followed by 4 DMF 
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washes (after addition of DMF, the suspension was agitated at a vortex rate of 1200 
RPM for 1 m, solvent removal was at a rate of 2 m). 
•   Wash: DMF was added to the reaction vial and agitated at a vortex rate of 1200 RPM 
for 1 m. The solvent was removed over 1 m and repeated for a total of 4 times. 
•   Final Wash: Resin was rinsed with CH2Cl2 (3 x 1 mL) and MeOH (3 x 1 mL). 
•   Drying for Storage/Weighing: After the final wash, the resin was placed on the 
lyophilizer overnight for drying. 
General Procedure for Capping - First, 25% acetic anhydride in DMF (3 mL) was added 
and agitated for 5 min. Then,1.5 eqiuv. of DIPEA was added to the reaction and agitated 
for 30 min. Finally, the reaction solution was filtered and the resin was washed with DMF 
(5 x 3 mL). 
Procedure for Resin Loading Analysis. Initial and final loading of resin was analyzed 
based on amount of Fmoc group. 
Fmoc Deprotection – 10 mg of the resin was weighed out and swelled in DMF in the 
peptide synthesizer. Then, 1.00 ml of 20% piperidine in DMF was added and it was 
allowed to vortex in the peptide synthesizer at room temperature for 3 min. After 3 min, 
the filtrate was collected in to a separate tube, another 1.00 ml of 20% piperidine in DMF 
was added to it and allowed to vortex in the peptide synthesizer at room temperature for 
10 min. The resulting filtrate was collected to the same tube and the deprotected resin 
was washed with DMF (4 x 1.75 ml). 
Sample preparation for UV analysis – From the collected ”deprotection solution” above, 
100 µL was transferred in to an eppendorf tube and it was diluted with 900 µl of DMF. 
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The resulting diluted sample was used to get the absorbance at 301 nm versus a DMF 
blank using a UV spectrometer with 1 cm cuvette. 
4.8.2 Experimental Procedures and Spectroscopic Data 
 
Reduced IAPP1-9 4.4.A. The resin 4.2.A (60 mg, 12 µmol) was first swelled in DMF (500 
µL). Then, a solution of 30% mercaptoethanol in DMF (1.0 mL) was added and agitated 
at 60 ºC under microwave condition for 1 hour. The reaction solution was filtered and the 
resin was washed with DMF (5 x 1 mL). To analyze the reaction 5 mg of the resulting 
resin was subjected to 300 µL of the cleavage mixture (1:1:3 TFE:AcOH:DCM) for 30 min. 
The resulting solution was filtered, concentrated and analyzed via MS, direct injections at 
a flow rate of 0.4 mL/min with 50% MeCN/H2O for 1.5 minutes. m/z ES calc’d for peptide 
4.4.A [(C70H107N11O16S2)+1]+: 1422.81; observed: 1423.55; m/z ES calc’d for 
[(C70H107N11O16S2 + 2)/2]+: 712.41; observed: 712.00. 
 
Figure 4.4 Analytical Column PDA for reduced IAPP1-9 4.4.A  
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General Procedure for Table 4.2. For each of the test reactions, the resin 4.4.A (10 mg, 
2 µmol) was first swelled in DMF (500 µL). Then, the stated amount of Ellman’s reagent 
in DMF (1.0 mL) was added and agitated for the stated amount of time. The reaction 
solution was filtered and the resin was washed with DMF (5 x 1 mL). The resulting resin 
was subjected to 300 µL of the cleavage mixture (1:1:3 TFE:AcOH:DCM) for 30 min. The 
resulting solution was filtered, concentrated and analyzed via RP-HPLC-MS using an 
analytical Thermo Scientific Hypersil Gold C8 column  at a flow rate of 1 mL/min with 10-
50% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 4.4.B 
[C70H107N11O16S2 + 1]+: 1420.79; observed: 1421.85. m/z ES calc’d for 
[(C70H107N11O16S2 + 2)/2]+: 711.39; observed: 711.20. m/z ES calc’d for peptide 4.4.C 
[C84H113N13O24S4 + 1]+: 1817.14; observed: 1817.15. m/z ES calc’d for 
[(C84H113N13O24S4 + 2)/2]+: 909.57; observed: 909.30. 
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Entry 1. A solution of Ellman’s reagent (0.8 mg, 2 µmol) in DMF (1.0 mL) was added and 
the reaction was agitated for 1 hour.  
  
Figure 4.5 Analytical Column PDA for Table 4.2 – Entry 1  
 
Entry 2. A solution of Ellman’s reagent (0.4 mg, 1 µmol) in DMF (1.0 mL) was added and 
the reaction was agitated for 2.5 hours.  
  
Figure 4.6 Analytical Column PDA for Table 4.2 – Entry 2  
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Entry 3. A solution of Ellman’s reagent (0.2 mg, 0.5 µmol) in DMF (1.0 mL) was added 
and the reaction was agitated for 3 hours.  
 
Figure 4.7. Analytical Column PDA for Table 4.2 – Entry 3  
 
 
 
SPPS of Linear Peptide 4.7.A. The standard Fmoc-SPPS protocol described was used 
to synthesize peptide 4.7.A on Rink Amide linker-Gly-Gly-Gly-ChemMatrix resin. The 
peptide was capped before the last coupling step. To analyze the peptide, 10 mg of the 
resin was subjected general ammonia cleavage protocol and the resulting crude product 
was dissolved in 10% MeCN:Water in presence of 0.05%TFA and analyzed via Rp-
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HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow rate 
of 1 mL/min with 10-50% MeCN/H2O gradient for 30 minutes. Final loading of the resin: 
0.15 mmol/g. m/z ES calc’d for peptide 4.X.B [(C58H92N22O17S4 + 2)/2]+: 749.87; 
observed: 746.60. m/z ES calc’d for [(C58H92N22O17S4 + 3)/3]+: 500.25; observed: 500.05. 
    
Figure 4.8 Analytical Column PDA for linear peptide 4.7.A; Gradient: 10-50% MeCN/H2O + 1% HCOOH  
over 30 min. Retention time 14.02 min 
  
 
 
Figure 4.9 ES-MS spectrum for linear peptide 4.7.A at retention time 14.02 min 
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Linear Peptide (4.7.A); [(M+3)/3]+ 
 
PDA 254 nm 
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General Procedure for Table 4.3. For each of the test reactions, the resin 4.7.A (10 mg, 
4 µmol) was first swelled in DMF (500 µL). Then, a freshly prepared solution of 
TFA:TIPS:DCM (5:5:90) was added and the reaction mixture was agitated at room 
temperature for 5 x 2 min. About 1 – 2 drops of more TIPS were added during the reaction 
until the orange-yellow color disappeared in the reaction mixture. The resulting TFA 
solution was filtered and the resin was washed with DCM (3 x 1 mL). After that, the resin 
was subjected to the stated amount of Ellman’s Reagent in DMF for the stated amount of 
time until the resin color changed from peach to yellow. Finally, the reaction solution was 
filtered and the resin was washed with DMF (6 x 1 mL) and DCM (6 x 1 mL). In order to 
confirmed the total Trt group removal, the resulting peptide was retreated with a solution 
of TFA:TIPS:DCM (5:5:90) for 5 x 1 min and re-subjected to the stated amount of Ellman’s 
Reagent in DMF. If the resin color changes to peach-orange color upon addition of 
Ellman’s reagent, the reaction was agitated further until the resin color changed from 
peach to yellow. This procedure was repeated until no color change was observed. When 
no color change was observed, the solution of Ellman’s reagent added was filtered and 
the resin was washed with DMF (6 x 1 mL) and DCM (6 x 1 mL). The resulting resin was 
subjected to 300 µL of the cleavage mixture TFA:TIPS:H2O (95:2.5.2.5) for 3 hours. The 
GCCSDPRCAWRC
tBu Pbf
Boc
SAcm
PbfTrt
H
STrt
RA Linker CMGGG
SAcm
STrt
12
NH2GCCSDPRCAWRC
SAcm
H
S
SAcm
S
12
NH2GCCSDPRCAWRC
SAcm
H
S
SAcm
S
12
TNB TNB
1) TFA:TIPS:DCM (5:5:90)
    5 x 1 min
2) X equiv. Ellman’s Reagent
    in DMF, t h
3) TFA:TIPS:H2O (95:2.5:2.5)
    3 h
4.7.A
4.7.D
4.7.E
 
 
182 
resulting the TFA solutions were collected, concentrated under a constant stream of air, 
crashed out with cold diethyl ether, centrifuged, and decanted to yield the crude peptide. 
The resulting pellet was dissolved in 10% MeCN:Water in presence of 0.05%TFA. This 
solution was analyzed via RP-HPLC-MS using an analytical Thermo Scientific Hypersil 
Gold C8 column at a flow rate of 1 mL/min with 10-50% MeCN/H2O gradient for 30 
minutes. m/z ES calc’d for peptide 4.7.D [(C58H90N22O17S4 + 2)/2]+: 748.87; observed: 
748.75. m/z ES calc’d for [(C58H90N22O17S4 + 3)/3]+: 499.58; observed: 499.40. m/z ES 
calc’d for peptide 4.7.E [(C72H98N24O25S6+ 2)/2]+: 947.04; observed: 946.75. m/z ES 
calc’d for [(C72H98N24O25S6+ 3)/3]+: 631.69; observed: 631.50 
 
Entry 1. A solution of Ellman’s reagent (1.6 mg, 4 µmol) in DMF (1.0 mL) was added and 
the reaction was agitated for 3 hours.  
  
Figure 4.10 Analytical Column PDA for reaction optimization; Table 4.3 – Entry 1  
        
Oxidized pdt (4.7.D); [(M+2)/2]+  
 
Byproduct (4.7.E); [(M+2)/2]+ 
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Entry 2. A solution of Ellman’s reagent (0.4 mg, 1 µmol) in DMF (1.0 mL) was added and 
the reaction was agitated for 12 hours  
  
Figure 4.11 Analytical Column PDA for reaction optimization; Table 4.3 – Entry 2  
 
Entry 3. A solution of Ellman’s reagent (0.2 mg, 0.5 µmol) in DMF (1.0 mL) was added 
and th reaction was agitated for 24 hours.  
  
Figure 4.12 Analytical Column PDA for reaction optimization; Table 4.3 – Entry 3 
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Synthesis of a-conotoxin ImI 4.7.F. The peptide 4.7.B (100 mg, 40 µmol) was first 
swelled in DCM (3 mL). Then, a solution of iodine (81.2 mg, 320 µmol) in DCM (3 mL) 
was added and allowed to agitate in a 10 mL vial at room temperature for 2 hours. The 
reaction solution was filtered and the resin was washed with DMF (10 x 1 mL) and DCM 
(10 x 1 mL).  The resulting resin was subjected to 300 µL of the cleavage mixture 
TFA:TIPS:H2O (95:2.5.2.5) for 3 hours. Finally, the TFA solutions were collected, 
concentrated under a constant stream of air, crashed out with cold diethyl ether, 
centrifuged, and decanted to yield the crude peptide. The resulting pellet was dissolved 
in 10% MeCN:Water in presence of 0.05%TFA and purified via RP-HPLC-MS using a 
Semi-Preparative Thermo Scientific Hypersil Gold C8 column at a flow rate of 5 mL/min 
with 5–40% MeCN/H2O gradient for 15 minutes to yield the pure peptide in 59% overall 
yield (11.9 mg). m/z ES calc’d for peptide 4.7.F [(C52H78N20O15S4 + 2)/2]+: 676.78; 
observed: 676.60. m/z ES calc’d for [(C52H78N20O15S4 + 3)/3]+: 451.52; observed: 451.35. 
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Figure 4.13 Analytical Column PDA of crude a-conotoxin ImI 4.7.F. Gradient: 10-50% MeCN/H2O + 1% HCOOH  
over 30 min.  
 
 
 
 
Figure 4.14 Analytical Column PDA of pure a-conotoxin ImI 4.7.F. Gradient: 5-40% MeCN/H2O + 1% HCOOH  
over 15 min. Retention time 10.01 min  
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Figure 4.15 ES-MS spectrum for pure a-conotoxin ImI 4.7.F at retention time 10.01 min  
 
 
 
 
 
SPPS of Linear Peptide 4.8.A. The standard Fmoc-SPPS protocol described was used 
to synthesize peptide 4.8.A on Rink Amide linker-Gly-Gly-Gly-ChemMatrix resin. The 
peptide was capped before the last coupling step. To analyze the peptide, 10 mg of the 
resin was subjected general ammonia cleavage protocol and the resulting crude product 
was dissolved in 10% MeCN:Water in presence of 0.05%TFA and analyzed via Rp-
HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow rate 
of 1 mL/min with 10-50% MeCN/H2O gradient for 30 minutes. Final loading of the resin: 
0.10 mmol/g. m/z ES calc’d for peptide 4.8.B [(C76H116N24O26S4 + 2)/2]+: 956.07; 
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observed: 955.80. m/z ES calc’d for [(C76H116N24O26S4 + 3)/3]+: 637.72; observed: 
637.60. 
 
Figure 4.16 Analytical Column PDA for linear peptide 4.8.A; Gradient: 10-50% MeCN/H2O + 1% HCOOH  
over 30 min. Retention time 17.35 min 
 
 
 
Figure 4.17 ES-MS spectrum for linear peptide 4.8.A at retention time 17.35 min 
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General Procedure for Table 4.4.  For each of the test reactions, the resin 4.8.A (10 mg, 
3 µmol) was first swelled in DMF (500 µL). Then, a freshly prepared solution of 
TFA:TIPS:DCM (5:5:90) was added and the reaction mixture was agitated at room 
temperature for 5 x 1 min. About 1 – 2 drops of more TIPS were added during the reaction 
until the orange-yellow color disappeared in the reaction mixture. The resulting TFA 
solution was filtered and the resin was washed with DCM (3 x 1 mL). After that, the resin 
was subjected to the stated amount of Ellman’s Reagent in DMF for the stated amount of 
time until the resin color changed from peach to yellow. Finally, the reaction solution was 
filtered and the resin was washed with DMF (6 x 1 mL) and DCM (6 x 1 mL). In order to 
confirmed the total Trt group removal, the resulting peptide was retreated with a solution 
of TFA:TIPS:DCM (5:5:90) for 5 x 1 min and re-subjected to the stated amount of Ellman’s 
Reagent in DMF. If the resin color changes to peach-orange color upon addition of 
Ellman’s reagent, the reaction was agitated further until the resin color changed from 
peach to yellow. This procedure was repeated until no color change was observed. When 
no color change was observed, the solution of Ellman’s reagent added was filtered and 
the resin was washed with DMF (6 x 1 mL) and DCM (6 x 1 mL). The resulting resin was 
subjected to 300 µL of the cleavage mixture TFA:TIPS:H2O (95:2.5.2.5) for 1 hour. The 
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resulting the TFA solutions were collected, concentrated under a constant stream of air, 
crashed out with cold diethyl ether, centrifuged, and decanted to yield the crude peptide. 
The resulting pellet was dissolved in 10% MeCN:Water in presence of 0.05%TFA. This 
solution was analyzed via RP-HPLC-MS using an analytical Thermo Scientific Hypersil 
Gold C8 column at a flow rate of 1 mL/min with 10-50% MeCN/H2O gradient for 30 
minutes. . m/z ES calc’d for peptide 4.8.D [(C76H114N24O26S4 + 2)/2]+: 955.06; observed: 
954.85. m/z ES calc’d for [(C76H114N24O26S4 + 3)/3]+: 637.04; observed: 636.95. m/z ES 
calc’d for peptide 4.8.E [(C90H122N26O34S6+ 3)/3]+: 769.16; observed: 769.00.  
 
Entry 1. A solution of Ellman’s reagent (1.2 mg, 3 µmol) in DMF (1.0 mL) was added and 
the reaction was agitated for 2 hours  
  
Figure 4.18 Analytical Column PDA for reaction optimization; Table 4.4 – Entry 1  
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Entry 2. A solution of Ellman’s reagent (0.3 mg, 0.75 µmol) in DMF (1.0 mL) was added 
and the reaction was agitated for 10 hours.  
 
Figure 4.19 Analytical Column PDA for reaction optimization; Table 4.4 – Entry 2  
 
Entry 3. A solution of Ellman’s reagent (0.15 mg, 0.375 µmol) in DMF (1.0 mL) was added 
and the reaction was agitated for 16 hours.  
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Figure 4.20 Analytical Column PDA for reaction optimization; Table 4.4 – Entry 3 
 
 
 
Synthesis of a4/7-conotoxin LvIA 4.8.F. The resin 4.8.B (100 mg, 30 µmol) was first 
swelled in DCM (3 mL). Then, a solution of iodine (60.9 mg, 240 µmol) in DCM (400 µL) 
was added and allowed to agitate in a 10 mL vial at room temperature for 6 hours. The 
reaction solution was filtered and the resin was washed with DMF (10 x 1 mL) and DCM 
(10 x 1 mL).  The resulting resin was subjected to 300 µL of the cleavage mixture 
TFA:TIPS:H2O (95:2.5.2.5) for 2 hours. Finally, the TFA solutions were collected, 
concentrated under a constant stream of air, crashed out with cold diethyl ether, 
centrifuged, and decanted to yield the crude peptide. The resulting pellet was dissolved 
in 10% MeCN:Water in presence of 0.05%TFA and purified via RP- HPLC-MS using a 
Semi-Preparative Thermo Scientific Hypersil Gold C8 column at a flow rate of 5 mL/min 
with 10–50% MeCN/H2O gradient for 15 minutes to yield the pure peptide in 24% overall 
yield (5.6 mg). m/z ES calc’d for a4/7-conotoxin LvIA [(C66H98N22O22S4 + 2)/2]+: 840.94; 
observed: 840.80; m/z ES calc’d for [(C66H98N22O22S4 + 3)/3]+: 560.96; observed: 560.85 
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Figure 4.21 Analytical Column PDA of pure a-conotoxin LvIA 4.8.F. Gradient: 10-50% MeCN/H2O + 1% HCOOH  
over 15 min. Retention time 6.97 min  
 
 
 
 
 
 
 
Figure 4.22 ES-MS spectrum for pure a-conotoxin LvIA 4.8.F at retention time 6.97 min  
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SPPS of Linear Peptide 4.10.A. The standard Fmoc-SPPS protocol described was used 
to synthesize resin 4.10.A on Rink Amide linker-Gly-Gly-Gly-ChemMatrix resin. The 
peptide was capped before the last coupling step. To analyze the peptide, 10 mg of the 
resin was subjected general ammonia cleavage protocol and the resulting crude product 
was dissolved in 10% MeCN:Water in presence of 0.05%TFA and analyzed via Rp-
HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow rate 
of 1 mL/min with 10-50% MeCN/H2O gradient for 30 minutes. Final loading of the resin: 
0.13 mmol/g. m/z ES calc’d for peptide 4.X.B [(C74H118N22O22S6 + 2)/2]+: 931.13; 
observed: 930.85. m/z ES calc’d for [(C74H118N22O22S6 + 3)/3]+: 621.08; observed: 
620.95. 
 
Figure 4.23 Analytical Column PDA for linear peptide 4.10.A; Gradient: 10-50% MeCN/H2O + 1% HCOOH  
over 30 min. Retention time 21.01 min 
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Figure 4.24 ES-MS spectrum for linear peptide 4.10.A at retention time 21.01 min 
 
 
 
 
 
 
Synthesis of Peptide 4.10.B. The resin 4.10.A (60 mg, 18 µmol) was first swelled in 
DMF (500 µL). Then, a solution of 30% mercaptoethanol in DMF (1.0 mL) was added and 
agitated at 60 ºC under microwave condition for 3 hour. The reaction solution was filtered 
and the resin was washed with DMF (5 x 1 mL). To analyze the reaction 10 mg of the 
resulting resin was subjected to 300 µL of the cleavage mixture (95:2.5:2.5 
TFA:TIPS:H2O) for 1 hour. The resulting TFA solutions were collected, concentrated 
under a constant stream of air, crashed out with cold diethyl ether, centrifuged, and 
decanted to yield the crude peptide. The resulting pellet was dissolved in 10% 
MeCN:Water in presence of 0.05%TFA and analyzed via RP-HPLC-MS using an 
analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 10–
50% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 4.10.B 
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SStBu SStBu
STrt STrt
RA Linker CMGGG
16
4.10.A
GCCSHPACNVDHPEIC
tBu tBu
Trt
tBu
TrtTrt
H
SH SH
STrt STrt
RA Linker CMGGG
16
4.10.B
30% Mercaptoethanol
60 ºC MW, 3 h
 
 
195 
[(C66H102N22O22S4 + 2)/2]+: 842.96; observed: 842.60. m/z ES calc’d for 
[(C66H102N22O22S4 + 3)/3]+: 561.97; observed: 562.05. 
  
Figure 4.25 Analytical Column PDA for Scheme 4.11 – Step 1  
 
 
 
 
 
 
Synthesis of Peptide 4.10.C. The peptide 4.10.B (50 mg, 15 µmol) was first swelled in 
NMP (1 mL). Then it was subjected to a solution of Ellman’s Reagent (6.0 mg, 15 µnol) 
in NMP for 30 min until the resin color changed from peach to yellow. Finally, the reaction 
solution was filtered and the resin was washed with NMP (6 x 1 mL) and DCM (6 x 1 mL). 
To analyze the reaction 10 mg of the resulting resin was subjected to 300 µL of the 
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cleavage mixture TFA:TIPS:H2O (95:2.5.2.5) for 1 hour. The resulting the TFA solutions 
were collected, concentrated under a constant stream of air, crashed out with cold diethyl 
ether, centrifuged, and decanted to yield the crude peptide. The resulting pellet was 
dissolved in 10% MeCN:Water in presence of 0.05%TFA. This solution was analyzed via 
RP-HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow 
rate of 1 mL/min with 10-50% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for 
peptide 4.10.C [C66H100N22O22S4 + 1]+: 1681.90; observed: 1682.60. m/z ES calc’d for 
[(C66H100N22O22S4 + 2)/2]+: 841.95; observed: 841.75. m/z ES calc’d for 
[(C66H100N22O22S4 + 3)/3]+: 561.63; observed: 561.50. 
 
  
Figure 4.26 Analytical Column PDA for Scheme 4.11 – Step 2  
 
 
        
Monocyclic Peptide (4.10.C); [(M+3)/3]+ 
Monocyclic Peptide (4.10.C); [(M+2)/2]+   
PDA, 214 nm 
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Synthesis of a4/7-Conotoxin LvIA 4.10.D. The resin 4.10.C (40 mg, 12 µmol) was first 
swelled in DCM (1 mL). Then, a freshly prepared solution of TFA:TIPS:DCM (5:5:90) was 
added and the reaction mixture was agitated at room temperature for 3 x 5 min. About 1 
– 2 drops of more TIPS were added during the reaction until the orange-yellow color 
disappeared in the reaction mixture. The resulting TFA solution was filtered and the resin 
was washed with DCM (3 x 1 mL). After that, the resin was subjected to a solution of 
Ellman’s Reagent (5.0 mg, 12 µmol) in DMF (1.5 mL) for 90 min until the resin color 
changed from peach to yellow. Finally, the reaction solution was filtered and the resin was 
washed with DMF (6 x 1 mL) and DCM (6 x 1 mL). In order to confirmed the total Trt group 
removal, the resulting peptide was retreated with a solution of TFA:TIPS:DCM (5:5:90) 
for 2 x 5 min and re-subjected to the stated amount of Ellman’s Reagent in NMP. If the 
resin color changes to peach-orange color upon addition of Ellman’s reagent, the reaction 
was agitated further until the resin color changed from peach to yellow. This procedure 
was repeated until no color change was observed. When no color change was observed, 
the solution of Ellman’s reagent added was filtered and the resin was washed with DMF 
(6 x 1 mL) and DCM (6 x 1 mL). The resulting resin was subjected to 300 µL of the 
cleavage mixture TFA:TIPS:H2O (95:2.5.2.5) for 2 hours. The resulting the TFA solutions 
were collected, concentrated under a constant stream of air, crashed out with cold diethyl 
ether, centrifuged, and decanted to yield the crude peptide. The resulting pellet was 
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dissolved in 10% MeCN:Water in presence of 0.05%TFA and analyzed via RP- HPLC-
MS using an analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 
mL/min with 10-50% MeCN/H2O gradient for 15 minutes. m/z ES calc’d for peptide 4.10.D 
[C66H98N22O22S4 + 1]+: 1679.88; observed: 1682.00. m/z ES calc’d for [(C66H98N22O22S4 
+ 2)/2]+: 840.94; observed: 840.75. m/z ES calc’d for [(C66H98N22O22S4 + 3)/3]+: 560.96; 
observed: 560.80. 
 
Figure 4.27 Analytical Column PDA of pure a-conotoxin LvIA 4.10.D. Gradient: 10-50% MeCN/H2O + 1% HCOOH  
over 15 min. Retention time 7.18 min 
 
 
 
Figure 4.28 ES-MS spectrum for pure a-conotoxin LvIA 4.10.D at retention time 7.18 min 
a-conotoxin LvIA  (4.10.D); [(M+3)/3]+ 
 
a-conotoxin LvIA  (4.10.D); [(M+2)/2]+  
  
 
PDA, 214 nm 
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CHAPTER 5: ON RESIN CONTROLLED FOLDING OF LINACLOTIDE 
 
 
5.1 Introduction  
 A majority of cysteine-rich bioactive peptides contain three or more disulfide bonds. 
They have higher potential as a valuable tool in biomedical and pharmaceutical research. 
Duo to their small size, chemical synthesis has become the method of choice over 
recombinant expression. Although there are several on-resin folding methods have been 
developed to synthesize one or two disulfide bonds in peptides, successful regioselective 
formation of three or more disulfide bonds with resin-bound peptides has not been 
reported. This chapter details the progress towards on-resin regioselective disulfide bond 
formation to access linaclotide, which contains three disulfide linkages. The synthetic 
procedure demonstrates utility of Allocam group as a cysteine protecting group and 
applicability of new Allocam cleavage - oxidation method and Ellman’s reagent - mediated 
on-resin disulfide bond formation method to access peptides with three disulfide bonds    
5.2. Linaclotide 
5.2.1 Linaclotide: Structure and Bioactivity 
 Linaclotide is a cyclic peptide consists of 14-amino acid residues. It derived from 
heat-stable enterotoxins, produced by various Escherichia coli strains which are a 
frequent cause of diarrhea.174 It is a small peptide with 43% cysteine residues in the 
sequence, and have three disulfide bonds in a constrained conformation. The disulfide 
bonds are lies between Cys1-Cys6, Cys2-Cys10 and Cys5-Cys13 (Figure 5.1). Linaclotide 
was approved by FDA in 2012 as a drug, marketed under the trade name Linzess in the 
US and Mexico, and as Constella in Canada. It can be used for the treatment of 
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gastrointestinal diseases such as chronic constipation (CC) and irritable bowel syndrome 
(IBS) in adults.175 The drug provides well tolerated relief in patients and acts by binding 
to guanylate cyclase C on the surface of intestinal epithelial cells.176,177,178 Activation of 
the cyclase triggers a signaling pathway that leads to chloride and fluid secretions into 
the lumen, increasing colonic transit. The location of this target in the intestine allows for 
linaclotide to be orally administered.179  
 
 
5.2.2 Reported Chemical Synthesis of Linaclotide  
 Albericio and co-workers have reported synthesis studies of linaclotide.180 The 
study illustrated 14 available strategies and only 2 were successful to give correctly-linked 
product as the major product. The two succeeded strategies have Trt protection of all 
cysteines, or Trt protection of all cysteines except StBu protection of Cys1 and Cys6 in the 
sequence (Scheme 5.1). The linear peptide 5.1.A was synthesized on CTC resin and all 
six cysteine residues were incorporated with Trt protecting group for the random folding 
strategy (A. Scheme 5.1). First, the protected peptide was cleaved from the resin by 1% 
TFA in DCM in presence of TIPS and then, it was subjected to 95% TFA condition for 
total side group deprotection.  
Cys1-Cys2-Glu3-Tyr4-Cys5-Cys6-Asn7-Pro8-Ala9-Cys10-Thr11-Gly12-Cys13-Tyr14H OH
S S
S S
14
A.
B.
Figure 5.1 A. Structure of Linaclotide B. Graphical representation of Linaclotide structure
OHCCEYCCNPACTGCY
S
H
SS
S S
S
S S
 
 
201 
 
The resulting reduced peptide 5.1.B was oxidized by three different in-solution folding 
conditions. An air oxidation was done by dissolving the peptide in buffer A (100 mM 
sodium phosphate, 2 M guanidine hydrochloride, pH 7.0) and stirred under open 
atmosphere at 25 ºC for 12 hours. Using the same buffer conditions, DMSO-mediated 
oxidation was done with 5% DMSO and the reaction was stirred under open atmosphere 
at 25 ºC for 12 hours. As the third method, the peptide was subjected to a mixture of 
PeptideH
STrt STrt
STrt STrt
Scheme 5.1 (A) Random folding strategy for synthesis of Linaclotide Cys(Trt)
                     (B) Semi-directed folding strategy for synthesis of Linaclotide Cys(StBu) and Cys(Trt)
c) Buffer A-ipOH (1:1), 2 mM GSH 
    (pH 7.4), 25 ºC, 12 h
1) TFA / TIPS / DCM, (1;5:94)
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buffer A:2-propanol (1:1) and 2 mM glutathione and the solution stirred at 25 ºC for 12 
hours under open atmosphere. In this strategy all the oxidation procedures gave 
completely oxidized peptide 5.1.C with desired disulfide bonds. A semi-regioselective 
strategy was done by protecting Cys1 and Cys6 residues with StBu group (B. Scheme 
5.1). After linear synthesis of the peptide 5.2.A on CTC resin, it was first treated with 20% 
mercaptoethanol and 0.1 M N-methylmorpholine in DMF on resin. The resulting peptide 
5.2.B was then cleaved from the resin with 1% TFA in DCM. The cleavage mixture was 
poured over H2O and the organic phase was evaporated under N2 prevent an increase in 
concentration of TFA, which prevent premature cleavage of Trt groups. The peptide 5.2.C 
is then lyophilized and subjected to DMSO oxidation form first disulfide bond. After 
purifying the mono cyclic peptide 5.2.D, it was re-subjected to DMSO oxidation to form 
two remaining disulfide bonds randomly in solution. This strategy also gave fully oxidized 
product 5.2.E with correct disulfide bond conformation. 
5.3 Synthesis of Linaclotide using On-resin Regioselective Folding Method  
 After analyzing both random and semi-regioselective strategies reported for 
linaclotide synthesis, we evaluated few on-resin regioselective folding methods to access 
correct disulfide bond pattern in for linaclotide. The findings form Albericio’s work,7 such 
as order of Cys residue pairing, best protecting group positioning for cysteine protection 
were applied to design our synthesis pathways. 
5.3.1 Synthesis of Linaclotide using Cys(StBu), Cys(Mmt), Cys(Allocam) and Cys(Trt) 
 The synthesis of a-conotoxin LvIA by the combination of a displacement method 
and simultaneous Allocam removal and oxidation (see Chapter 02) inspired this design 
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of synthesis for linaclotide (Scheme 5.2). The linear synthesis of linaclotide 5.3.A was 
done on Wang resin and StBu, Mmt, Allcam and Trt was used to protect cysteine 
residues.  
 
As described in Chaper 01 and Chapter 02, StBu and Mmt groups were used to form the 
first disulfide bond vis a displacement method. Deprotection of Cys(StBu) was achieved 
with 20% mercaptoethanol, 0.1 NMM in DMF at room temperature, after 18 hours. 
Microwave heating was also tried to remove StBu group with 30% mercaptoethanol, but 
significant peptide cleavage was observed. The free thiol group  resulting from Cys(StBu) 
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2) 10 equiv. DTNP in DCM
3) TFA:TIPS:DCM (1:5:94)
3.0 Pd(OAc)2 in
5%AcOH-DMSO-3%NMM
Scheme 5.2. On-resin synthesis of Linaclotide using Cys(StBu),
                      Cys(Mmt), Cys(Allocam) and Cys(Trt)
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deprotection was activated with 5-Npys group by treating the peptide with excess DTNP. 
To form the first disulfide bond, Mmt group needed to be removed in present of Trt group. 
This was a very challenging step since both the group have slightly different TFA 
tolerance. The general 1% TFA cleavage condition didn’t work for removal of Mmt group 
in this substrate. When higher TFA conditions were used, Trt group was started to cleave 
together with Mmt group. Therefore, we couldn’t continue the synthetic steps as planned. 
Failure to remove Mmt group in presence of Trt group made this proposed synthetic route 
a challenge.     
5.3.2 Synthesis of Linaclotide using Cys(Allocam), Cys(Trt) and Cys(Acm) 
 A synthetic route using Cys(Allocam), Cys(Trt) and Cys(Acm) was designed to 
access correct disulfide bonds in linaclotide (Scheme 5.3). Allocam group was used to 
form the first disulfide bond by NCS oxidation. Neither Pd-DMSO based simultaneous 
Allocam removal and oxidation conditions nor iodine oxidation can be used in this step. 
Because from our previous studies in Chapter 02, we observed that Acm group is 
sensitive to Pd-DMSO based simultaneous Allocam removal and oxidation conditions and 
both Acm and Trt groups are not stable to iodine oxidation. Therefore, the choice of 
oxidation method was NCS-mediated oxidation. The linear peptide 5.4.A was subjected 
to NCS in DMF and it caused cleavage of not only Allocam group, but also other two 
cysteine protecting group. This illustrated the sensitivity of both Trt and Acm groups 
toward NCS oxidation. There was no other method for Allocam cleavage and oxidation in 
presence of Trt and Acm groups, and therefore, this proposed synthetic design also failed 
to access desired selectivity in disulfide bond formation .   
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5.3.3 Synthesis of Linaclotide using Cys(StBu), Cys(Allocam) and Cys(Trt) 
 After the discovery of Ellman’s reagent as a mild oxidant to form on-resin disulfide 
bonds in reduced peptides (see chapter 04), a new synthetic route was designed using 
combination of Cys(StBu), Cys(Allocam) and Cys(Trt) groups (Scheme 5.4). Linear 
synthesis of the peptide 5.5.A was done on Wang resin using StBu, Allocam and Trt to 
protect cysteine residues. First, optimized Cys(StBu) deprotection condition reported in 
Albericio and co-workers’ studies,7 was applied to remove StBu groups in the peptide. 
The peptide was treated with 20% mercaptoethanol, 0.1 NMM in DMF for 18 hours and 
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the resulting free thiols in the peptide 5.5.B were subjected to 1.0 equivalent of Ellman’s 
reagent in DMF to form the first disulfide bond.  
 
The reaction was monitors by color change of the resin, from dark peach-orange to yellow. 
After 3 hours, when the resin color changed to yellow, reagents were filtered off and the 
resin was washed thoroughly with DMF and DCM. With 1.0 equivalent of Ellman’s reagent 
the mono-cyclic peptide 5.5.C was obtained with zero by products. Next, the mono-cyclic 
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Scheme 5.4. On-resin regioselective synthesis of Linaclotide using Cys(StBu),
                      Cys(Trt) and Cys(Allocam)
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peptide 5.5.C was subjected to Pd-DMSO based simultaneous Allocam removal and 
oxidation conditions and the second disulfide bond formation 5.5.D was observed in 7 
hours. Thereafter, the Cys(Trt) deprotection was done with 5% TFA in DCM using TIPS 
as the scavenger to get free cysteine residues. Finally, another Ellman’s reagent-based 
on-resin oxidation was done to get the fully folded product 5.5.E. In this last step, 1.0 
equivalent of Ellman’s reagent in DMF was used and the reaction was run for 5 hours 
until the resin color changes from dark peach-orange to yellow.    
5.4 Summary and Future Directions  
 Different on-resin regioselective methods to access three disulfide bonds in 
peptides were evaluated using linaclotide as a target peptide. Out of the three proposed 
synthetic designs, orthogonal combination of StBu, Allocam and Trt groups allowed 
regioselective disulfide bond formation to access desired disulfide pattern. To our 
knowledge, this is the first on-resin regioselective synthesis of a peptide with more than 
two bonds.  
Several modifications could be done to improve this on-resin regioselective 
synthesis of linaclotide. As iodine-mediated simultaneous Allocam removal and oxidation 
is more effective (see chapter 03) than Pd-DMSO mediated Allocam removal and 
oxidation, the Allocam-mediated disulfide bond formation step (Step 3) in linaclotide 
synthesis could be done using iodine oxidation. In order to perform an iodine oxidation on 
Allocam group, change in the positioning of cysteine protecting groups should be done in 
the synthetic design. As Allocam group is sensitive to iodine oxidation, Trt group removal 
with 5% TFA in DCM followed by Ellman’s oxidation should be done to form the second 
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disulfide bond. Allocam protection should be done for Cys5-Cys13 residues and iodine-
mediated simultaneous Allocam removal and oxidation could be done to form the final 
disulfide bond. In addition, Ellman’s oxidation could be done in NMP to increase the rate 
of disulfide formation (see chapter 4). The higher density of both cysteine residues and 
side-chain protecting groups in linaclotide made the on-resin synthesis a very challenging 
process. In order to have higher swelling power of the resin, which increases the reactivity 
of peptide (see chapter 2 and 3), the synthesis could be rerun on ChemMatric resin with 
Wang linker. Moreover, to increase the flexibility of peptide backbone and get effective 
folding of the peptide, a long linker could be introduce between the resin and the peptide, 
similar to the modification done in the synthesis of a4/7-conotoxin LvIA (see chapter 3).  
5.5 Methods and Material 
5.5.1 General Information 
 Unless otherwise specified, all commercially available reagents were purchased from 
Sigma-Aldrich and used without further purification. Anhydrous Et2O, MeCN, DMF, 
DMSO, CH2Cl2 were purchased from Fisher. These were passed through a commercial 
solvent purification system (2 columns of alumina) and used without further drying. 
Hünig’s base was distilled over CaH2 immediately prior to use. All amino acids were 
purchased from Chem-Impex Int’l. Inc. unless otherwise noted. HATU were purchased 
from Chem-Impex Int’l. Inc. Unless otherwise noted, all reactions were performed in 2 mL, 
5 mL and 10 mL Biotage reactor vials with PTFE frit (depend on reaction volume) at room 
temperature. All yields refer to chromatographically and spectroscopically pure products. 
All HPLC analyses and purifications were performed on a Custom Reverse Phase 
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Shimadzu Liquid Chromatograph Mass Spectrometer (LCMS-2020), which can toggle 
between analytical and semi-preparative columns. This instrument has a photodiode 
array (PDA) detector (D2 & W lamp), which collects a range of wavelengths, in place of 
a traditional single channel UV detector. RP-HPLC-MS mobile phases (MeCN and H2O) 
contained 0.1% Formic Acid. Analytical HPLC was performed on a Phenomenex Kinetex 
C18 column (5 µm, 250 x 4.6 mm) and a Thermo Scientific Hypersil Gold C8 column (5 
µm, 250 x 4.6 mm). Semi-Preparative HPLC was conducted using a Thermo Scientific 
Hypersil Gold C8 column (5 µm, 150 x 10 mm). All peptide yields are calculated based 
on the final loading. 
SPPS General Information. Solid-phase peptide synthesis was executed on a Biotage 
Isolera+ semi-automated synthesizer with microwave heating. 
•   Reactor Vials [Vial size (Volume range allowed)]: 2 mL reactor vial (0.8-1.1 mL), 5 mL 
reactor vial (1.6-3.2 mL), and 10 mL reactor vial (3.2-6.4 mL) 
•   Swelling + Heat: DMF was added and vortexed at 1200 RPM for 20 m at 70 ºC. The 
solvent was then removed over 1 m followed by two DMF washes (DMF was added 
and the suspension was vortexed at 600 RPM for 45 s, followed by the removal of 
solvent (over 2 m)).  
•   Coupling: A solution of Fmoc-aa-OH (3 equiv), HATU (3 equiv), and DIPEA (6 equiv) 
in DMF was made immediately prior to addition to the reaction vial containing the 
resin. Once the solution was added, the suspension was heated to 75 ºC (except for 
Fmoc-Cys-OH which was heated to 50 ºC) for 5 minutes with a vortex rate of 1200 
RPM. After the reaction, the solution was removed (over 2 m) and the resin was rinsed 
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with DMF 4 times (after addition of DMF, the suspension was agitated at a vortex rate 
of 1200 RPM for 1 m, solvent removal was at a rate of 2 m). 
•   Fmoc Removal (Deprotection): The reactor vial was filled with 20% piperidine in DMF. 
The suspension was vortexed at 1200 RPM for 3 m at RT. The solvent is removed 
followed by addition of 20% piperidine in DMF. The suspension is vortexed again at 
1200 RPM for 10 m at RT. The solvent was removed over 2 m, followed by 4 DMF 
washes (after addition of DMF, the suspension was agitated at a vortex rate of 1200 
RPM for 1 m, solvent removal was at a rate of 2 m). 
•   Wash: DMF was added to the reaction vial and agitated at a vortex rate of 1200 RPM 
for 1 m. The solvent was removed over 1 m and repeated for a total of 4 times. 
•   Final Wash: Resin was rinsed with CH2Cl2 (3 x 1 mL) and MeOH (3 x 1 mL). 
•   Drying for Storage/Weighing: After the final wash, the resin was placed on the 
lyophilizer overnight for drying. 
General Procedure for Capping - First, 25% acetic anhydride in DMF (3 mL) was added 
and agitated for 5 min. Then,1.5 eqiuv. of DIPEA was added to the reaction and agitated 
for 30 min. Finally, the reaction solution was filtered and the resin was washed with DMF 
(5 x 3 mL). 
Procedure for Resin Loading Analysis. Initial and final loading of resin was analyzed 
based on amount of Fmoc group. 
Fmoc Deprotection – 10 mg of the resin was weighed out and swelled in DMF in the 
peptide synthesizer. Then, 1.00 ml of 20% piperidine in DMF was added and it was 
allowed to vortex in the peptide synthesizer at room temperature for 3 min. After 3 min, 
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the filtrate was collected in to a separate tube, another 1.00 ml of 20% piperidine in DMF 
was added to it and allowed to vortex in the peptide synthesizer at room temperature for 
10 min. The resulting filtrate was collected to the same tube and the deprotected resin 
was washed with DMF (4 x 1.75 ml). 
Sample preparation for UV analysis – From the collected ”deprotection solution” above, 
100 µL was transferred in to an eppendorf tube and it was diluted with 900 µl of DMF. 
The resulting diluted sample was used to get the absorbance at 301 nm versus a DMF 
blank using a UV spectrometer with 1 cm cuvette. 
5.5.2 Experimental Procedures and Spectroscopic Data 
 
 
SPPS of Linear Peptide 5.5.A. The standard Fmoc-SPPS protocol described was used 
to synthesize peptide 5.5.A on pre-loaded Wang resin 5.5 A’ (500 mg, 0.15 mmol). The 
peptide was capped before the last coupling step. To analyze the peptide, 10 mg of the 
resin was subjected 300 µL of the cleavage mixture TFA:TIPS:H2O (95:2.5.2.5) for 3 
hours. The resulting the TFA solutions were collected, concentrated under a constant 
stream of air, crashed out with cold diethyl ether, centrifuged, and decanted to yield the 
crude peptide. The resulting pellet was dissolved in 10% MeCN:Water in presence of 
0.05%TFA. This solution was analyzed via RP-HPLC-MS using an analytical Thermo 
Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 10-50% MeCN/H2O 
CCEYCCNPACTGCY
tBu
tBu
Trt
tBu
STrt
H
SStBuSStBu
SAllocan SAllocam
Wang
STrt
tBu
14
5.5.A
SPPS
O Wang
FmocHN
O
O
5.5.A’
 
 
212 
gradient for 30 minutes. Final loading of the resin: 0.10 mmol/g. m/z ES calc’d for peptide 
5.5.A [(C77H115N17O25S8 + 1]+: 1935.34; observed: 1936.50. m/z ES calc’d for 
[(C77H115N17O25S8 + 2)/2]+: 968.67; observed: 968.45. 
 
Figure 5.2. Analytical Column PDA for linear peptide 5.5.A; Gradient: 10-50% MeCN/H2O + 1% HCOOH  
over 30 min. Retention time 25.34 min 
  
 
 
Figure 5.3. ES-MS spectrum for linear peptide 5.5.A at retention time 25.34 min 
 
 
 
 
        
Linear Peptide (5.5.A); [(M+2)/2]+ 
 
Linear Peptide – 1Allocam; [(M+2)/2]+ 
 
PDA 214 nm 
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Synthesis of Reduced Peptide 5.5.B. The peptide 5.5.A (200 mg, 60 µmol) was first 
swelled in DMF (3 mL). Then, a solution of 20% mercaptoethanol, 0.1 M NMM in DMF 
(5.0 mL) was added and agitated at room temperature for 18 hours. The reaction solution 
was filtered and the resin was washed with DMF (5 x 3 mL). To analyze the reaction 10 
mg of the resulting resin was subjected to 300 µL of the cleavage mixture (95:2.5:2.5 
TFA:TIPS:H2O) for 1 hour. The resulting TFA solutions were collected, concentrated 
under a constant stream of air, crashed out with cold diethyl ether, centrifuged, and 
decanted to yield the crude peptide. The resulting pellet was dissolved in 10% 
MeCN:Water in presence of 0.05%TFA and analyzed via RP-HPLC-MS using an 
analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 10–
50% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 5.5.B 
[(C69H99N17O25S6 + 1]+: 1759.01 observed: 1759.80. m/z ES calc’d for 
[(C69H99N17O25S6 + 2)/2]+: 880.50; observed: 880.20. 
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Figure 5.4. Analytical Column PDA for Scheme 5.4. Step 01 
 
 
 
 
Synthesis of Mono Cyclic Peptide 5.5.C. The peptide 5.5.B (200 mg, 60 µmol) was first 
swelled in DMF (3 mL). Then it was subjected to a solution of Ellman’s Reagent (23.70 
mg, 60 µmol) in DMF (3 mL) for 16 hours until the resin color changed from dark peach-
orange to yellow. Finally, the reaction solution was filtered and the resin was washed with 
DMF (6 x 3 mL) and DCM (6 x 3 mL). To analyze the reaction 10 mg of the resulting resin 
was subjected to 300 µL of the cleavage mixture TFA:TIPS:H2O (95:2.5.2.5) for 3 hours. 
The resulting the TFA solutions were collected, concentrated under a constant stream of 
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air, crashed out with cold diethyl ether, centrifuged, and decanted to yield the crude 
peptide. The resulting pellet was dissolved in 10% MeCN:Water in presence of 
0.05%TFA. This solution was analyzed via RP-HPLC-MS using an analytical Thermo 
Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min with 10-50% MeCN/H2O 
gradient for 30 minutes. m/z ES calc’d for peptide 5.5.C [(C69H97N17O25S6 + 2)/2]+: 
879.49; observed: 879.30. 
 
 
Figure 5.5. Analytical Column PDA for Scheme 5.4. Step 02 
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Synthesis of Bicyclic Peptide 5.5.D. First, the resin 5.5.C (100 mg, 30 µmol) was 
swelled in DMF (3 mL). A solution of Pd(OAc)2 (20.2 mg, 90 µmol) in 5% AcOH/DMSO 
(3.75 mL) solution was added, and then the NMM (113 µL) was added. The cartridge/vial 
was capped on the top, attached to a magnetic stir bar retriever using a rubber band, and 
agitated for 7 hours. The reaction was filtered, and the resin was washed successively 
with with DMF (3 x 2 min), CH2Cl2 (3 x 2 min), 0.2 M sodium diethyldithiocarbamate in 
DMF (3 x 30 min), MeOH (3 x 1 min), DMF (5 x 1 min) and CH2Cl2 (3 x 1 min). *Note: 
resin changes from dark orange/brownish to yellowish/tan. To analyze the reaction 10 mg 
of the resulting resin was subjected to 300 µL of the cleavage mixture TFA:TIPS:H2O 
(95:2.5.2.5) for 3 hours. The resulting the TFA solutions were collected, concentrated 
under a constant stream of air, crashed out with cold diethyl ether, centrifuged, and 
decanted to yield the crude peptide. The resulting pellet was dissolved in 10% 
MeCN:Water in presence of 0.05%TFA. This solution was analyzed via RP-HPLC-MS 
using an analytical Thermo Scientific Hypersil Gold C8 column at a flow rate of 1 mL/min 
with 10-40% MeCN/H2O gradient for 30 minutes. m/z ES calc’d for peptide 5.5.D 
[C59H81N15O21S6 + 1]+: 1528.74; observed: 1528.45. m/z ES calc’d for 
[(C59H81N15O21S6 + 2)/2]+: 765.37; observed: 765.20. 
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Figure 5.6 Analytical Column PDA for Scheme 5.4. Step 03  
 
 
 
Synthesis of Linaclotide 5.5.F. The resin 5.5.E (90 mg, 27 µmol) was first swelled in 
DMF (3 mL). Then, a freshly prepared solution (500 µL) of TFA:TIPS:DCM (5:5:90) was 
added and the reaction mixture was agitated at room temperature for 5 x 1 min. About 1 
– 2 drops of more TIPS were added during the reaction until the orange-yellow color 
disappeared in the reaction mixture. The resulting TFA solution was filtered and the resin 
was washed with DCM (3 x 5 mL). After that, the resin was subjected to Ellman’s Reagent 
(10.8 mg, 27 µmol) in DMF (2 mL) for 5 hours until the resin color changed from peach to 
yellow. Finally, the reaction solution was filtered and the resin was washed with DMF (6 
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x 3 mL) and DCM (6 x 3 mL). In order to confirmed the total Trt group removal, the 
resulting peptide was retreated with a solution (500 µL) of TFA:TIPS:DCM (5:5:90) for 5 
x 1 min and re-subjected to the same amount of Ellman’s Reagent in DMF. No color 
change was observed, the solution of Ellman’s reagent added was filtered and the resin 
was washed with DMF (6 x 3 mL) and DCM (6 x 3 mL). The resulting resin was subjected 
to 300 µL of the cleavage mixture TFA:TIPS:H2O (95:2.5.2.5) for 1 hour. The resulting the 
TFA solutions were collected, concentrated under a constant stream of air, crashed out 
with cold diethyl ether, centrifuged, and decanted to yield the crude peptide. The resulting 
pellet was dissolved in 10% MeCN:Water in presence of 0.05%TFA. This solution was 
analyzed via RP-HPLC-MS using an analytical Thermo Scientific Hypersil Gold C8 
column at a flow rate of 1 mL/min with 15-45% MeCN/H2O gradient for 20 minutes. m/z 
ES calc’d for peptide 5.5.E [(C59H79N15O21S6 + 2)/2]+: 764.37; observed: 764.20. 
 
Figure 5.7 Analytical Column PDA for crude Linaclotide 5.5.E; Gradient: 15-45% MeCN/H2O + 1% HCOOH  
over 20 min. Retention time 11.89 min 
        
Product isotope; [(M+2)/2]+ 
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Figure 5.8 ES-MS spectrum for linear peptide 5.5.E at retention time 11.89 min 
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CHAPTER 6: SUMMARY 
 Peptide – based pharmaceuticals are becoming increasingly important over 
traditional small molecule pharmaceuticals. This is mainly because of the greater 
specificity, potency and lower toxicity profile of the disulfide-rich mini proteins. Disulfide 
linkages play an important role to improve the thermal, chemical, and enzymatic stability 
of these polypeptides. The synthesis of disulfide – containing mini-peptides become a 
challenge in field of peptide chemistry, and hence, there is a demand for broadly 
applicable methods to construct correct disulfide connectivity in bioactive peptides. This 
dissertation detailed development of efficient deprotection methods for Allocam group and 
utility of Allocam as cysteine protecting group to form on-resin disulfide bonds in more 
complex peptides. In addition, oxidation potential of Ellman’s reagent to access on-resin 
disulfide bonds was evaluated along with its interesting colorimetric behavior.  
 First, little-used Allocam group was studied for better p-allyl deprotection 
conditions to overcome limitations which prevent its general use in the field. A one-pot 
approach with Pd-mediated deprotection-oxidation was developed to form disulfide bonds 
on resin. As an on-resin method, it minimizes the number of time consuming purification 
steps and the reaction can be done with bench-stable reagents. The utility of the method 
was evaluated by solid phase synthesis and folding of the carboxy-oxytocin. However, 
detailed investigations into the mechanism of Pd-DMSO mediated simultaneous Allocam 
removal and oxidation needed to be done. 
 In addition to oxytocin, a4/7-conotoxin LvIA was synthesized to demonstrated the 
applicability of novel Pd-DMSO mediated simultaneous Allocam removal and oxidation 
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condition to access more complex disulfide – rich peptides.  Two routes were introduced 
based on position of the Allocam protected cysteines and selection of compatible other 
cysteine protecting groups for each of the synthetic routes. In addition to Pd-DMSO based 
simultaneous on-resin Allocam removal and oxidation condition, both I2 oxidation and 
NCS oxidation can be used in on-resin Allocam removal and oxidation. Selection of the 
best method is highly depend on design of synthetic protocol.  
 The potential of Ellman’s reagent as a colorimetric and mild oxidizing agent to form 
on-resin disulfide bonds in peptides was evaluated. The reaction procedure is simple, no 
complex time consuming reaction set up is needed and the reaction can be monitored 
easily by observing the color change of the resin. The colorimetric behavior of Ellman’s 
reagent can be seen both in DMF and NMP. Ellman’s reagent – mediated disulfide bond 
formation in DMF is relatively slower while it shows faster reaction rates in NMP. The 
insight of colorimetric behavior of Ellman’s reagent in disulfide bond formation process 
needed to be further investigated.  
 The new Allocam cleavage - oxidation method and Ellman’s reagent - mediated 
on-resin disulfide bond formation method was carefully combined in a synthetic protocol 
to access linaclotide, which contains three disulfide bonds. For best of our knowledge, 
this is the first on-resin synthesis of three disulfide linkages.    
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ABSTRACT 
PROGRESS TOWARD CONTROLLED DISULFIDE FORMATION TO ACCESS 
NEUROACTIVE CONOTOXINS 
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Major: Chemistry (Organic) 
Degree: Doctor of Philosophy 
Conotoxins are mini proteins isolated from marine snails of the Conus family. They 
have shown activity in the selective inhibition of various ion channels. Therefore, they 
present an opportunity as possible therapy for a myriad of neurological ailments. The 
synthesis of conotoxins would enable both biological studies and evaluation of these 
structures as lead targets for therapeutics. However, establishing a reliable method to 
consistently folding disulfide rich proteins, including conotoxin, into their native structure 
has been challenging over few decades. In this research project, it is shown the progress 
towards a mild, efficient, and broadly applicable methods to generate the desired pattern 
of disulfide linkages in synthetic polypeptides.  
p-allyl chemistry mediated deprotection conditions for Allocam group was optimized 
to overcome the limitations which prevent its general use in the field. A one-pot approach 
with Pd-mediated deprotection-oxidation was developed to form disulfide bonds on resin. 
The utility of the method was evaluated by solid phase synthesis and folding of the 
carboxy-oxytocin. In addition, a4/7-conotoxin LvIA was synthesized to demonstrate the 
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applicability of novel Pd-DMSO mediated simultaneous Allocam removal and oxidation 
condition to access more complex disulfide – rich peptides.  Two routes were introduced 
based on position of the Allocam protected cysteines and selection of compatible other 
cysteine protecting groups for each of the synthetic routes.  
 The potential of Ellman’s reagent as a colorimetric and mild oxidizing agent to form 
on-resin disulfide bonds in peptides was evaluated. The reaction procedure is simple, no 
complex time consuming reaction set up is needed and the reaction can be monitored 
easily by observing the color change of the resin. The colorimetric behavior of Ellman’s 
reagent in different solvents were examined. Ellman’s reagent – mediated disulfide bond 
formation in DMF is relatively slower while it shows faster reaction rates in NMP. This new 
colorimetric method was utilized in the synthesis of a4/7-conotoxin LvIA and a-conotoxin 
ImI and obtained excellent overall yields.  
For the first time, a regioselective on-resin synthesis of three disulfide linkages was 
achieved by synthesizing linaclotide with careful orthogonal combination of the new 
Allocam cleavage - oxidation method and Ellman’s reagent - mediated on-resin disulfide 
bond formation method.   
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